

Connecting via Winsock to STN

STN STRUCTURE SEARCH (REGISTRY/CAPLUS)

Welcome to STN International! Enter x:x

LOGINID:SSPTAJMN1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * Welcome to STN International * * * * *
```

NEWS	1			Web Page for STN Seminar Schedule - N. America
NEWS	2	OCT	02	CA/CAPLUS enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	3	OCT	19	BEILSTEIN updated with new compounds
NEWS	4	NOV	15	Derwent Indian patent publication number format enhanced
NEWS	5	NOV	19	WPIX enhanced with XML display format
NEWS	6	NOV	30	ICSD reloaded with enhancements
NEWS	7	DEC	04	LINPADOCDB now available on STN
NEWS	8	DEC	14	BEILSTEIN pricing structure to change
NEWS	9	DEC	17	USPATOLD added to additional database clusters
NEWS	10	DEC	17	IMSDRUGCONF removed from database clusters and STN
NEWS	11	DEC	17	DGENE now includes more than 10 million sequences
NEWS	12	DEC	17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	13	DEC	17	MEDLINE and LMEALINE updated with 2008 MeSH vocabulary
NEWS	14	DEC	17	CA/CAPLUS enhanced with new custom IPC display formats
NEWS	15	DEC	17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	16	JAN	02	STN pricing information for 2008 now available
NEWS	17	JAN	16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	18	JAN	28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	19	JAN	28	MARPAT searching enhanced
NEWS	20	JAN	28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	21	JAN	28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	22	JAN	28	MEDLINE and LMEALINE reloaded with enhancements
NEWS	23	FEB	08	STN Express, Version 8.3, now available
NEWS	24	FEB	20	PCI now available as a replacement to DPCI
NEWS	25	FEB	25	IFIREF reloaded with enhancements
NEWS	26	FEB	25	IMSPRODUCT reloaded with enhancements
NEWS	27	FEB	29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	28	MAR	31	IFICDB, IFIPAT, and IFIUIDB enhanced with new custom IPC display formats
NEWS	29	MAR	31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	30	MAR	31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	31	MAR	31	LPCI now available as a replacement to LDPCI

NEWS 32 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:21:13 ON 02 APR 2008

=> FIL REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.05	1.05

FILE 'REGISTRY' ENTERED AT 14:24:22 ON 02 APR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 APR 2008 HIGHEST RN 1011527-65-3
DICTIONARY FILE UPDATES: 1 APR 2008 HIGHEST RN 1011527-65-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10539151\formula XIIb claim 20.str



```

chain nodes :
10 11 13 16 17
ring nodes :
1 2 3 4 5 6 7 8 9
ring/chain nodes :
12 14 15
chain bonds :
7-10 8-16 10-11 11-12 11-13
ring/chain bonds :
12-14 12-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
5-7 6-9 7-8 8-9 11-12 11-13 12-14 12-15
exact bonds :
7-10 8-16 10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:Atom


```

L1 STRUCTURE UPLOADED

=> D

L1 HAS NO ANSWERS

L1 STR



CLAIM 20

Structure attributes must be viewed using STN Express query preparation.

=> S L1

SAMPLE SEARCH INITIATED 14:24:49 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2324 TO ITERATE

86.1% PROCESSED 2000 ITERATIONS

2 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 43589 TO 49371


PROJECTED ANSWERS: 2 TO 137

L2 2 SEA SSS SAM L1


=> D SCAN

L2 2 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Indole-3-acetamide, N,N-diethyl-5-methoxy-1-phenethyl-, picrate (7CI)
MF C23 H28 N2 O2 . C6 H3 N3 O7

CM 1



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> S L1 FULL
FULL SEARCH INITIATED 14:25:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 45697 TO ITERATE

100.0% PROCESSED 45697 ITERATIONS 130 ANSWERS
SEARCH TIME: 00.00.01

L3 130 SEA SSS FUL L1

=> FIL CAPLUS		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	178.36	179.41

FILE 'CAPLUS' ENTERED AT 14:25:15 ON 02 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Apr 2008 VOL 148 ISS 14
FILE LAST UPDATED: 1 Apr 2008 (20080401/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L3
L4 71 L3

=> D IBIB 1-10

L4 ANSWER 1 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:1145534 CAPLUS
 DOCUMENT NUMBER: 147:448797
 TITLE: Preparation of aminopyrrolidine derivatives as MC4 receptor antagonists for treatment of depression, anxiety disorder, etc.
 INVENTOR(S): Okubo, Taketoshi; Kumagai, Toshihito; Ishii, Takaaki; Nakamura, Toshio; Abe, Kumi; Amada, Yuri; Ishizaka, Tomoko; Sun, Xiang-Min; Sekiguchi, Yoshinori; Sasako, Shigetada; Shimizu, Takanori; Nagatsuka, Takayuki
 PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 230pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007114323	A1	20071011	WO 2007-JP57054	20070330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: JP 2006-102744 A 20060404

OTHER SOURCE(S): MARPAT 147:448797
 REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 2 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:730896 CAPLUS
 DOCUMENT NUMBER: 147:143468
 TITLE: Heterocyclic derivatives as modulators of ion channels and their preparation, pharmaceutical compositions and use in the treatment of diseases
 INVENTOR(S): Wilson, Dean; Fanning, Lev T. D.; Sheth, Urvi; Martinborough, Esther; Termin, Andreas; Neubert, Timothy; Zimmermann, Nicole; Knoll, Tara; Whitney, Tara; Kawatkar, Aarti; Lehsten, Danielle; Stamos, Dean; Zhou, Jinglan; Arumugam, Vijayalakshmi; Gutierrez, Corey
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 369pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007075895	A2	20070705	WO 2006-US48802	20061221
WO 2007075895	A3	20071129		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

US 20080027067 A1 20080131 US 2006-643622 20061221
 PRIORITY APPLN. INFO.: US 2005-752926P P 20051221

US 2006-791181P P 20060411
 US 2006-799797P P 20060512
 US 2006-839444P P 20060823

OTHER SOURCE(S): MARPAT 147:143468

L4 ANSWER 3 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1286256 CAPLUS
 DOCUMENT NUMBER: 146:45728
 TITLE: Preparation of proline stilbenediamine amides and related compounds as inhibitors of HCV replication
 INVENTOR(S): Serrano-Wu, Michael; Belema, Makonen; Snyder, Lawrence
 B.; Meanwell, Nicholas A.; St. Laurent, Denis R.; Kakarla, Ramesh; Nguyen, Van N.; Qiu, Yuping; Yang, Xuejie; Leet, John E.; Gao, Min; O'Boyle, Donald R.; Lemm, Julie A.; Yang, Fukang
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 156pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060276511	A1	20061207	US 2006-446788	20060605
WO 2006133326	A1	20061214	WO 2006-US22197	20060606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1893573	A1	20080305	EP 2006-772480	20060606
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: US 2005-687760P P 20050606

WO 2006-US22197 W 20060606

OTHER SOURCE(S): MARPAT 146:45728

L4 ANSWER 4 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:1228649 CAPLUS
 DOCUMENT NUMBER: 145:505339
 TITLE: Preparation of 2-(1-arylalkylamino)-1-pyridylethanol dihydrochloride hydrates
 INVENTOR(S): Tanaka, Masahiko; Nakamura, Akihiko
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan; Dainippon Pharmaceutical Co., Ltd.
 SOURCE: Jpn. Kokai Tokkyo Koho, 11pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006315992	A	20061124	JP 2005-139419	20050512
PRIORITY APPLN. INFO.:			JP 2005-139419	20050512

OTHER SOURCE(S): MARPAT 145:505339

L4 ANSWER 5 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:703152 CAPLUS
DOCUMENT NUMBER: 145:145754
TITLE: Preparation of indole derivatives as intermediates for
INVENTOR(S): β 3-adrenoceptor agonists
PATENT ASSIGNEE(S): Umezome, Takashi; Yokoyama, Tatsuo
Jpn. Kokai Tokkyo Koho, 34 pp.
SOURCE: CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
JP 2006188505 A 20060720 JP 2005-355247 20051208
PRIORITY APPLN. INFO.: JP 2004-359139 A 20041210
OTHER SOURCE(S): MARPAT 145:145754

L4 ANSWER 6 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:600233 CAPLUS
DOCUMENT NUMBER: 145:293206
TITLE: Application of the Rh(II) Cyclization/Cycloaddition Cascade for the Total Synthesis of (+)-Aspidophytine
AUTHOR(S): Mejia-Oneto, Jose M.; Padwa, Albert
CORPORATE SOURCE: Department of Chemistry, Emory University, Atlanta, GA, 30322, USA
SOURCE: Organic Letters (2006), 8(15), 3275-3278
CODEN: ORLEP7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:293206
REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 7 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:269508 CAPLUS
DOCUMENT NUMBER: 144:331420
TITLE: Preparation of bicyclic anilide spiro lactam cgrp receptor antagonists
INVENTOR(S): Bell, Ian M.; Theberge, Cory R.; Stump, Craig A.; Zhang, Xufang; Gallicchio, Steven N.; Zartman, C. Blair
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2006031610 A2 20060323 WO 2005-US32041 20050909
WO 2006031610 A3 20060831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
AU 2005285109 A1 20060323 AU 2005-285109 20050909
CA 2579847 A1 20060323 CA 2005-2579847 20050909
EP 1797073 A2 20070620 EP 2005-795448 20050909
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
CN 101018781 A 20070815 CN 2005-80030605 20050909
IN 2007DN01493 A 20070803 IN 2007-DN1493 20070223
PRIORITY APPLN. INFO.: US 2004-609292P P 20040913
WO 2005-US32041 W 20050909
OTHER SOURCE(S): MARPAT 144:331420

L4 ANSWER 8 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:325699 CAPLUS
DOCUMENT NUMBER: 142:392292
TITLE: Preparation of heterocyclic compounds, e.g., N-alkylpiperidin-3-yl substituted analogs as ligands for monoamine receptors and transporters for treating drug addiction or drug dependence
INVENTOR(S): Aquila, Brian M.; Bannister, Thomas D.; Cuny, Gregory D.; Hauske, James R.; Holland, Joanne M.; Persons, Paul E.; Radeke, Heike S.; Wang, Fengjiang; Shao, Liming
PATENT ASSIGNEE(S): Sepracor, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 161 pp., Cont.-in-part of U.S. Ser. No. 607,457.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
US 20050080078 A1 20050414 US 2004-771519 20040204
US 7294637 B2 20071113
US 20030050309 A1 20030313 US 2001-951130 20010912
US 20040077706 A1 20040422 US 2003-607457 20030626
US 7132551 B2 20061107
WO 2005077463 A2 20050825 WO 2005-US3629 20050204
WO 2005077463 A3 20060126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2000-231667P P 20000911
US 2001-273530P P 20010305
US 2001-298057P P 20010613
US 2001-951130 A3 20010912
US 2003-607457 A2 20030626
US 2004-771519 A 20040204
OTHER SOURCE(S): MARPAT 142:392292
REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 8 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L4 ANSWER 9 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:902086 CAPLUS
 DOCUMENT NUMBER: 141:388753
 TITLE: Heterocyclic compound modulators of Tie-2 and other kinases, and therapeutic use
 INVENTOR(S): Chen, Jeff; Dalrymple, Lisa; Epshteyn, Sergery; Forsyth, Timothy; Huynh, Tai; Leahy, James; Mann, Grace; Mann, Larry W.; Ridgway, Brian; Sangalang, Joan
 PATENT ASSIGNEE(S): C.; Takeuchi, Craig
 SOURCE: Exelixis, Inc., USA
 PCT Int. Appl., 126 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091480	A2	20041028	WO 2004-US10626	20040408
WO 2004091480	A3	20050811		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004229392	A1	20041028	AU 2004-229392	20040408
CA 2520255	A1	20041028	CA 2004-2520255	20040408
EP 1611123	A2	20060104	EP 2004-759191	20040408
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
HR				
JP 2006522813	T	20061005	JP 2006-509755	20040408
US 20060293342	A1	20061228	US 2006-552424	20060705
PRIORITY APPLN. INFO.:			US 2003-461471P	P 20030409
			WO 2004-US10626	A 20040408
OTHER SOURCE(S):		MARPAT 141:388753		

L4 ANSWER 10 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:718536 CAPLUS
 DOCUMENT NUMBER: 141:243546
 TITLE: Preparation of N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
 INVENTOR(S): Alegria, Larry Andrew; Chong, Wesley Kwan Mung; Chu, Shaosong; Duvadie, Rohit Kumar; Li, Lin; Romines, William Henry, III; Yang, Yi
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: PCT Int. Appl., 307 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074283	A1	20040902	WO 2004-IB433	20040209
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2516234	A1	20040902	CA 2004-2516234	20040209
EP 1597256	A1	20051123	EP 2004-709302	20040209
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2004007618	A	20060221	BR 2004-7618	20040209
JP 2006518368	T	20060810	JP 2006-502453	20040209
US 20050101595	A1	20050512	US 2004-783887	20040220
MX 2005PA88878	A	20051005	MX 2005-PA88878	20050819
PRIORITY APPLN. INFO.:			US 2003-448843P	P 20030221
			WO 2004-IB433	W 20040209

OTHER SOURCE(S): MARPAT 141:243546
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

=> D IBIB ABS HITSTR 8-71

L4 ANSWER 8 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:325699 CAPLUS
 DOCUMENT NUMBER: 142:392292
 TITLE: Preparation of heterocyclic compounds, e.g., N-alkylpiperidin-3-yl substituted analogs as ligands for monoamine receptors and transporters for treating drug addiction or drug dependence
 INVENTOR(S): Aquila, Brian M.; Bannister, Thomas D.; Cuny, Gregory D.; Hauske, James R.; Holland, Joanne M.; Persons, Paul E.; Radeke, Heike S.; Wang, Fengjiang; Shao, Liming
 PATENT ASSIGNEE(S): Sepracor, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 161 pp., Cont.-in-part of U.S. Ser. No. 607,457.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050080078	A1	20050414	US 2004-771519	20040204
US 7294637	B2	20071113		
US 20030050309	A1	20030313	US 2001-951130	20010912
US 20040077706	A1	20040422	US 2003-607457	20030626
US 7132551	B2	20061107		
WO 2005077463	A2	20050825	WO 2005-US3629	20050204
WO 2005077463	A3	20060126		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,

SM
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
 US 2000-231667P P 20000911
 US 2001-273530P P 20010305
 US 2001-298057P P 20010613
 US 2001-951130 A3 20010912
 US 2003-607457 A2 20030626
 US 2004-771519 A 20040204


OTHER SOURCE(S): MARPAT 142:392292
 GI

L4 ANSWER 8 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title comps. (4 Markush structures given), e.g., I [X = C(R3)2, O, SOO-2, NR2, NC(O)R7, NC(O)OR2, NS(O)2R7, C=O; Z = C(R3)2, C(O), O, NR, NC(O)OR, SOO-2; m = 1-5; n = 1-2; p = 0-2; q = 0-3; R = H, (cyclo)alkyl, (hetero)aryl, aralkyl, heteroaralkyl; R1 = H, alkyl, (hetero)aryl, aralkyl, heteroaralkyl; R, R1 may be connected through a covalent bond;
 R2 = H, alkyl, fluoroalkyl, aryl, heteroaryl, cycloalkyl; R3 = H, alkyl, aryl, OR2, OC(O)R2, CH2OR2, CO2R2; wherein any two instances of R3 may be connected by a covalent tether whose backbone consists of 1, 2, 3, or 4-carbon atoms; R4 = H, alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, OR; R5-6 = H, alkyl, (CH2)qY, aryl, heteroaryl, F, OR2, OC(O)R2, or an instance of CR5R6 taken together is C(O); R7 = (cyclo)alkyl, (hetero)aryl, aralkyl, or heteroaralkyl; R8-9 = H, alkyl, (CH2)qY, (hetero)aryl, F, OR2, OC(O)R2, or an instance of CR8R9 taken together is C(O); Y = OR2, N(R2)2, SOO-2R2, P(O)OR2)2; any two instances of R2 may be connected through a covalent bond; a covalent bond may connect R4 and an instance of R5 or R6;
 any two instances of R5 and R6 may be connected through a covalent bond; any two geminal or vicinal instances of R8 and R9 may be connected through a covalent bond; and the stereochem. configuration at any stereocenter of I is R, S or a mixture of these configurations.] were prepared. Examples include synthesis of several hundred comps. of structure I, functional assays for norepinephrine (NE), dopamine (DA) and serotonin (5-HT) antagonism, determination of NE, DA and 5-HT reuptake inhibition, spontaneous locomotor activity/antidepressant behavioral assay in rats and the synthesis of a 96-member combinatorial library in which the library comps. were screened for monoamine uptake inhibition. For instance, 3-((4-trifluoromethylphenoxy)methyl)piperidine trifluoroacetate was alkylated with 1-[(4-chlorophenyl)cyclobutyl]-2-chloroethanone (preparation given) and the resulting product reduced with NaBH4 to give II. All 4 enantiomers of II were prepared by a stereospecific synthesis, and X-ray crystallog. determination of one enantiomer allowed the absolute stereochem. of III to be assigned. III had EC50 < 10 nM for DA reuptake inhibition compared to nomifensine = 11 nM. I are useful for the treatment of cocaine addiction or methamphetamine addiction.
 IT 405089-92-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclic comps., e.g., N-alkylpiperidin-3-yl substituted analogs as ligands for monoamine receptors and

L4 ANSWER 8 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 transporters)
 RN 405089-92-1 CAPLUS
 CN Piperidine, 1-[(5-methoxy-1H-indol-3-yl)acetyl]-3-[[4-(trifluoromethyl)phenoxy)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 9 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:902086 CAPLUS
 DOCUMENT NUMBER: 141:388753
 TITLE: Heterocyclic compound modulators of Tie-2 and other kinases, and therapeutic use
 INVENTOR(S): Chen, Jeffrey; Dalrymple, Lisa; Epshteyn, Sergey; Forsyth, Timothy; Huynh, Tai; Leahy, James; Mann, Grace; Mann, Larry W.; Ridgway, Brian; Sangalang, Joan
 C.; Takeuchi, Craig
 PATENT ASSIGNEE(S): Exelixis, Inc., USA
 SOURCE: PCT Int. Appl., 126 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004091480	A2	20041028	WO 2004-US10626	20040408
WO 2004091480	A3	20050811		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2004229392 A1 20041028 AU 2004-229392 20040408
 CA 2520255 A1 20041028 CA 2004-2520255 20040408
 EP 1611123 A2 20060104 EP 2004-759191 20040408
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
 HR JP 2006522813 T 20061005 JP 2006-509755 20040408
 US 20060293342 A1 20061228 US 2006-552424 20060705
 PRIORITY APPLN. INFO.: US 2003-461471P P 20030409
 WO 2004-US10626 A 20040408

OTHER SOURCE(S): MARPAT 141:388753
 AB The invention provides heterocyclic comps. for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Comps. of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the comps. and pharmaceutical comps. thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention. Preparation of triazolyl comps. of the invention is included.
 IT 783330-82-5 783330-6
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

L4 ANSWER 9 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (Biological study); USES (Uses)
 (heterocyclic compd. modulators of Tie-2 and other kinases, and
 therapeutic use)
 RN 783330-82-5 CAPLUS
 CN 1H-Indole-3-acetamide, 5-bromo-N-cyclopentyl-N-[2-[5-methyl-3-(4-
 pyridinyl)-1H-1,2,4-triazol-1-yl]ethyl]- (CA INDEX NAME)



RN 783330-83-6 CAPLUS
 CN 1H-Indole-3-acetamide, N-cyclopentyl-5-methoxy-N-[2-[5-methyl-3-(4-
 pyridinyl)-1H-1,2,4-triazol-1-yl]ethyl]- (CA INDEX NAME)




L4 ANSWER 10 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:718536 CAPLUS
 DOCUMENT NUMBER: 141:243546
 TITLE: Preparation of N-heterocyclyl-substituted
 amino-thiazole derivatives as protein kinase
 inhibitors
 INVENTOR(S): Alegria, Larry Andrew; Chong, Wesley Kwan Mung; Chu,
 Shaosong; Duvadie, Rohit Kumar; Li, Lin; Romines,
 William Henry, III; Yang, Yi
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: PCT Int. Appl., 307 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074283	A1	20040902	WO 2004-1B433	20040209
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2516234	A1	20040902	CA 2004-2516234	20040209
EP 1597256	A1	20051123	EP 2004-709302	20040209
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2004007618	A	20060221	BR 2004-7618	20040209
JP 2006518368	T	20060810	JP 2006-502453	20040209
US 20050101595	A1	20050512	US 2004-783887	20040220
MX 2005PA08878	A	20051005	MX 2005-PA8878	20050819
PRIORITY APPLN. INFO.:			US 2003-448843P	P 20030221
			WO 2004-1B433	W 20040209


OTHER SOURCE(S): MARPAT 141:243546
 GI

L4 ANSWER 10 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB The title aminothiazole compds. with N-containing cycloalkyl at the
 2-amino
 position [I; N-containing heterocyclyl = (un)substituted N-containing
 3-10 membered heterocyclyl; R1 = H, alkyl, alkenyl, alkoxy, etc.; R2 =
 (un)substituted alkyl, cycloalkyl, alkoxy, aryl, 4-10 membered
 heterocyclyl] and their pharmaceutically acceptable prodrugs or salts
 which modulate and/or inhibit the cell proliferation and activity of
 protein kinases, were prepared. Thus, reacting [4-amino-2-(piperidin-4-
 yl amino)thiazol-5-yl] (2,6-difluorophenyl)methanone (preparation given)
 with
 1-methylpiperidine-4-carboxylic acid afforded 65% II which showed Ki of
 0.46 μ M against CDK2, Ki of 0.13 μ M against CDK4, and IC50 of >5
 μ M in HCT-116 assay for cell growth inhibition. Biol. data were given
 for over 1100 compds. I. The pharmaceutical compds. comprising the
 compound
 I are claimed.
 IT 750582-26-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of N-heterocyclyl-substituted amino-thiazole derivs. as
 protein
 kinase inhibitors)
 RN 750582-26-4 CAPLUS
 CN 4-Piperidinamine, N-[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]-1-[5-
 fluoro-1H-indol-3-yl]acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 11 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:546477 CAPLUS
 DOCUMENT NUMBER: 141:89009
 TITLE: Synthesis of tryptamine derivatives and intermediates thereof
 INVENTOR(S): Berens, Ulrich; Dosenbach, Oliver; Sprenger, Daniel
 PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
 SOURCE: PCT Int. Appl., 84 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056769	A2	20040708	WO 2003-EP50992	20031212
WO 2004056769	A3	20040916		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG				
CA 2508290	A1	20040708	CA 2003-2508290	20031212
AU 2003299227	A1	20040714	AU 2003-299227	20031212
EP 1572647	A2	20050914	EP 2003-799560	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1729174	A	20060201	CN 2003-80107086	20031212
JP 2006516128	T	20060622	JP 2004-561492	20031212
US 20060058367	A1	20060316	US 2005-539151	20050616
IN 2005CN01638	A	20070622	IN 2005-CN1638	20050719
IN 2007CN05032	A	20080321	IN 2007-CN5032	20071107
PRIORITY APPLN. INFO.:			EP 2002-406128	A 20021220
			WO 2003-EP50992	W 20031212
			IN 2005-CN1638	A3 20050719

OTHER SOURCE(S): MARPAT 141:89009
 GI

L4 ANSWER 11 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB Indoleacetates I [R = CO2R3; R1 = (un)substituted alkyl, aryl, heterocyclyl, alkylsulfonyl, OH, SH, NO2, halogen, CN, CONH2, CONHNH2, CO2H, alkenyl, alkynyl, cycloalkyl, acyloxy, NH2, NHH2, B(OH)2; R2 = H, (un)substituted alkyl, CO2H, arylsulfonyl, alkylsulfonyl, aryl, CONH2, silyl; R3 = (un)substituted alkyl; n = 0-4] were prepared and converted


to I [R = CONR4R5; R4, R5 = (un)substituted alkyl; R4R5 = (un)substituted alkylene] which were in turn converted to indoleacetamides and tryptamines. The synthesis methods and products are useful in the synthesis of pharmaceuticals. Thus, 5-bromoindole-3-yl was treated with CH2(CO2H)2 and ClCONMe2 to give I [R = CONMe2, R1 = 5-Br, R2 = H] which was treated with BF3.Et2O and BH3.Me2SO to give

2-(5-bromo-1H-indol-3-yl)-N,N-dimethylacetamide or with BF3.Et2O and NaBH4 to give [2-(5-bromo-1H-indol-3-yl)ethyl]-N,N-dimethylacetamide.


IT 717139-79-2P 717139-83-8P
 R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of tryptamine derivs. and intermediates thereof)
 RN 717139-79-2 CAPLUS
 CN 1H-Indole-3-acetamide, 5-bromo-N,N-dimethyl- (CA INDEX NAME)




RN 717139-83-8 CAPLUS
 CN 1H-Indole-3-acetamide, 5-iodo-N,N-dimethyl- (CA INDEX NAME)



L4 ANSWER 11 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 IT 717139-80-5P 717139-84-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of tryptamine derivs. and intermediates thereof)
 RN 717139-80-5 CAPLUS
 CN 1H-Indole-3-acetamide, 5-bromo-N,N-dimethyl-1-(phenylmethyl)- (CA INDEX NAME)




RN 717139-84-9 CAPLUS
 CN 1H-Indole-3-acetamide, 5-iodo-N,N-dimethyl-1-(phenylmethyl)- (CA INDEX NAME)



L4 ANSWER 12 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:525891 CAPLUS
 DOCUMENT NUMBER: 141:89110
 TITLE: Preparation of piperazinylethylindolecarbonitriles as serotonin reuptake inhibitors and 5-HT1A/5-HT1B receptor ligands.
 INVENTOR(S): Heinrich, Timo; Boettcher, Henning; Schiemann, Kai; Hoelzemann, Guenter; van Amsterdam, Christoph; Bartoszyk, Gerd; Leibrock, Joachim; Seyfried, Christoph
 PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
 SOURCE: Ger. Offen., 23 pp.
 CODEN: GWXXBK
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10259244	A1	20040701	DE 2002-10259244	20021217
CA 2510169	A1	20040701	CA 2003-2510169	20031217
WO 2004054972	A1	20040701	WO 2003-EP13374	20031217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG				
AU 2003298145	A1	20040709	AU 2003-298145	20031127
EP 1572646	A1	20050914	EP 2003-795848	20031127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017422	A	20051108	BR 2003-17422	20031127
CN 1729173	A	20060201	CN 2003-80106737	20031127
JP 2006511522	T	20060406	JP 2004-559727	20031127
MX 2005PA06385	A	20050829	MX 2005-PA6385	20050614
US 20060122191	A1	20060608	US 2005-539516	20050617
ZA 2005005684	A	20060426	ZA 2005-5684	20050714
PRIORITY APPLN. INFO.:			DE 2002-10259244	A 20021217
			WO 2003-EP13374	W 20031127

OTHER SOURCE(S): MARPAT 141:89110
 GI




L4 ANSWER 12 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB Title compds. [I; R11, R111 = H, cyano, halo, A, OA, OH, COR2, CH2R2; R2 = OH, OA, NH2, NHA, NA2; A = (fluoro-substituted) alkyl optionally interrupted by O, S, CH:CH; Ar = (partially or completely saturated) (substituted) mono- or polycyclic carbo- or heterocyclyl; n = 0-4], were prepared Thus, 3-(2-chloroeth-1-yl)-1H-indole-5-carbonitrile (preparation given), 1-(2,3-dihydrobenzo[1,4]-dioxin-5-yl)piperazine, ethyldiisopropylamine, and N-methylpyrrolidinone were heated together at 120° for 12 h to give 3-[2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethyl]-1H-indole-5-carbonitrile. The latter showed SSRI, 5-HT1A, and 5-HT1B receptor activity at 11 nM, 17 nM, and 11 nM, resp.

IT 714954-07-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of piperazinylethylindolecarbonitriles as serotonin reuptake inhibitors and receptor ligands)


RN 714954-07-1 CAPLUS
 CN Piperazine, 1-[2-(5-cyano-1H-indol-3-yl)ethyl]-4-[(5-fluoro-1H-indol-3-yl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:796490 CAPLUS
 DOCUMENT NUMBER: 139:307794
 TITLE: Preparation of N-hydroxy (piperazinesulfonyl)- or (piperazinecarbonyl)arylpropenamides as inhibitors of histone deacetylase and antiproliferative agents for the treatment of cancer and psoriasis
 INVENTOR(S): Watkins, Clare J.; Romero-Martin, Maria-Rosario; Ritchie, James; Finn, Paul W.; Kalvinsh, Ivars; Loza, Elnars; Dikowska, Klara; Starchenkov, Igor; Lolya, Daina; Gailite, Vija
 PATENT ASSIGNEE(S): Prolifix Limited, UK
 SOURCE: PCT Int. Appl., 217 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082288	A1	20031009	WO 2003-GB1463	20030403
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2479906	A1	20031009	CA 2003-2479906	20030403
AU 2003229883	A1	20031013	AU 2003-229883	20030403
BR 2003008908	A	20050104	BR 2003-8908	20030403
EP 1492534	A1	20050105	EP 2003-722719	20030403
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005527556	T	20050915	JP 2003-579825	20030403
NZ 536116	A	20070126	NZ 2003-536116	20030403
MX 2004PA09490	A	20050608	MX 2004-PA9490	20040929
US 20050143385	A1	20050630	US 2004-509732	20040930
NO 2004004744	A	20041102	NO 2004-4744	20041102
PRIORITY APPLN. INFO.:			US 2002-369337P	P 20020403
			WO 2003-GB1463	W 20030403
OTHER SOURCE(S):		MARPAT 139:307794		
GI				

L4 ANSWER 13 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB N-hydroxyamides I [J1 = single bond, C(=O), J2 = C(=O), SO2; Q1 = single bond, OX, SX, XOY, XSX, XO, XS; Q2 = (un)substituted C4-C8 alkylene at least four carbon atoms in length; R = (un)substituted cycloalkyl, heterocycloalkyl, or aryl; R1 = C1-C4 alkyl; X, Y = (un)substituted alkanediyl; n = 0-8] containing piperazine moieties, particularly N-hydroxy piperazinesulfonylarylpropenamides such as II, are prepared as inhibitors of histone deacetylase (HDAC) for the treatment of proliferative diseases, cancer, and psoriasis in both humans and animals. Biol. data on the inhibition of HDAC in vitro, the inhibition of cellular proliferation in vitro, and the in vivo testing of I on mice containing i.p. P388 tumors are given for a subset of I. Most of the compds. I tested inhibit HDAC with IC50 values between 20 nM and 200 nM, inhibit proliferation of four cell lines with IC50 values between 1 μM and 10 μM, and give log rank statistics for mice with P388 tumors (5 each) of between -3 and -5. II gives a log rank statistic for tumors in five mice of -9.62. Preparative data for approx. fifty of the title compds. are given.

IT 610801-57-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (claimed compds.; preparation of N-hydroxy (piperazinesulfonyl)- or (piperazinecarbonyl)arylpropenamides as inhibitors of histone deacetylase and antiproliferative agents for the treatment of cancer and psoriasis)


RN 610801-57-5 CAPLUS
 CN 1-Piperazineoctanamide, N-hydroxy-4-[(5-methoxy-1H-indol-3-yl)acetyl]-η-oxo- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 610802-13-6P 610802-39-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediates; preparation of N-hydroxy (piperazinesulfonyl)- or (piperazinecarbonyl)arylpropenamides as inhibitors of histone deacetylase and antiproliferative agents for the treatment of cancer and psoriasis)

RN 610802-13-6 CAPLUS
 CN Piperazine, 1-[(5-methoxy-1H-indol-3-yl)acetyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE



FORMAT

L4 ANSWER 14 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:656572 CAPLUS
 DOCUMENT NUMBER: 139:197363
 TITLE: Preparation of 1-arylsulfonyl-3-substituted indoles and indolines for the treatment of central nervous system disorders
 INVENTOR(S): Spinks, Daniel; Armer, Richard E.; Miller, David J.; Rankovic, Zoran; Spinks, Gayle; Mestres, Jordi; Jaap, David Robert
 PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068220	A1	20030821	WO 2003-EP50010	20030205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003208711	A1	20030904	AU 2003-208711	20030205
EP 1476151	A1	20041117	EP 2003-706618	20030205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 200526033	T	20050902	JP 2003-567402	20030205
US 20050154023	A1	20050714	US 2004-504556	20040812
PRIORITY APPLN. INFO.:			EP 2002-75584	A 20020212
			WO 2003-EP50010	W 20030205

OTHER SOURCE(S): MARPAT 139:197363
 GI

L4 ANSWER 14 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB The title compds. [I; Ar = (un)substituted (hetero)aryl; n = 0-1; m = 0-5; R6 = H, alkyl, alkoxy, etc.; R7 = H, alkyl, aryl, arylalkyl; or R7 together with R9 or with one of R8 forms 4-7 membered saturated ring; R8 = H, alkyl, aryl; or one of R8 together with R7 or R9 or the geminal R11 forms 4-7 membered saturated ring, and other R8 = H, alkyl or (un)substituted aryl; R9, R10 = H, alkyl, aryl, arylalkyl; or NR9R10 = 5-7 membered (un)saturated ring optionally containing O or N atoms; R11 = H, alkyl; or one of R11 together with R10 or with the geminal R8 forms 4-7 membered saturated ring, and the other R11 = H, alkyl], useful in the treatment of central nervous disorders such as psychosis, schizophrenia, manic depressions, depressions, neurol. disorders, cognitive enhancement, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease, were prepared E.g., a 4-step synthesis of II (starting from 1H-indole-3-carboxylic acid) which showed pKi of > 7.5 against 5-HT6 receptor binding, was given. Pharmaceutical composition comprising the compound I is claimed.

IT 583814-43-1P 583814-57-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 for the preparation of 1-arylsulfonyl-3-substituted indoles and indolines

L4 ANSWER 14 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 treatment of central nervous system disorders)
 RN 583814-43-1 CAPLUS
 CN 1H-Indole-3-acetamide,
 1-[(5-bromo-2-thienyl)sulfonyl]-5-methoxy-N-methyl-
 N-(1-methyl-4-piperidinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 583814-42-0
 CMP C22 H26 Br N3 O4 S2



CM 2

CRN 76-05-1
 CMP C2 H F3 O2




RN 583814-57-7 CAPLUS
 CN 1H-1,4-Diazepine, hexahydro-1-[[5-methoxy-1-[(4-methoxy-1-naphthalenyl)sulfonyl]-1H-indol-3-yl]acetyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 583814-56-6
 CMP C27 H29 N3 O5 S

L4 ANSWER 14 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2

CRN 76-05-1
 CMP C2 H F3 O2



IT 583815-11-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 1-arylsulfonyl-3-substituted indoles and indolines for the treatment of central nervous system disorders)
 RN 583815-11-6 CAPLUS
 CN 1H-1,4-Diazepine-1-carboxylic acid,
 hexahydro-4-[[5-methoxy-1-[(4-methoxy-1-naphthalenyl)sulfonyl]-1H-indol-3-yl]acetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 15 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 2003:319488 CAPLUS
DOCUMENT NUMBER: 138:337988
TITLE: Novel 2-[(iminomethyl)amino]phenyl derivatives useful as inhibitors of NO synthase and lipid peroxidation, their preparation, their application as medicines, and pharmaceutical compositions containing them
INVENTOR(S): Chabrier De Lassauniere, Pierre Etienne; Auvin, Serge;
PATENT ASSIGNEE(S): Bigg, Dennis; Auguet, Michel; Harnett, Jeremiah Societe de Conseils de Recherches et D'Applications scientifiques (S.C.R.A.S.), Fr.
SOURCE: U.S. Pat. Appl. Publ., 78 pp., Cont.-in-part of U.S. Ser. No. 882,264.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030078420	A1	20030424	US 2002-191950	20020709
US 6809088	B2	20041026		
FR 2761066	A1	19980925	FR 1997-3528	19970324
FR 2761066	B1	20001124		
FR 2764889	A1	19981224	FR 1997-7701	19970620
FR 2764889	B1	20000901		
WO 9842696	A1	19981001	WO 1998-FR288	19980216
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MM, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GM, GN, ML, MR, NE, SN, TD, TG				
WO 9858934	A1	19981230	WO 1998-FR1250	19980615
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MM, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GM, GN, ML, MR, NE, SN, TD, TG				
US 6335445	B1	20020101	US 1999-456205	19991207
US 20020007062	A1	20020117	US 2001-882264	20010615
US 6630461	B2	20031007		
US 20050043397	A1	20050224	US 2004-898916	20040726
US 7122535	B2	20061017		
US 20050187272	A1	20050825	US 2005-105291	20050413
IN 2006DE01211	A	20071123	IN 2006-DE1211	20060517
PRIORITY APPLN. INFO.:				A 19970324

L4 ANSWER 15 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
FR 1997-7701 A 19970620

WO 1998-FR288 W 19980216
WO 1998-FR1250 W 19980615
US 1999-456205 A3 19991207
US 2001-882264 A2 20010615
IN 1998-DE599 A3 19980309
US 1999-381749 A2 19990922
US 2002-191950 A3 20020709
US 2004-898916 A3 20040726

OTHER SOURCE(S): MARPAT 138:337988
GI




AB Title compds., e.g., N-[4-[[[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl]amino]methyl]phenyl]thiophene-2-carboximidamide (I) are prepared. The compds. are inhibitors of NO synthases, and are also antioxidants which inhibit lipid peroxidn. Approx. 70 examples are prepared.
I had IC50 for inhibiting rat neuronal NO synthase in vitro < 3.5 μM, and the IC50 for inhibiting rat cerebral lipid peroxidn. in vitro is < 30 μM.


IT 214123-85-0P, N-[4-[4-[[[(5-Methoxy-1H-indol-3-yl)methyl]carbonyl]-1-piperazinyl]phenyl]-2-thiophenecarboximidamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and testing of 2-[(iminomethyl)amino]phenyl derivs. as inhibitors of NO synthase and lipid peroxidn.)

RN 214123-85-0 CAPLUS
CN Piperazine, 1-[4-[(iminomethyl)amino]phenyl]-4-[(5-methoxy-1H-indol-3-yl)acetyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 214124-59-1P, 1-[[[(5-Methoxy-1H-indol-3-yl)methyl]carbonyl]-4-(4-nitrophenyl)piperazine 214124-60-4P, 1-[[[(5-Methoxy-1H-indol-3-yl)methyl]carbonyl]-4-(4-aminophenyl)piperazine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and testing of 2-[(iminomethyl)amino]phenyl derivs. as inhibitors of NO synthase and lipid peroxidn.)
RN 214124-59-1 CAPLUS
CN Piperazine, 1-[(5-methoxy-1H-indol-3-yl)acetyl]-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 214124-60-4 CAPLUS
CN Piperazine, 1-(4-aminophenyl)-4-[(5-methoxy-1H-indol-3-yl)acetyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 16 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:832569 CAPLUS
 DOCUMENT NUMBER: 137:337880
 TITLE: Preparation of indole, azaindole, and related heterocyclic piperazinecarboxamides for treatment of AIDS
 INVENTOR(S): Wang, Tao; Wallace, Owen B.; Meanwell, Nicholas A.; Zhang, Zhongxing; Bender, John A.; Kadow, John F.; Yeung, Kap-Sun
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 111 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085301	A2	20021031	WO 2002-US12856	20020423
WO 2002085301	A3	20030227		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20030096825	A1	20030522	US 2002-127256	20020422
US 6825201	B2	20041130		
CA 2445190	A1	20021031	CA 2002-2445190	20020423
AU 2002307505	A1	20021105	AU 2002-307505	20020423
EP 1381366	A2	20040121	EP 2002-764315	20020423
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002009153	A	20040720	BR 2002-9153	20020423
CN 1520295	A	20040811	CN 2002-812629	20020423
JP 2004527538	T	20040909	JP 2002-582877	20020423
HU 2004001503	A2	20041228	HU 2004-1503	20020423
MX 2003PA09680	A	20040212	MX 2003-PA9680	20031022
AU 2007237294	A1	20071220	AU 2007-237294	20071130
PRIORITY APPLN. INFO.:			US 2001-286347P	P 20010425
			AU 2002-307505	A3 20020423
			WO 2002-US12856	W 20020423

OTHER SOURCE(S): MARPAT 137:337880
 GI

L4 ANSWER 16 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I




II

AB This invention provides indole, azaindole, and related heterocyclic piperazinecarboxamides Q(C(O))m(CR8R8')n(C(O))pTC(O)A (I; variables defined below; e.g. N-(benzoyl)-N'-(2-(indol-2-yl)-2-oxo-1-cyanoethyl)piperazine (shown as I)) having drug and bio-affecting properties, their pharmaceutical compns. and method of use. These compds. possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. EC50 ranges against HIV-1 are given for about 30 of the claimed compds.; for example, N-(benzoyl)-N'-(2-(6-methoxyindol-2-yl)-2-oxo-1-cyanoethyl)-3-methylpiperazine has an EC50 <1μM. Although the methods of preparation are not claimed, 32 example preps. of 1 and 6 example preps. of intermediates are included. In 1: Q is shown as II (dotted line may be a bond); A is Cl-6alkoxy, Cl-6alkyl, C3-7cycloalkyl, Ph, and heteroaryl; T is piperazine-1,4-diyl; U is NR7, O, or S; V is C(H)kR1, O or N(R7)k; W is CR3 or NR10; X is CR4 or NR10; Y is CR5 or NR10; Z is CR6 or NR10; k is 0 or 1; m, n, and p are 0-2 provided that the sum of m, n, and p must equal 1 or 2; R8 and R8 are H, hydroxy, Cl-6alkyl, Cl-6alkoxy, cyano, and fluoro, or R8 and R8' taken together form -O-, -S-, -NOR9, or -NH; other variables and provisos are given in the claims.

IT 474012-42-5P, 3-[2-(4-Benzoylpiperazin-1-yl)-2-oxoethyl]-4-fluoro-1H-indole-7-carboxylic acid methylamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of indole, azaindole, and related heterocyclic piperazinecarboxamides for treatment of AIDS)
 RN 474012-42-5 CAPLUS
 CN 1H-Indole-7-carboxamide, 3-[2-(4-benzoyl-1-piperazinyl)-2-oxoethyl]-4-fluoro-N-methyl- (CA INDEX NAME)

L4 ANSWER 16 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 17 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:220550 CAPLUS
 DOCUMENT NUMBER: 136:263097
 TITLE: Preparation of heterocyclic compounds, e.g., N-alkylpiperidin-3-yl substituted analogs as ligands for monoamine receptors and transporters.
 INVENTOR(S): Aquila, Brian M.; Bannister, Thomas D.; Cuny, Gregory D.; Hauske, James R.; Holland, Joanne M.; Persons, Paul E.; Radeke, Heike; Wang, Fengjian; Shao, Liming
 PATENT ASSIGNEE(S): Sepracor, Inc., USA
 SOURCE: PCT Int. Appl., 275 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022572	A2	20020321	WO 2001-US28654	20010912
WO 2002022572	A3	20020801		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2422055	A1	20020321	CA 2001-2422055	20010912
AU 2001090873	A	20020326	AU 2001-90873	20010912
EP 1318988	A2	20030618	EP 2001-970926	20010912
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004509103	T	20040325	JP 2002-526825	20010912
PRIORITY APPLN. INFO.:			US 2000-231667P	P 20000911
			US 2001-273530P	P 20010305
			US 2001-298057P	P 20010613
			US 2000-273530P	P 20010305
			US 2000-298057P	P 20010613
			WO 2001-US28654	W 20010912


OTHER SOURCE(S): MARPAT 136:263097
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. (4 Markush structures given), e.g., I [X = C(R3)2, O, SOO-2, NR2, NC(O)R7, NC(O)OR2, NS(O)2R7, C=O; Z = C(R3)2, C(O), O, NR,


L4 ANSWER 17 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 NC(O)OR, SOO-2; m = 1-5; n = 1-2; p = 0-2; q = 0-3; R = H, (cyclo)alkyl, (hetero)aryl, aralkyl, heteroaralkyl; R1 = H, alkyl, (hetero)aryl, aralkyl, heteroaralkyl; R, R1 may be connected through a covalent bond;
 R2 = H, alkyl, fluoroalkyl, aryl, heteroaryl, cycloalkyl; R3 = H, alkyl, aryl, OR2, OC(O)R2, CH2OR2, CO2R2; wherein any two instances of R3 may be connected by a covalent tether whose backbone consists of 1, 2, 3, or 4-carbon atoms; R4 = H, alkyl, cycloalkyl, aryl, heteroaryl, alkenyl, OR; R5-6 = H, alkyl, (CH2)qY, aryl, heteroaryl, F, OR2, OC(O)R2, or an instance of CR5R6 taken together is C(O); R7 = (cyclo)alkyl, (hetero)aryl, aralkyl, or heteroaralkyl; R8-9 = H, alkyl, (CH2)qY, (hetero)aryl, F, OR2, OC(O)R2, or an instance of CR8R9 taken together is C(O); Y = OR2, N(R2)2, SOO-2R2, P(O)(OR2)2; any two instances of R2 may be connected through a covalent bond; a covalent bond may connect R4 and an instance of R5 or R6;
 any two instances of R5 and R6 may be connected through a covalent bond; any two geminal or vicinal instances of R8 and R9 may be connected through a covalent bond; and the stereochem. configuration at any stereocenter of I is R, S or a mixt. of these configurations.] were prepd. Examples include synthesis of several hundred compds. of structure I, functional assays for norepinephrine (NE), dopamine (DA) and serotonin (5-HT) antagonism, detn. of NE, DA and 5-HT reuptake inhibition, spontaneous locomotor activity/antidepressant behavioral assay in rats and the synthesis of a 96-member combinatorial library in which the library compds. were screened for monoamine uptake inhibition. For instance, 3-((4-trifluoromethylphenoxy)methyl)piperidine trifluoroacetate was alkylated with 1-[[4-(4-chlorophenyl)cyclobutyl]-2-chloroethanone (prepn. given) and the resulting product reduced with NaBH4 to give II. All 4 enantiomers of II were prepd. by a stereospecific synthesis, and X-ray crystallog. detn. of one enantiomer allowed the abs. stereochem. of III to be assigned. III had EC50 < 10 nM for DA reuptake inhibition compared to nomifensine = 11 nM. I are useful for the treatment of depression, sexual dysfunction, Alzheimer's disease, anxiety, etc.
 IT 405089-92-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclic compds., e.g., N-alkylpiperidin-3-yl substituted analogs as ligands for monoamine receptors and transporters)
 RN 405089-92-1 CAPLUS
 CN Piperidine, 1-[(5-methoxy-1H-indol-3-yl)acetyl]-3-[[4-(trifluoromethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:172553 CAPLUS
 DOCUMENT NUMBER: 136:355101
 TITLE: Aromatization of 1,6,7,7a-Tetrahydro-2H-indol-2-ones by a Novel Process. Preparation of Key-Intermediate Methyl 1-Benzyl-5-methoxy-1H-indole-3-acetate and the Syntheses of Serotonin, Melatonin, and Bufotenin
 Revial, Gilbert; Jabin, Ivan; Lim, Sethy; Pfau, Michel
 CORPORATE SOURCE: Laboratoire de Chimie Organique, CNRS (ESA 7084), ESPCI, Paris, 75231, Fr.
 SOURCE: Journal of Organic Chemistry (2002), 67(7), 2252-2256
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:355101
 GI

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 NAME)



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT




AB The imine of 1,4-cyclohexanedione mono-ethylene ketal was reacted with maleic anhydride, affording the cyclized adduct I. Me esterification of I, accompanied by transacetalization, led to the dihydrooxindole derivative II. Aromatization of II was then accomplished with POC13, leading directly to the key-intermediate title compound III in 74% yield from the ketone. Serotonin, melatonin, and bufotenin were then obtained by standard reactions.
 IT 419569-94-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (novel aromatization of tetrahydro-2H-indol-2-ones in the preparation of key-intermediate 1-benzyl-5-methoxy-1H-indole-3-acetate)
 RN 419569-94-1 CAPLUS
 CN 1H-Indole-3-acetamide, 5-methoxy-N,N-dimethyl-1-(phenylmethyl)- (CA INDEX NAME)

L4 ANSWER 19 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:113840 CAPLUS
 DOCUMENT NUMBER: 136:167283
 TITLE: Preparation of acetylpiiperidinebutanediamines as
 calcium ion-permeable AMPA receptor antagonists
 INVENTOR(S): Mimura, Tetsuya; Kawajiri, Shinichi
 PATENT ASSIGNEE(S): Daiichi Seliyaku Co., ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 93 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002047272	A	20020212	JP 2000-225300	20000726
PRIORITY APPLN. INFO.:			JP 2000-225300	20000726

OTHER SOURCE(S): MARPAT 136:167283
GI



AB The compds. I (R1 = aryl, arylcarbonyl, aryloxy, cycloalkyl heterocyclyl, etc.; X = single bond, (un)substituted alkyl, alkenyl, cycloalkyl, monocyclic heterocyclyl; G = CO, SO₂; n = 0-3; A = NR₂, O, S, single bond;

R2 = H, alkyl, OH; Y = alkylene, alkynylene, alkenylene; Q = NR3R4, OR5, SR5; R3, R4 = H, alkyl, cycloalkyl, aralkyl, etc.; R5 = alkyl, cycloalkyl,


aryl heterocyclyl, etc.), their salts, and solvates are prepared. The compounds are useful for cerebral infarction, senile dementia, Alzheimer's disease, Parkinson's disease, and Huntington's disease. Cyclohexanol was reacted with oxalyl chloride in the presence of DABCO and Et₃N in CH₂Cl₂ at -78°C to give N-(tert-butoxycarbonyl)-N-methyl-N-[(1-(1-naphthylacetyl)pyrrolidine for 1 h to give 82% N-(tert-butoxycarbonyl)-N-cyclohexylmethyl-N-[(1-(1-naphthylacetyl)piperidin-4-ylmethyl]-1,4-butanediamine, which was treated with HCl in EtOH at room temperature for 5 h to give N-cyclohexylmethyl-N-[(1-(1-

naphthylacetyl)piperidin-4-ylmethyl]-1,4-butanediamine hydrochloride showing good AMPA receptor blocking activity in vitro.

IT 396071-91-3P 396071-92-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses).


(preparation of acetylpiperidinebutanediamines as calcium ion-permeable AMPA

L4 ANSWER 19 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
receptor antagonists)
RN 396071-91-3 CAPLUS
CN 4-Piperidinylmethanamine, 1-[(5-fluoro-1H-indol-3-yl)acetyl]-N-[4-[(4-
piperidinyl)methyl]aminobutyl]-, trihydrochloride (9CI) (CA INDEX NAME)

 $\bullet 3 \text{ HCl}$

RN 396071-92-4 CAPLUS
CN 4-Piperidinemethanamine,
1-[(5-fluoro-1H-indol-3-yl)acetyl]-N-[4-[(2S)-2-
pyrrolidinylmethyl]amino]butyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


 $\bullet_3 \text{HCl}$

14 ANSWER 20 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:6386 CAPLUS
 DOCUMENT NUMBER: 136:69731
 TITLE: Preparation of N-phenylthiophenecarboxamidines and
 analogs as NO synthase and lipid peroxidation
 inhibitors
 INVENTOR(S): Chabrier de Lassauniere, Pierre Etienne; Auvin,
 Serge;
 PATENT ASSIGNEE(S): Bigg, Dennis; Auguet, Michel; Harnett, Jeremiah
 Societe de Conseils de Recherches et d'Applications
 Scientifiques (S.C.R.A.S.), Fr.
 SOURCE: U.S., 63 pp., Cont.-in-part of U. S. Ser. No.
 381,749.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6335445	B1	20020101	US 1999-456205	19991207
FR 2761066	A1	19980925	FR 1997-3528	19970324
FR 2761066	B1	20001124		
FR 2764889	A1	19981224	FR 1997-7701	19970620
FR 2764889	B1	20000901		
WO 9842696	A1	19981001	WO 1998-FR288	19980216
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, ES, FI, GB, GE, GR, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MX, NA, NI, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, BG, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 6340700	B1	20020122	US 1999-381749	19990922
US 2002007062	A1	20020117	US 2001-892264	20010615
US 6630461	B2	20031007		
US 20020045753	A1	20020418	US 2001-945282	20010904
US 6599903	B2	20030729		
US 20020042511	A1	20020411	US 2001-953682	20010917
US 6586454	B2	20030701		
US 20030078420	A1	20030424	US 2002-191950	20020709
US 6809088	B2	20041026		
US 20050043937	A1	20050224	US 2004-898916	20040726
US 7125235	B2	20061017		
US 20050187272	A1	20050825	US 2005-105291	20050413
IN 2006DE01211	A	20071123	IN 2006-DE1211	20060517
PRIORITY APPLN. INFO.:			FR 1997-7701	A 19970620
			WO 1998-FR288	W 19980216
			US 1999-381749	A2 19990922
			IN 1998-DE599	A3 19980309
			WO 1998-FR1250	W 19980615

L4	ANSWER 20 OF 71	CAPLUS	COPYRIGHT 2008 ACS on STN	(Continued)
			US 1999-456205	A3 19991207
			US 2001-082264	A3 20010615
			US 2002-191950	A3 20020709
			US 2004-0808916	A3 20040726

OTHER SOURCE(S): MARPAT 136:69731
GI




AB RZZ12Z3N:C(NH2)R1 [I; R = H, (un)substituted C6H4OR3, indolyl, etc.; R1
= alkyl or (un)substituted (hetero)aryl; R3 = H, alkyl, etc.; Z = bond, CO,
alkylene(carbonyl), CONH, etc.; Z1 = bond or heterocyclylene; Z2 = bond, alkylene(oxy), etc.; Z3 = (un)substituted phenylene] were prepared Thus,
4-(O2N)C6H4NH2 was amidated by 3,5-di-tert-butyl-4-hydroxybenzoic acid

and the reduced product amidated by S-methyl-2-thiophenethiocarboximide hydroiodide to give title compound II. Data for biol. activity of I were given.

IT 214123-85-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(uses)
(preparation of N-phenylthiophenecarboxamides and analogs as NO synthase
and lipid peroxidn. inhibitors)

RN 214123-85-0 CAPLUS
CN Piperazine, 1-[4-[(imino-2-thienylmethyl)amino]phenyl]-4-[(5-methoxy-1H-indol-3-yl)acetyl]- (9CI) (CA INDEX NAME)




IT 214124-59-1P 214124-60-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of N-phenylthiophenecarboxamides and analogs as NO
synthase

L4 ANSWER 20 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
and lipid peroxidn. inhibitors)
RN 214124-59-1 CAPLUS
CN Piperazine, 1-[(5-methoxy-1H-indol-3-yl)acetyl]-4-(4-nitrophenyl)- (9CI)
(CA INDEX NAME)



RN 214124-60-4 CAPLUS
CN Piperazine, 1-(4-aminophenyl)-4-[(5-methoxy-1H-indol-3-yl)acetyl]- (9CI)
(CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


L4 ANSWER 21 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:868447 CAPLUS
DOCUMENT NUMBER: 136:5917
TITLE: Preparation of (hetero)arylacetyl-piperidinyl-benzylamines for use as tryptase inhibitors
INVENTOR(S): Astles, Peter C.; Eastwood, Paul R.; Houille, Olivier;
Levell, Julian; Pauls, Heinz; Czekaj, Mark; Liang, Guyan; Gong, Yong; Pribish, James; Neuenschwander, Kent
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., USA
SOURCE: PCT Int. Appl., 267 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001090101	A1	20011129	WO 2001-US13811	20010427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20030187020	A1	20031002	US 2001-843126	20010426
US 6977263	B2	20051220		
CA 2409827	A1	20011129	CA 2001-2409827	20010427
EP 1296972	A1	20030402	EP 2001-930925	20010427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011206	A	20030415	BR 2001-11206	20010427
HU 2003002485	A2	20031229	HU 2003-2485	20010427
HU 2003002485	A3	20070928		
JP 2004510697	T	20040408	JP 2001-586288	20010427
CN 1740169	A	20060301	CN 2005-10106304	20010427
AU 2001257413	B2	20070118	AU 2001-257413	20010427
MX 2002PA11400	A	20030523	MX 2002-PA11400	20021119
IN 2002CN01892	A	20050211	IN 2002-CN1892	20021120
NO 2002005601	A	20030106	NO 2002-5601	20021121
ZA 2002009484	A	20040223	ZA 2002-9484	20021121
HK 1057899	A1	20060728	HK 2004-100765	20040206
US 20050228018	A1	20051013	US 2005-57809	20050214
PRIORITY APPLN. INFO.:			GB 2000-12362	A 20000522
			US 2001-843126	A 20010426
			CN 2001-811952	A3 20010427
			WO 2001-US13811	W 20010427

L4 ANSWER 21 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 136:5917
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Ar = (hetero)aryl, where the two groups on the Ar ring are β to each other; R1-2 = H, alkyl; R3 = (un)substituted(hetero)aryl, arylalkenyl, cycloalkenyl, cycloalkyl, etc.; R4 = H, acyl, alkoxy, alkyloxycarbonyl, carboxy, CN, halo, etc.; n = 0 - 4] were prepared Over 300 synthetic examples were disclosed. For instance, 3-bromobenzylbromide was converted in two steps to boronate II. II was coupled to the triflate ester derivative of the enol of 4-oxo-N-benzoyloxycarbonylpiperidine (DMF, K₂CO₃, PdCl₂(dppf)•CH₂Cl₂, 80°C, 18 h) to give the corresponding bicyclic intermediate. This intermediate was deprotected and reduced to the piperidine (EtOH, 10% Pd-C/H₂, room temperature, 5 h) and coupled to 5-phenethylthiophene-2-carboxylic acid (DMF, HAPyU, iPr₂NET, room temperature, 18 h) to give III. III had Ki = 50 nM for tryptase. I are useful in the treatment of e.g., asthma and inflammatory diseases.
IT 375851-79-9P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of (hetero)arylacetyl-piperidinyl-benzylamines for use as tryptase inhibitors)
RN 375851-79-9 CAPLUS
CN Piperidine, 4-[3-(aminomethyl)phenyl]-1-[(5-bromo-1H-indol-3-yl)acetyl]-, trifluoroacetate (9CI) (CA INDEX NAME)
CM 1
CRN 375851-78-8
CMF C22 H24 Br N3 O



CM 2
CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 21 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


L4 ANSWER 22 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:851126 CAPLUS
 DOCUMENT NUMBER: 135:371760
 TITLE: Preparation of pyrazolylpyrimidines and analogs as TNF- α signaling modulators
 INVENTOR(S): Sneddon, Scott F.; Kane, John L.; Hirth, Bradford H.; Vinick, Fred; Qiao, Shuang; Nahill, Sharon R.
 PATENT ASSIGNEE(S): Genzyme Corporation, USA
 SOURCE: PCT Int. Appl., 108 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087849	A2	20011122	WO 2001-US15027	20010510
WO 2001087849	A3	20020606		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2408408	A1	20011122	CA 2001-2408408	20010510
US 20020119988	A1	20020829	US 2001-852965	20010510
US 6969728	B2	20051129		
EP 1294699	A2	20030326	EP 2001-933253	20010510
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 200353515	T	20031111	JP 2001-584245	20010510
BR 2001011158	A	20040406	BR 2001-11158	20010510
MX 2002PA10993	A	20030310	MX 2002-PA10993	20021108
NO 2002005405	A	20030109	NO 2002-5405	20021111
US 20040171617	A1	20040902	US 2004-797244	20040310
US 7034031	B2	20060425		
US 20060173010	A1	20060803	US 2005-292325	20051201


PRIORITY APPLN. INFO.:
 US 2000-203784P P 20000512
 US 2000-205213P P 20000518
 US 2001-852965 A3 20010510
 WO 2001-US15027 W 20010510
 US 2004-797244 A1 20040310

OTHER SOURCE(S): MARPAT 135:371760
 GI

L4 ANSWER 22 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB Title compds. [I; R1 = H or NH2; R2 = ZZ3(CH2)nR; R = (un)substituted Ph or -heterocyclyl; R4 = (alkyl-substituted) 2-pyridinyl or -pyrazinyl; Z = (un)substituted pyrazole-1,4-diyl; Z1,Z2 = N or CH; Z3 = O, CH2, S, SO2; n = 0-2] were prepared. Thus, 4-(Me2HC)C6H4OH was condensed with (MeCO)2CHN2 and the product cyclocondensed with 4-(2-pyridinyl)-2-pyrimidinylhydrazine to give title compound II. Data for biol. activity of I were given.
 IT 374080-55-4P 374080-62-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pyrazolylpyrimidines and analogs as TNF- α signaling modulators)
 RN 374080-55-4 CAPLUS
 CN 1H-Indole-3-acetamide, 5-bromo-N-[1-(3-cyanophenyl)-2-[[2-(4-methoxyphenyl)ethyl]amino]-2-oxoethyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 374080-62-3 CAPLUS
 CN 1H-Indole-3-acetamide, 5-bromo-N-[1-(3-cyanophenyl)-2-[[2-(4-methoxyphenyl)ethyl]amino]-2-oxoethyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI)
 (CA)

L4 ANSWER 22 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 INDEX NAME)





L4 ANSWER 23 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:762989 CAPLUS
 DOCUMENT NUMBER: 135:318419
 TITLE: Synthesis of substituted biperidines and their use as H1 antagonists
 INVENTOR(S): Lawrence, Louise; Rigby, Aaron; Sangane, Hitesh; Springthorpe, Brian
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
 SOURCE: PCT Int. Appl., 160 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077101	A1	20011018	WO 2001-SE751	20010405
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2403012	A1	20011018	CA 2001-2403012	20010405
EP 1274701	A1	20030115	EP 2001-920053	20010405
EP 1274701	B1	20050629		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001009922	A	20030218	BR 2001-9922	20010405
CN 1433411	A	20030730	CN 2001-810683	20010405
JP 2003530393	T	20031014	JP 2001-575574	20010405
NZ 521543	A	20041029	NZ 2001-521543	20010405
EP 1493743	A1	20050105	EP 2004-20599	20010405
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR			
AT 298748	T	20050715	AT 2001-920053	20010405
CN 1660839	A	20050831	CN 2004-10102245	20010405
AU 2001246997	B2	20070703	AU 2001-246997	20010405
US 20020077337	A1	20020620	US 2001-827488	20010406
US 6525070	B2	20030225		
ZA 2002007700	A	20040102	ZA 2002-7700	20020925
NO 2002004774	A	20021129	NO 2002-4774	20021003
MX 2002PA09885	A	20030327	MX 2002-PA9885	20021007
US 20040006080	A1	20040108	US 2003-341027	20030113
US 6903115	B2	20050607		
US 20040014783	A1	20040122	US 2003-436582	20030513
US 7238811	B2	20070703		
HK 1051193	A1	20051028	HK 2003-103424	20030514
US 20050171092	A1	20050804	US 2005-76773	20050310
US 7179922	B2	20070220		
US 20070179297	A1	20070802	US 2007-732411	20070403

PRIORITY APPLN. INFO.:
 GB 2000-8626 A 20000408
 GB 2000-19111 A 20000803

L4 ANSWER 23 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 SE 2000-3664 A 20001011
 CN 2001-810683 A3 20010405
 EP 2001-920053 A3 20010405
 WO 2001-SE751 W 20010405
 US 2001-827488 A3 20010406
 US 2003-341027 A1 20030113
 US 2003-436582 A3 20030513

OTHER SOURCE(S): MARPAT 135:318419
 GI




AB Title compds. I [q, s, t = 0 - 1; n, r = 0 - 5; m, p = 0 - 2; X = CH, C(O), O, S, S(O), S(O), N-; provided that when m and p are both 1 then X is not CH; Y = NHR2, OH; T = C(O), C(S), S(O), CH2; R1 = H, alkyl, aryl, heterocyclyl; R2, R47 = H, alkyl, aryl-alkyl, CO-alkyl; R3 = alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, thioaryl, thioheterocyclyl] were prepared. Examples include: data for over 600 compds., 4 solid oral dosage and 1 parenteral (general) formulations, a bioassay for Ca2+ flux, human eosinophil chemotaxis and H1 antagonism. E.g., 4-(3,4-dichlorophenoxy)piperidine was alkylated with 1-(tert-butoxycarbonyl)-4-piperidone (1,2-dichloroethane, NaBH(OAc)3, HOAc, 18 h, room temperature) to give an intermediate [1,4']bipiperidine. This

L4 ANSWER 24 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:760046 CAPLUS
 DOCUMENT NUMBER: 135:303899
 TITLE: Synthesis of heterocycloalkylbenzocyclobutanes and heteroarylbenzocyclobutanes and their use as inhibitors of serotonin and noradrenaline reuptake
 INVENTOR(S): Peglioni, Jean-Louis; Dessinges, Aimee; Goument, Bertrand; Millan, Mark; Lejeune, Francoise; Brocco, Maurice
 PATENT ASSIGNEE(S): Adir Et Compagnie, Fr.; Servier Lab
 SOURCE: Eur. Pat. Appl., 47 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1146041	A1	20011017	EP 2001-400940	20010412
EP 1146041	B1	20031112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2807753	A1	20011019	FR 2000-4742	20000413
FR 2807753	B1	20020607		
MX 2001PA03553	A	20020604	MX 2001-PA3553	20010406
JP 2001302599	A	20011031	JP 2001-111169	20010410
JP 3761796	B2	20060329		
NO 2001001862	A	20011015	NO 2001-1862	20010411
NO 318158	B1	20050207		
BR 2001001444	A	20011204	BR 2001-1444	20010411
ZA 2001003065	A	20011018	ZA 2001-3065	20010412
US 20020019380	A1	20020214	US 2001-833827	20010412
US 6420413	B2	20020716		
HU 2001001503	A2	20020529	HU 2001-1503	20010412
HU 2001001503	A3	20030228		
NZ 511092	A	20021025	NZ 2001-511092	20010412
AT 254102	T	20031115	AT 2001-400940	20010412
PT 1146041	T	20040331	PT 2001-400940	20010412
ES 2210104	T3	20040701	ES 2001-400940	20010412
AU 777825	B2	20041104	AU 2001-35187	20010412
CN 1323794	A	20011128	CN 2001-116386	20010413
CA 2344255	A1	20011013	CA 2001-2344255	20010417
CA 2344255	C	20060711		
HK 1042477	A1	20050506	HK 2002-102196	20020322
PRIORITY APPLN. INFO.:			FR 2000-4742	A 20000413

OTHER SOURCE(S): MARPAT 135:303899
 GI

L4 ANSWER 23 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 intermediate was deprotected (DCM, TFA, 4 h, room temp.) and the resulting
 bipiperidine condensed with 3-methanesulfonylbenzoic acid (THF, PYBROP, (i-Pr)2NEt, 18 h, room temp.) to give example compd. II isolated as the acetate salt. I are used in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
 IT 367497-01-6P 367498-68-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug; synthesis of substituted bipiperidines and use as H1 antagonists)
 RN 367497-01-6 CAPLUS
 CN 1,4'-Bipiperidine, 4-(3,4-dichlorophenoxy)-1'-[(5-hydroxy-1H-indol-3-yl)acetyl]- (9CI) (CA INDEX NAME)






RN 367498-68-8 CAPLUS
 CN 1,4'-Bipiperidine, 4-(3,4-dichlorophenoxy)-1'-[(5-methoxy-1H-indol-3-yl)acetyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 24 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB Title compds. I [n = 1 - 6; R1-2 = H, alkyl, aryl, arylalkyl, cycloalkyl(alkyl), alkenyl, alkynyl, heterocyclyl, etc.; X = CH:CH, O, SOO-2, NR3; Y = CH/CH2; T = cycloalkyl (mono or polycyclic), heterocyclyl] were prepared. Forty example compds. were disclosed. E.g., 6-cyano-1-methylsulfonyl-5,6-dihydrocyclobuta[f]indole (preparation given) was desulfonylated (K, MeOH, reflux, 12 h) and converted to tetrahydro derivative II (HOAc, NaCNBH3, room temperature, 2 h). II was alkylated with cyclohexanone (THF, n-BuLi, -80°C) and the resulting nitrile reduced to aminomethyl derivative III (MeOH, H2-Ra/Ni, 30 bar, 60°C, 24 h). In competitive binding assays, compds. of the invention showed affinity for serotonin reuptake binding sites, pKi > 7 and noradrenaline reuptake binding sites, pKi ≥ 6. I are used to treat depression, panic attacks, anxiety, obesity, etc.
 IT 367263-60-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; synthesis of heterocycloalkylbenzocyclobutanes and heteroarylbenzocyclobutanes and their use as inhibitors of serotonin and noradrenaline reuptake)
 RN 367263-60-3 CAPLUS
 CN 1H-Indole-3-acetamide, N-[[[1,2-dihydro-1-(1-hydroxycyclopentyl)cyclobuta[b]naphthalen-1-yl]methyl]-5-fluoro-N-methyl]- (CA INDEX NAME)


L4 ANSWER 24 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 25 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:667283 CAPLUS
 DOCUMENT NUMBER: 136:179
 TITLE: From Hit to Lead. Combining Two Complementary Methods for Focused Library Design. Application to μ Opiate Ligands
 AUTHOR(S): Poulain, Rebecca; Horvath, Dragos; Bonnet, Beatrice; Eckhoff, Christian; Chapelain, Beatrice; Bodinier, Marie-Christine; Deprez, Benoit
 CORPORATE SOURCE: Department of Chemistry, CEREP, Lille, F-59000, Fr.
 SOURCE: Journal of Medicinal Chemistry (2001), 44(21), 3378-3390
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:179
 GI



AB Compound I obtained by random screening and displaying a micromolar activity on the μ opiate receptor was chosen as a starting point for optimization. Two complementary concepts of similarity were used for the design of analogs and compared. These are based, resp., on a computer-aided comparison of pharmacophoric patterns and on topol. similarity. The structure-activity relationships are discussed in light of both similarity concepts. An N-methyl-3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decyl)acetamide derivative, designed by combining the structure-activity relationships enlightened by each method, has a subnanomolar affinity for μ (h) receptor (IC₅₀ = 0.9 nM). It is a promising lead, allowing the design of a new series of analogs substituted at the N-3 of the spirocycle moiety.
 IT 372956-13-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (combining two complementary methods for focused library design and application to μ opiate ligands)
 RN 372956-13-3 CAPLUS
 CN Piperazine, 1-[(5-bromo-1H-indol-3-yl)acetyl]-4-(7-nitro-2,1,3-benzoxadiazol-4-yl)- (9CI) (CA INDEX NAME)


L4 ANSWER 25 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 26 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:662562 CAPLUS
 DOCUMENT NUMBER: 135:352346
 TITLE: From Hit to Lead. Analyzing Structure-Profile Relationships
 AUTHOR(S): Poulain, Rebecca; Horvath, Dragos; Bonnet, Beatrice; Eckhoff, Christian; Chapelain, Beatrice; Bodinier, Marie-Christine; Deprez, Benoit
 CORPORATE SOURCE: Department of Chemistry, CEREP, Lille, F-59000, Fr.
 SOURCE: Journal of Medicinal Chemistry (2001), 44(21), 3391-3401
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Two compds., (piperidine and piperazine carboxylic acid derivs.) obtained by random screening, and displaying micromolar activities on the μ opiate receptor were used as starting points for optimization. In that work, the traditional concept of the activity of a compound (related to one or a few targets) was extended to the comprehensive pharmacol. profile of that compound on more than 70 receptors, transporters, and channels relevant to a CNS-oriented project. Using the two complementary design strategies based on two similarity concepts described in the previous paper, we have obtained analogs with IC₅₀ values ranging between 0.9 nM and a few micromolar on the μ receptor and displaying qual. different profiles. We discuss here, both on a case-by-case basis and from a statistical standpoint, the pharmacol. profiles in light of the two similarity concepts.
 IT 372956-13-3
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (piperidine- and piperazine carboxylic acid derivative opiod receptor structure-activity relationship, and compound preparation)
 RN 372956-13-3 CAPLUS
 CN Piperazine, 1-[(5-bromo-1H-indol-3-yl)acetyl]-4-(7-nitro-2,1,3-benzoxadiazol-4-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 26 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


L4 ANSWER 27 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:565002 CAPLUS
DOCUMENT NUMBER: 135:152713
TITLE: Aromatic amides as novel melanocortin receptor agonists and antagonists
INVENTOR(S): Lundstedt, Torbjorn; Skottner, Anna; Seifert, Elisabeth; Starchenkov, Igor; Trapencieris, Peteris; Kauss, Valerjans; Kalvins, Ivars; Boman, Arne
PATENT ASSIGNEE(S): Melacure Therapeutics AB, Swed.
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXX22
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055106	A2	20010802	WO 2001-GB346	20010129
WO 2001055106	A3	20020321		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2398728	A1	20010802	CA 2001-2398728	20010129
BR 2001007893	A	20021105	BR 2001-7893	20010129
EP 1254114	A2	20021106	EP 2001-946850	20010129
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003520850	T	20030708	JP 2001-555048	20010129
ZA 2002005886	A	20040621	ZA 2002-5886	20020723
MX 2002PA07289	A	20030922	MX 2002-PA7289	20020726
US 20030195212	A1	20031016	US 2002-182192	20021120
PRIORITY APPLN. INFO.:			GB 2000-1948	A 20000128
			GB 2000-2060	A 20000128
			WO 2001-GB346	W 20010129

OTHER SOURCE(S): MARPAT 135:152713
AB The present invention relates to novel aromatic amides (I; B-E-X-N(R8)-C(O)-Y-F-A and pharmacol. active salts thereof) and to the use of these amides for the treatment of obesity, anorexia, inflammation, mental disorders and other diseases associated with the melanocortin receptors or related systems, e.g. the melanocyte stimulating hormones. In I: E and F are independently a saturated or unsatd., acyclic hydrocarbon group having 1-5 C atoms. X and Y are independently methylene; one of X and Y are absent (i.e. a single bond); or X can be -CH(QR10)- and/or Y can

L4 ANSWER 27 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
be -CH(MR9)- (M and Q are independently a satd. or unsatd., straight or branched chain acyclic hydrocarbon group with 1-6 C atoms; or M and/or Q are absent (i.e. M and/or Q are single bonds)). R8, R9 and R10 are H, -PR4, -C(O)DR4 (P and D are independently a satd. or unsatd., straight or branched chain acyclic hydrocarbon group having 1-6 C atoms; or D is absent (i.e. D is a single bond)). R4 is hydroxy, Me, cyclohexyl, cyclopentyl, aminoguanidine, guanidine, carboxy, or (possibly substituted)
amino, carbamoyl, alkoxy, alkoxycarbonyl, acyl, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, Ph, isoindolyl, indenyl, pyridinyl, indolyl, pyrrolyl, cyclopentadienyl wherein R4 in R8, R9 and R10 may be the same or different. A and B are the same or different and are (possibly substituted) quinolinyl, isoquinolinyl, isoindolyl, naphthyl, pyridinyl, indolyl, pyrazinyl, cyclopentadienyl, pyrimidinyl, Ph, indenyl. Several claimed compds. (N-(3-aminopropyl)-3-(1H-indol-3-yl)-2-(2-naphthalen-1-ylacetylamino)propionamide hydrochloride (1:1.2), N-[1-[benzyl(4-guanidinobutyl)carbamoyl]-2-(1H-indol-3-yl)ethyl]-4-phenylbutyramide monohydrochloride, N-benzyl-N-(4-guanidinobutyl)-3-(1H-indol-3-yl)-2-(2-naphthalen-2-ylacetylamino)propionamide monohydrochloride, N-[1-(9-ethyl-9H-carbazol-3-yl)carbamoyl]-2-(1H-indol-3-yl)ethyl]-4-guanidinobutylamide monohydrochloride, 4-amino-N-[1-(9-ethyl-9H-carbazol-3-yl)carbamoyl]-2-(1H-indol-3-yl)ethyl]butyramide monohydrochloride, 2-(3-aminopropionylamino)-N-(9-ethyl-9H-carbazol-3-yl)-3-(1H-indol-3-yl)propionamide monohydrochloride) were tested (results given) for affinity for melanocortin receptors (MC1, MC3, MC4, MC5) and/or influence on cAMP. In vivo effects on food intake and anti-inflammatory effects were also detd. on selected compds. Two example preps. are given.
IT 352277-28-2P
RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aromatic amides as novel melanocortin receptor agonists and antagonists and their preparation)
RN 352277-28-2 CAPLUS
CN 1H-Indole-3-acetamide, 5-bromo-N-[1-(2-bromophenyl)-2-(cyclohexylamino)-2-oxoethyl]-N-[2-(dimethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




L4 ANSWER 28 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:237851 CAPLUS
 DOCUMENT NUMBER: 134:252261
 TITLE: Preparation of heterocyclylcarbonylamino-modified phenylpropanes and their use as integrin VLA-4 binding inhibitors
 INVENTOR(S): Yokota, Masaki; Nagashima, Shinya; Sugane, Takashi; Igarashi, Susumu; Moridaira, Koichiro; Miura, Ayanori;
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001089448	A	20010403	JP 1999-271096	19990924
PRIORITY APPLN. INFO.:			JP 1999-271096	19990924

OTHER SOURCE(S): MARPAT 134:252261
 AB 4-RcCH₂CONRdC6H₄CH(NReCORb)CH₂CO₂Ra [Ra = H, ester residue (prodrug); Rb = morpholino, 2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl; Rc = (un)substituted (hetero)aryl; Rd, Re = H, lower alkyl], useful for treatment of asthma, allergy, rheumatoid arthritis, autoimmune disease, rejection, inflammation, arteriosclerosis, cancer metastasis, diabetes, etc., are prepared Thus, a solution of 5-methoxyindoleacetic acid and Et (RS)-3-(4-aminophenyl)-3-[(morpholine-4-carbonyl)amino]propanoate in DMF was treated with WSC.HCl and HOBt at room temperature for 20 h to give the corresponding amide.


IT 331681-06-2P 331681-19-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclylcarbonylamino-modified phenylpropanes as integrin VLA-4 binding inhibitors for treatment of diseases)
 RN 331681-06-2 CAPLUS
 CN Benzenepropanoic acid, 4-[[[(5-methoxy-1H-indol-3-yl)acetyl]methylamino]-β-[(4-morpholinylcarbonyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 29 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:83714 CAPLUS
 DOCUMENT NUMBER: 134:311061
 TITLE: Synthesis of 5-(sulfamoylmethyl)indoles
 AUTHOR(S): Bosch, J.; Roca, T.; Armengol, M.; Fernandez-Fornier, D.
 CORPORATE SOURCE: Laboratory of Organic Chemistry, Faculty of Pharmacy, University of Barcelona, Barcelona, 08028, Spain
 SOURCE: Tetrahedron (2001), 57(6), 1041-1048
 CODEN: TETRA; ISSN: 0040-4020
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:311061
 AB The synthesis of 5-(sulfamoylmethyl)indoles bearing a two-carbon chain at C-3 (aminoethyl, acetate, hydroxyethyl, ethyl) either by the Grandberg modification of the Fischer indolization or by intramol. Heck reaction of suitable o-halotrifluoroacetanilides is reported.
 IT 334981-21-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 5-(sulfamoylmethyl)indoles)
 RN 334981-21-4 CAPLUS
 CN 1H-Indole-3-acetamide, 5-[[[(1,1-dimethylethyl)amino]sulfonyl]methyl]-N,N-dimethyl- (CA INDEX NAME)




REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L4 ANSWER 28 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 331681-19-7 CAPLUS
 CN Benzenepropanoic acid, 4-[[[(5-methoxy-1H-indol-3-yl)acetyl]methylamino]-β-[(4-morpholinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 30 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:77719 CAPLUS
 DOCUMENT NUMBER: 134:222897
 TITLE: Cascading single-step stereoselective construction of the α-alloyohimbine framework: a new synthesis of (-)-nitrarine
 AUTHOR(S): Sakaami, Hideki; Ogasawara, Kunio
 CORPORATE SOURCE: Pharmaceutical Institute, Tohoku University, Sendai, 980-8578, Japan
 SOURCE: Heterocycles (2001), 54(1), 43-47
 CODEN: HETCYM; ISSN: 0385-5414
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:222897
 GI



AB (-)-Nitrarine (I, R = H) and its 10-methoxy analog (I, R = OMe) having an α-alloyohimbine framework have been constructed stereoselectively in a cascading single step sequence from chiral mono-substituted N-2-(3-indolyl)ethyltetrahydropyridine precursors under the Heck reaction conditions.
 IT 329771-40-6P 329771-41-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis of (-)-nitrarine via a cascading single-step stereoselective construction of the α-alloyohimbine framework)
 RN 329771-40-6 CAPLUS
 CN Pyridine, 1,2,3,6-tetrahydro-1-[(5-methoxy-1H-indol-3-yl)acetyl]-3-(3-methoxy-2-propenyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 329771-41-7 CAPLUS

L4 ANSWER 30 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2-Pentenoic acid, 2-bromo-5-[(3S)-1,2,3,6-tetrahydro-1-[(5-methoxy-1H-indol-3-yl)acetyl]-3-pyridinyl]-, methyl ester, (2Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

14 ANSWER 31 of 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:772622 CAPLUS
DOCUMENT NUMBER: 133:335167
TITLE: Preparation of diaryl carboxylic acids and
derivatives
as peroxisome proliferator-activated receptor
ligands.
INVENTOR(S): Jayyosi, Zaid; McGeehan, Gerard M.; Kelley, Michael
F.; Labaudiniere, Richard F.; Zhang, Litao;
Groneberg,
Robert D.; McGarry, Daniel G.; Caulfield, Thomas J.;
Minnich, Anne; Bobko, Mark
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., USA
SOURCE: ECT Int. Appl., 167 pp.
CODEN: FIFXK2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064888	A1	200011102	WO 2000-US11833	200004228
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, ES, FI, FR, GB, GD, GE, GH, GM, HR, HU, IT, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, TJ, TM, TR, TT, UA, UG, UJ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NG, TD, TG				
CA 2370250	A1	200011102	CA 2000-2370250	200004228
EP 1717187	A1	20020206	EP 2002-928698	200004228
EP 1717187	B1	20070725		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LT, LU, NL, SE, MC, PT, IE, SI, LT, CY, FI				
BR 2000010605	A	20020213	BR 2000-10605	200004228
HU 2002001291	A2	20020928	HU 2002-1291	200004228
HU 2002001291	A3	20021128		
EE 200100556	A	20030217	EE 2001-556	200004228
NZ 515086	A	20030313	NZ 2000-515086	200004228
AU 781264	B2	20050512	AU 2000-46895	200004228
RU 2267484	C2	20060610	RU 2001-132080	200004228
AT 156037	A	20070815	AT 2007-156037	200004228
CN 101070316	A	20071114	CN 2007-10112173	200004228
ES 2287016	T3	20071216	ES 2000-928698	200004228
US 6635655	B1	20031021	US 2000-662649	20000914
NO 2001005075	A	20011123	NO 2001-5075	20011018
NO 323643	B1	20070618		
ZA 2001008798	A	20030305	ZA 2001-8798	200110124
MX 2001PA10880	A	20020506	MX 2001-PA10880	20011026
HR 2001000795	A1	20030215	HR 2001-795	20011026
HK 1045515	A1	20080201	HK 2002-107034	20020926
PRIORITY APPL. INFO.:			US 1999-134155P	P 199904228

L4 ANSWER 31 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2000-806908 A3 20000428
WO 2000-US11833 W 20000428

OTHER SOURCE(S): MARPAT 133:335167

AB Ar1(CR1R2)AA(CR3R4)baR2(CR5R6)c(CR7R8)dEZ[Ar1, Ar2 = aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocycloalkenyl, fused arylheterocycloalkyl, heteroaryl, fused heteroarylheterocycloalkyl, fused heteroarylheterocycloalkyl, fused heteroarylheterocycloalkyl, etc.; A = O, S, SO, SO2, NR13, CO, NR14CO, CNR15, NR14CNR15, CR14N, bond, etc.; B = O, S, NR19, bond, CO, NR20CO, CNR20; E = bond, CH2CH2; F = R21OC2, R21OC, cycloimide, cyano, R21O2SNHCO, R21O2SNH, (R21)NCO, R21O-substituted 2,4-haloalolidinediyl, tetrazolyl; a, d = 0-6; b, c = 0-4; R1, R3, R5, R7 = H, halo, alkyl, CO2H, alkoxycarbonyl, aralkyl; R2, R4, R6, R8 = (CH2)qx;

Q = 0-3; R14, R15, R20 = H, alkyl, aralkyl, CO, alkoxycarbonyl; R14R15 = atoms to form a 5-6 membered azaheterocyclyl; R19, R21 = H, aryl, alkyl, cycloalkyl, aralkyl; were prepared as agonists or antagonists of the

PPAR receptor (no data). Thus, 3-(quinolin-2-ylmethoxy)propan-1-ol in

DMPU/THF at 0° was treated with NaH and then with Me 2-bromomethyl-6-methylbenzoate followed by stirring overnight at room temperature to

give Me 2-methyl-6-[3-(quinolin-2-ylmethoxy)propoxymethyl]benzoate.

IT 141835-21-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaryl carboxylic acids and derivs. as PPARG ligands)


RN 141835-21-4 CARBUS

CN 2-Propenoic acid, 3-[3-[2-[methyl(2-phenylethyl)amino]-2-oxoethyl]-5-(phenylethoxy)-1H-indol-1-yl]- [CA INDEX NAME]




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 2000:72637 CAPLUS
 DOCUMENT NUMBER: 134:86116
 TITLE: Design, Synthesis, and Biological Evaluation of
 Potent and Selective Amidino Bicyclic Factor Xa Inhibitors
 AUTHOR(S): Han, Qi; Dominguez, Celia; Stouten, Pieter F. W.;
 Park, Jeongsook M.; Duffy, Daniel E.; Galemno, Robert
 A., Jr.; Rossi, Karen A.; Alexander, Richard S.;
 Smallwood, Angela M.; Wong, Pancras C.; Wright,
 Matthew M.; Leuttgen, Joseph M.; Knabb, Robert M.;
 Wexler, Ruth R.
 CORPORATE SOURCE: DuPont Pharmaceuticals Company, Wilmington, DE,
 19880-0500, USA
 SOURCE: Journal of Medicinal Chemistry (2000), 43 (23),
 4398-4415
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 134:86116
 GI:




AB	A novel series of factor Xa (FXa) inhibitors incorporating an amidino 6,5-fused bicyclic moiety, e.g. I (R = Me, F, Cl, Br, etc.), has been designed and synthesized based on mol. modeling studies. Structure-activity relationship (SAR) studies have led to selective subnanomolar FXa inhibitors. The most potent FXa inhibitor in this series
	I (R = Br) has a potent inhibition constant (K _i = 0.3 nM), is 350-fold selective for FXa over trypsin, and also shows good in vivo efficacy in a rabbit arterio-venous thrombosis model (ID ₅₀ = 0.14 μmol/kg/h). An X-ray crystal structure of I (R = Br) complexed to bovine trypsin was completed, and its binding mode with FXa has been proposed based on modeling with human Des-Gla-FXa.
IT	202124-24-1P
(Biological	RL: BAC (Biological activity or effector, except adverse); BSU study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
	(preparation and antithrombotic activities of amidino bicyclic factor
Xa	inhibitors)
RN	202124-24-1. CAPLUS

L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 1H-Indole-3-acetamide, 5-(aminomethyl)-N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-N-methyl- (CA INDEX NAME)



IT 316364-41-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and antithrombotic activities of amidino bicyclic factor


Xa inhibitors)
 RN 316364-41-7 CAPLUS
 CN 1H-Indole-3-acetamide,
 N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-5-cyano-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 33 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:31350 CAPLUS
 DOCUMENT NUMBER: 132:78470
 TITLE: Preparation of spiro-substituted azacycles as neurokinin antagonists
 INVENTOR(S): Maccoss, Malcolm; Mills, Sander G.; Shah, Shrenik K.; Chiang, Yuan-ching P.; Dunn, Patrick T.; Koyama,
 Hiroo
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: U.S., 49 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6013652	A	20000111	US 1997-985338	19971204
PRIORITY APPLN. INFO.:			US 1997-985338	19971204
OTHER SOURCE(S):		MARPAT 132:78470		
GI				



AB The title compds. [I; 1, m = 0-5 (with the proviso that 1 + m = 1-5); R1 =
 H, alkyl, alkenyl, etc.; W = a bond, (un)substituted alkyl; Q = O, S, SO,
 SO2, NR2 (with the proviso that when W = a bond and X = alkyl, then Q
 must
 be NR2; R2 = H, alkyl, etc.); X = a bond, (un)substituted alkyl, NHCO,
 etc.; YZ considered together are 2 adjoining atoms of Ph, naphthyl,
 heteroaryl, the nitrogen in one of the rings is optionally quaternized
 with alkyl or phenylalkyl or is optionally present as an N-oxide],
 tachykinin receptor antagonists useful in the treatment of inflammatory
 diseases, pain or migraine, and asthma, were prepared. E.g., a 2-step
 synthesis of 3-(S)-II was given. In particular compds. I are shown to be
 neurokinin antagonists, and, e.g., they have been found to displace
 radioactive ligand for the NK-1 receptor at 0.01 nM to 1.0 μ M, for the
 NK-2 receptor, 0.01 nM to 5 μ M, and for the NK-3 receptor, 1.0 nM to
 10 μ M.

L4 ANSWER 33 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 IT 167485-09-8P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
 (Reactant or reagent); USES (Uses)
 (preparation of spiro-substituted azacycles as neurokinin antagonists)
 RN 167485-09-8 CAPLUS
 CN Spiro[3H-indole-3,4'-piperidine],
 1'-[(5-fluoro-1H-indol-3-yl)acetyl]-1,2-
 dihydro-1-(methylsulfonyl)- (3CI) (CA INDEX NAME)




REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:635463 CAPLUS
 DOCUMENT NUMBER: 131:243191
 TITLE: Spiro-substituted azacycles as modulators of
 chemokine
 receptor activity
 INVENTOR(S): Mills, Sander G.; MacCoss, Malcolm; Springer, Martin
 S.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: U.S., 97 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5962462	A	19991005	US 1997-989947	19971212
PRIORITY APPLN. INFO.:			US 1996-32735P	19961213
			US 1996-33558P	19961220

OTHER SOURCE(S): MARPAT 131:243191
 GI



AB The invention is directed to spiro-substituted azacycles which are useful
 as modulators of chemokine receptor activity. Specifically, I [R1 = H,
 (un)substituted alk(en/yn)yl; W = bond, (un)substituted alkylene; Q =
 (un)substituted NH, O, S, S(O), SO2; X = bond, (un)substituted alkylene,
 S, S(O), NHCO, OC(O), etc.; YZ = fused aryl or heteroaryl nucleus; m, n =
 0 to 5; (m+n) = 1 to 5] were prepared. The compds. are useful as
 modulators
 of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4,
 CCR-5, CXCR-3, and/or CXCR-4 (no data), and are thereby useful as
 antiinflammatory and immunomodulating agents. Use for the treatment of
 HIV infection and/or AIDS is claimed specifically. For instance,
 1'-methylspiro[indoline-3,4'-piperidine] underwent a sequence of

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 N-benzoyloxycarbonylation (71%), N'-demethylation (73%), reductive
 of N'-alkylation with a corresponding polyfunctional aldehyde, and removal
 of the benzoyloxycarbonyl protecting group, to give title compd. II.
 IT 167485-09-8P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
 (Reactant or reagent); USES (Uses)
 (target compound; preparation of spiro-substituted azacycles as
 modulators of chemokine receptor activity)
 RN 167485-09-8 CAPLUS
 CN Spiro[3H-indole-3,4'-piperidine],
 1'-[(5-fluoro-1H-indol-3-yl)acetyl]-1,2-
 dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 36 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 ACCESSION NUMBER: 1999:205361 CAPLUS
 DOCUMENT NUMBER: 130:252241
 TITLE: Preparation of amidinoindoles and analogs as factor
 Xa inhibitors
 INVENTOR(S): Dominguez, Celia; Han, Qi; Duffy, Daniel Emmett;
 Park, Jeongsok Maria; Quan, Mimi Lifan; Rossi, Karen
 Anita;
 PATENT ASSIGNEE(S): Wexler, Ruth Richmond
 SOURCE: Dupont Pharmaceuticals Company, USA
 U.S., 46 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5886191	A	19990323	US 1997-916736	19970818
US 6043257	A	20000328	US 1998-176037	19981021
PRIORITY APPLN. INFO.:			US 1997-916736	A3 19970818

OTHER SOURCE(S): MARPAT 130:252241
 GI




AB Title compds., e.g., I [R1 = H or Me; R2 = (CH2)nZZ1R; R = C(:NH)NH2,
 CH2Ph, C6H4(SO2NHR4)-2, etc.; R3 = C(:NH)NH2, cyano, etc.; R4 = alkyl; Z
 = CO, CONH, etc.; Z1 = C6H4, CH2C6H4, pyridine-2,4-diyl, etc.; n = 0 or 1;
 dashed line = optional addnl. bond] were prepared as factor Xa inhibitors
 (no data). Thus, 5-cyanoindole was acylated by (COCl)2 and the product
 converted in 3 steps to 5-cyanoindole-3-acetic acid which was amidated by
 4-(2-aminosulfonylphenyl)-2-pyridinamine to give, in 2 addnl. steps, I
 [R1 = H, R2 = CH2CONH21C6H4(SO2NH2)-2, R3 = C(:NH)NH2, Z1 =
 pyridine-2,4-diyl,
 dashed line = bond].
 IT 202123-90-8P 202123-94-2P 202123-96-4P
 202123-97-5P 202123-98-6P 202124-01-4P
 202124-04-7P 202124-24-1P 202124-28-5P
 202126-86-1P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 35 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:306450 CAPLUS
 DOCUMENT NUMBER: 131:102423
 TITLE: A new synthesis of psilocin
 AUTHOR(S): Sakagami, Hideki; Ogasawara, Kunio
 CORPORATE SOURCE: Pharmaceutical Institute, Tohoku University, Sendai,
 980-8578, Japan
 SOURCE: Heterocycles (1999), 51(5), 1131-1135
 CODEN: HETCYM; ISSN: 0385-5414
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 131:102423
 GI




AB A new route to the hallucinogenic alkaloid psilocin (I), isolated from
 the mushroom species *Psilocybe mexicana*, has been established.
 IT 52335-79-2P, N,N-Dimethyl-4-methoxyindole-3-acetamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (new synthesis of psilocin from methoxy aniline dimethoxydihydrofuran)
 RN 52335-79-2 CAPLUS
 CN 1H-Indole-3-acetamide, 4-methoxy-N,N-dimethyl- (CA INDEX NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 36 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (prepn. of amidinoindoles and analogs as factor Xa inhibitors)
 RN 202123-90-8 CAPLUS
 CN Piperazine, 1-[[5-(aminoiminomethyl)-1H-indol-3-yl]acetyl]-4-[(4-
 methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 202123-94-2 CAPLUS
 CN Piperazine, 1-[[5-(aminoiminomethyl)-1H-indol-3-yl]acetyl]-4-
 [(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 202123-96-4 CAPLUS
 CN Piperazine, 1-[[5-(aminoiminomethyl)-1H-indol-3-yl]acetyl]-4-
 (phenylmethyl)- (9CI) (CA INDEX NAME)




RN 202123-97-5 CAPLUS
 CN Glycine, N-[[5-(aminoiminomethyl)-1-methyl-1H-indol-3-yl]acetyl]-N-[[3-
 (aminoiminomethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 36 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 202123-98-6 CAPLUS
 CN Glycine, N-[[5-(aminoiminomethyl)-1-methyl-1H-indol-3-yl]acetyl]-N-[[4-(aminoiminomethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 202124-01-4 CAPLUS
 CN Piperazine, 1-[[5-(aminoiminomethyl)-1-methyl-1H-indol-3-yl]acetyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 202124-04-7 CAPLUS
 CN Piperazine, 1-[[5-(aminoiminomethyl)-1H-indol-3-yl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 36 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 202124-97-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of amidinoindoles and analogs as factor Xa inhibitors)
 RN 202124-97-8 CAPLUS
 CN Piperazine, 1-[[5-(cyano-1H-indol-3-yl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)




IT 202124-91-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of amidinoindoles and analogs as factor Xa inhibitors)
 RN 202124-91-2 CAPLUS
 CN Piperazine, 1-[[5-(cyano-1H-indol-3-yl)acetyl]-4-[[4-(methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 36 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 202124-24-1 CAPLUS
 CN 1H-Indole-3-acetamide, 5-(aminoiminomethyl)-N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-N-methyl- (CA INDEX NAME)



RN 202124-28-5 CAPLUS
 CN 1H-Indole-3-acetamide, 5-(aminoiminomethyl)-N-methyl-N-[2'-(methylamino)sulfonyl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 202126-86-1 CAPLUS
 CN Piperidine, 1-[[5-(aminoiminomethyl)-1H-indol-3-yl]acetyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:96240 CAPLUS
 DOCUMENT NUMBER: 130:153571
 TITLE: Preparation of indole and 2,3-dihydroindole derivatives as potent serotonin reuptake inhibitors and 5-HT1A receptor antagonists
 INVENTOR(S): Moltzen, Ejner Knud; Perregaard, Jens Kristian; Mikkelsen, Ivan; Smith, Garrick Paul
 PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9905140	A1	19990204	WO 1998-DK336	19980720
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
ZA 9806237	A	19990331	ZA 1998-6237	19980714
CA 2297825	A1	19990204	CA 1998-2297825	19980720
CA 2297825	C	20060314		
AU 9885340	A	19990216	AU 1998-85340	19980720
AU 736596	B2	20010802		
EP 1007523	A1	20000614	EP 1998-936270	19980720
EP 1007523	B1	20031022		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200000231	T2	20000721	TR 2000-231	19980720
BR 9810790	A	20000725	BR 1998-10790	19980720
HU 2000002830	A2	20010928	HU 2000-2830	19980720
HU 2000002830	A3	20011029		
HU 225101	B1	20060628		
NZ 502252	A	20010928	NZ 1998-502252	19980720
JP 2003524571	T	20030819	JP 2000-504136	19980720
IL 133990	A	20030917	IL 1998-133990	19980720
CN 1127501	B	20031112	CN 1998-807554	19980720
AT 252575	T	20031115	AT 1998-936270	19980720
PT 1007523	T	20040227	PT 1998-936270	19980720
ES 2206963	T3	20040516	ES 1998-936270	19980720
CN 1515568	A	20040728	CN 2003-2003106002	19980720
CN 1515569	A	20040728	CN 2003-2003106003	19980720
CZ 295937	B6	20051214	CZ 2000-285	19980720
SK 284866	B6	20060105	SK 2000-95	19980720
PL 190924	B1	20060228	PL 1998-338194	19980720
IN 1998MA01631	A	20050304	IN 1998-MA1631	19980722
MX 200000700	A	20010131	MX 2000-700	20000120
NO 2000000372	A	20000321	NO 2000-372	20000125
NO 318610	B1	20050418		
US 6476035	B1	20021105	US 2000-491204	20000125
BG 104148	A	20010531	BG 2000-104148	20000210

L4 ANSWER 37 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
BG 64904 B1 20060831
HK 1030220 A1 20041126 HK 2001-101274 20010221
US 20030018050 A1 20030123 US 2002-223046 20020816
US 6727263 B2 20040427
HK 1066806 A1 20070713 HK 2004-109852 20041213
HK 1066807 A1 20070817 HK 2004-109853 20041213
PRIORITY APPLN. INFO.: DK 1997-892 A 19970725

US 1997-53713P P 19970725
WO 1998-DK336 W 19980720
US 2000-491204 A3 20000125

OTHER SOURCE(S): MARPAT 130:153571
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; X = O, S, CR4R5; Y = CR6R7, CR6R7CR8R9, CR6:CR7; XY
= CR4:CR5, CR4:CR5CR6R7; Z = O, S; W = N, C, CH; A = II-IV; R1-R3,
R11-R17

= H, halo, CF3, etc.; R4-R9 = H, alkyl; R11 = H, alkyl, alkenyl, etc.]
and

their salts which are potent serotonin reuptake inhibitors and have
5-HT1A
receptor antagonistic activity, were prepared. Thus, treatment of
5-chloroindole with oxalyl chloride in Et2O followed by reaction of the
resulting 2-(5-chloro-1H-indol-3-yl)-2-oxoacetyl chloride with
1-(1,4-benzodioxan-5-yl)piperazine, and then reduction of the
intermediate
with LiAlH4 in THF afforded V.oxalate which showed IC50 of 5.0 nM against
serotonin reuptake.

IT 220251-80-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(preparation of indole and 2,3-dihydroindole derivs. as potent
serotonin

reuptake inhibitors and 5-HT1A receptor antagonists)

RN 220251-80-9 CAPLUS

CN Piperazine, 1-[(6-chloro-1H-indol-3-yl)acetyl]-4-(2,3-dihydro-1,4-
benzodioxin-5-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 37 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 38 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:672540 CAPLUS
DOCUMENT NUMBER: 129:302557
TITLE: Novel 2-[(iminomethyl)amino]phenyl derivatives useful
as inhibitors of NO synthase and lipid peroxidation,
their preparation, their application as medicines,
and
pharmaceutical compositions containing them
INVENTOR(S): Chabrier De Lassauniere, Pierre-Etienne; Auvin,
Serge;
PATENT ASSIGNEE(S): Bigg, Dennis; Auguet, Michel
Societe De Conseils De Recherches Et D'Applications
Scientifiques (S.C.R.A.S, Fr.
SOURCE: FCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842696	A1	19981001	WO 1998-FR288	19980216
W: AL, AM, AT, AU, AZ, BA, BE, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HT, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2761066	A1	19980925	FR 1997-3528	19970324
FR 2761066	B1	20001124		
CA 2285037	A1	19981001	CA 1998-2285037	19980216
CA 2285037	C	20070213		
AU 9864043	A	19981020	AU 1998-64043	19980216
AU 733173	B2	20010510		
EP 973763	A1	20000126	EP 1998-909540	19980216
EP 973763	B1	20030528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
BR 9808427	A	20000523	BR 1998-8427	19980216
TR 9902382	T2	20000621	TR 1999-2382	19980216
HU 2000001438	A2	20010528	HU 2000-1438	19980216
HU 2000001438	A3	20010928		
JP 2001518114	T	20011009	JP 1998-545109	19980216
RU 2183211	C2	20020610	RU 1999-122343	19980216
SK 282773	B6	20021203	SK 1999-1298	19980216
AT 241612	T	20030615	AT 1998-909540	19980216
PT 973763	T	20031031	PT 1998-909540	19980216
ES 2200318	T3	20040301	ES 1998-909540	19980216
IL 131915	A	20040601	IL 1998-131915	19980216
CZ 297562	B6	20070207	CZ 1999-3373	19980216
PL 194688	B1	20070629	PL 1998-335838	19980216
TW 587080	B	20040511	TW 1998-87103327	19980307
IN 1998DE00599	IN	19971012	IN 1998-DE599	19980309
ZA 9802203	A	19980916	ZA 1998-2203	19980316
US 6340700	B1	20020122	US 1999-381749	19990922
NO 9904620	A	19991110	NO 1999-4620	19990923

L4 ANSWER 38 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
NO 324065 B1 20070806
MX 9908724 A 20000630 MX 1999-8724 19990923
US 6335445 B1 20020101 US 1999-456205 19991207
HK 1027563 A1 20050107 HK 2000-106581 20001018
US 20020007062 A1 20020117 US 2001-882264 20010615
US 6630461 B2 20031007
US 20020045753 A1 20020418 US 2001-945782 20010904
US 6599903 B2 20030729
US 20020042511 A1 20020411 US 2001-953682 20010917
US 6586454 B2 20030701
US 20030078420 A1 20030424 US 2002-191950 20020709
US 6809088 B2 20041026
US 20050043397 A1 20050224 US 2004-898916 20040726
US 7122535 B2 20061017
US 20050187272 A1 20050825 US 2005-105291 20050413
IN 2006DE01211 A 20071123 IN 2006-DE1211 20060517
PRIORITY APPLN. INFO.: FR 1997-3528 A 19970324
FR 1997-7701 A 19970620
WO 1998-FR288 W 19980216
IN 1998-DE599 A3 19980309
WO 1998-FR1250 W 19980615
US 1999-381749 A2 19990922
US 1999-456205 A3 19991207
US 2001-882264 A3 20010615
US 2002-191950 A3 20020709
US 2004-898916 A3 20040726


OTHER SOURCE(S): MARPAT 129:302557
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention concerns novel 2-[(iminomethyl)amino]phenyl derivs., their
preparation, their application as medicines, and pharmaceutical compns.
containing

them. In particular, compds. I [A = radical G1, G2, or G3; R1, R2 = H,
OH, alkyl, alkoxy; R3 = H, alkyl, COR4; R4 = alkyl; R5 = H, OH, alkyl,
alkoxy; B = alkyl, (un)substituted 5- or 6-membered aryl or heteroaryl
(O,
S, or N); X = Z1, Z1CO, CH:CHCO, Z1NR3CO, Z1NR3CS, Z1NR3SO2, bond; Y =
Z2Q, piperazine, homopiperazine, 2-methylpiperazine, 2,5-
dimethylpiperazine, 4-aminopiperidine, NR3Z2Q, NR3COZ2Q, NR3NHCOZ2,
NHNH2, NR3OZ2, NR3SO2NR3Z2, OZ2Q, COOZ2Q, or SZ2Q; Q = bond, OZ3, R3NZ3,
or SZ3; Z1, Z2, Z3 = bond, alkylene, and preferably (CH2)m; m = 0-6; R6 =
H, OH] and salts are claimed. The compds. are inhibitors of NO
synthases,

L4 ANSWER 38 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
and are also antioxidants which inhibit lipid peroxidn. Approx. 60
examples of salts and free bases were prepd. and/or claimed. For
instance, the benzopyran deriv. Trolox® was activated with
1,1'-carbonyldiimidazole and amidated with 1-(4-nitrophenyl)piperazine
(79%), followed by hydrogenation of the nitro group to amino (66%),
condensation with S-methyl-2-thiophenethiocarboximide hydriodide, and
conversion to the HCl salt (40% for 2 steps), to give title compd.
II.HCl.
The IC50 of the latter for inhibiting rat neuronal NO synthase in vitro
was < 3.5 μ M, and the IC50 for inhibiting rat cerebral lipid peroxidn.
in vitro was < 30 μ M.
IT 214124-59-1P 214124-60-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of [(iminomethyl)amino]phenyl derivs.
useful as
inhibitors of NO synthase and lipid peroxidn.)
RN 214124-59-1 CAPLUS
CN Piperazine, 1-[(5-methoxy-1H-indol-3-yl)acetyl]-4-(4-nitrophenyl)- (9CI)
(CA INDEX NAME)



RN 214124-60-4 CAPLUS
CN Piperazine, 1-(4-aminophenyl)-4-[(5-methoxy-1H-indol-3-yl)acetyl]- (9CI)
(CA INDEX NAME)




IT 214123-85-0P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [(iminomethyl)amino]phenyl derivs. useful as
inhibitors of
NO synthase and lipid peroxidn.)
RN 214123-85-0 CAPLUS
CN Piperazine, 1-[4-[(imino-2-thienylmethyl)amino]phenyl]-4-[(5-methoxy-1H-
indol-3-yl)acetyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 39 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:402304 CAPLUS
DOCUMENT NUMBER: 129:81760
TITLE: Preparation of spiro-substituted azacycles as
modulators of chemokine receptor activity
INVENTOR(S): Mills, Sander G.; Springer, Martin S.; MacCoss,
Malcolm
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Mills, Sander G.; Springer,
Martin S.; MacCoss, Malcolm
SOURCE: PCT Int. Appl., 297 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9825605	A1	19980618	WO 1997-US23586	19971212
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9858033	A	19980703	AU 1998-58033	19971212
PRIORITY APPLN. INFO.:			US 1996-32735P	P 19961213
			US 1996-33558P	P 19961220
			GB 1997-3005	A 19970213
			WO 1997-US23586	W 19971212

OTHER SOURCE(S): MARPAT 129:81760
GI




II

L4 ANSWER 38 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE



L4 ANSWER 39 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
AB Spiroazacycles I [R1 = H, alkyl, aminoalkyl, arylalkyl, etc.; Q = O, S, S(O), SO2, N; W = X bond, alkyl, substituted alkyl, etc.; YZ = fused aryl, fused heteroaryl; m = n = 0 - 5 and m + n = 1 - 5] were prepared for use as modulators of chemokine receptor activity (no data). Thus, spiroindoline II (R = 3,5-dimethylbenzoyl) was prepared starting from 3,5-dimethylbenzoic acid, 1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidine] monohydrochloride, and (S)-3,4-dichloro-N-methyl- β -2-propenylbenzeneethanamine.
IT 167485-09-8P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of spiro-substituted azacycles as modulators of chemokine receptor activity)
RN 167485-09-8 CAPLUS
CN Spiro[3H-indole-3,4'-piperidine], 1'-[(5-fluoro-1H-indol-3-yl)acetyl]-1,2-dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 40 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1998:65894 CAPLUS
 DOCUMENT NUMBER: 128:128015
 TITLE: Preparation of amidinoindoles and amidinoazoles as inhibitors of factor Xa and of thrombin
 INVENTOR(S): Dominguez, Celia; Han, Qi; Duffy, Daniel Emmett; Park, Jeongsook Maria; Quan, Mimi Lifan; Rossi, Karen
 Anita;
 PATENT ASSIGNEE(S): Wexler, Ruth Richmond
 SOURCE: Du Pont Merck Pharmaceutical Co., USA
 PCT Int. Appl., 176 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9801428	A1	19980115	WO 1997-US11325	19970630
W: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2259573	A1	19980115	CA 1997-2259573	19970630
AU 9736456	A	19980202	AU 1997-36456	19970630
EP 960102	A1	19991201	EP 1997-933214	19970630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
NZ 333696	A	20000623	NZ 1997-333696	19970630
PRIORITY APPLN. INFO.:			US 1996-676766	A 19960708
			US 1997-49519P	P 19970613
			WO 1997-US11325	W 19970630

OTHER SOURCE(S): MARPAT 128:128015
 GI




AB The title compds. [I; W, W3 = CH, N; W1, W2 = C, CH, N (provided that one of W1 and W2 is C(C(=NH)NH2) and at most two of W, W1, W2, and W3 are N);


L4 ANSWER 40 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 202123-96-4 CAPLUS
 CN Piperazine, 1-[[5-(aminoiminomethyl)-1H-indol-3-yl]acetyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 202123-97-5 CAPLUS
 CN Glycine, N-[[5-(aminoiminomethyl)-1-methyl-1H-indol-3-yl]acetyl]-N-[[3-(aminoiminomethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 202123-98-6 CAPLUS
 CN Glycine, N-[[5-(aminoiminomethyl)-1-methyl-1H-indol-3-yl]acetyl]-N-[[4-(aminoiminomethyl)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 202124-01-4 CAPLUS
 CN Piperazine, 1-[[5-(aminoiminomethyl)-1-methyl-1H-indol-3-yl]acetyl]-4-

L4 ANSWER 40 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 one of D, Da = H, Cl-4 alkoxy, CN, etc. and the other is absent; one of Ja and Jb is substituted by -(CH2)n-Z-A-B; J, Ja, Jb combine to form an arom.


heterocyclic system contg. from 1-2 heteroatoms (N, O, and S), a heterocyclic ring wherein Jb = N and J and Ja = (un)substituted CH2, a heterocyclic ring wherein Jb = CH, J = (un)substituted NH and Ja = (un)substituted CH; Z = CH:CH, SO2CH2, etc.; A = (un)substituted PhCH2, PhCH2CH2, etc.; B = C3-6 alkyl, (un)substituted PhCH2, 5-10 membered heterocyclic system, etc.), useful as inhibitors of factor Xa or thrombin,

were prepd. and formulated. Thus, reaction of 5-cyanoindole-1-acetic acid

with 4-benzylpiperidine followed by treatment of the resulting 1-(4-benzylpiperidinocarbonyl)methyl-5-cyanoindole with HCl(g) in MeOH, and then with (NH4)2CO3 in MeOH afforded the title compd. II. Some compds. I were evaluated and showed Ki of < 5 μM against thrombin.


IT 202123-90-8P 202123-94-2P 202123-96-4P
 202123-97-5P 202123-98-6P 202124-01-4P
 202124-04-7P 202124-24-1P 202124-28-5P
 202126-86-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of amidinoindoles and amidinoazoles as inhibitors of factor Xa and of thrombin)

RN 202123-90-8 CAPLUS
 CN Piperazine, 1-[[5-(aminoiminomethyl)-1H-indol-3-yl]acetyl]-4-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 202123-94-2 CAPLUS
 CN Piperazine, 1-[[5-(aminoiminomethyl)-1H-indol-3-yl]acetyl]-4-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 40 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (phenylmethyl)- (9CI) (CA INDEX NAME)



RN 202124-04-7 CAPLUS
 CN Piperazine, 1-[[5-(aminoiminomethyl)-1H-indol-3-yl]acetyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 202124-24-1 CAPLUS
 CN 1H-Indole-3-acetamide, 5-(aminoiminomethyl)-N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-N-methyl- (CA INDEX NAME)




RN 202124-28-5 CAPLUS
 CN 1H-Indole-3-acetamide, 5-(aminoiminomethyl)-N-methyl-N-[2'-(methylamino)sulfonyl][1,1'-biphenyl]-4-yl]- (CA INDEX NAME)


L4 ANSWER 40 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 202126-86-1 CAPLUS
 CN Piperidine, 1-[[5-(aminoiminomethyl)-1H-indol-3-yl]acetyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT 202124-97-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of amidinoindoles and amidinoazoles as inhibitors of factor Xa and of thrombin)
 RN 202124-97-8 CAPLUS
 CN Piperazine, 1-[(5-cyano-1H-indol-3-yl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 202124-91-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of amidinoindoles and amidinoazoles as inhibitors of factor Xa and of thrombin)
 RN 202124-91-2 CAPLUS

L4 ANSWER 41 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1997:579718 CAPLUS
 DOCUMENT NUMBER: 127:248104
 TITLE: Preparation of aryloxooxazolidinylmethylacetamides and related compounds as antibacterials.
 INVENTOR(S): Gravestock, Michael Barry
 PATENT ASSIGNEE(S): Zeneca Ltd., UK; Gravestock, Michael Barry
 SOURCE: PCT Int. Appl., 111 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730995	A1	19970828	WO 1997-GB462	19970220
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,				
YU				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GR, GN, ML, MR, NE, SN, TD, TG				
ZA 9701469	A	19970825	ZA 1997-1469	19970220
AU 9718053	A	19970910	AU 1997-18053	19970220
EP 882042	A1	19981209	EP 1997-903509	19970220
R: CH, DE, FR, GB, IT, LI				
JP 11514662	T	19991214	JP 1997-529888	19970220
IN 1937DE00443	A	20050311	IN 1997-DE443	19970221
US 5981528	A	19991109	US 1997-945160	19971021
US 6271383	B1	20010807	US 1999-364389	19990730
US 6365751	B1	20020402	US 2001-836095	20010417
PRIORITY APPLN. INFO.:			GB 1996-3939	A 19960224
			GB 1996-18404	A 19960904
			WO 1997-GB462	W 19970220
			US 1997-945160	A3 19971021
			US 1999-364389	A3 19990730

OTHER SOURCE(S): MARPAT 127:248104
 GI



L4 ANSWER 40 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN Piperazine,
 1-[(5-cyano-1H-indol-3-yl)acetyl]-4-[(4-methylphenyl)sulfonyl]-
 (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 41 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB Title compds. (I; R1 = OH, Cl, Br, F, alkylsulfonyloxy, amino, N3, alkoxy, alkylthio, alkylaminocarbonyloxy, etc.; R2, R3 = H, F; D = O, S, SO, SO2, imino, acylimino; R4, R5 = H, Br, O, alkyl, alkanoylaminoalkyl, hydroxyalkyl, CO2H, alkoxycarbonyl, etc.; R6 = H, alkyl, OH, alkoxy, alkanoyloxy; AB = C:CRa, CHCHRa, or C(OH)CHRa; Ra = H, alkyl), were prepared
 Thus, a mixture of tert-Bu 1,2,3,6-tetrahydro-4-(trifluoromethylsulfonyloxy)pyridine-1-carboxylate, Pd2(dibenzylideneacetone)2, Ph3As, and LiCl in N-methylpyrrolidine was treated with (S)-5-acetamidomethyl-3-(4-trimethyltinphenyl)oxazolidin-2-one (preparation given) followed by stirring at room temperature to 40° to give 23% (S)-N-[3-[4-(1-tert-butyloxycarbonyl-1,2,5,6-tetrahydropyrid-4-yl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide. The latter showed a min. inhibitory concentration of 1.0 µg/mL against Staphylococcus aureus Oxford.
 IT 195816-92-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aryloxooxazolidinylmethylacetamides and related compds. as antibacterials)
 RN 195816-92-3 CAPLUS
 CN Acetamide,
 N-[[3-[4-[1-[(5-fluoro-1H-indol-3-yl)acetyl]-1,2,3,6-tetrahydro-4-pyridinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 42 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:507924 CAPLUS
 DOCUMENT NUMBER: 127:190580
 TITLE: Synthesis of iodine 131 derivatives of indolealkylamines for brain mapping
 AUTHOR(S): Sintas, Jose A.; Vitale, Arturo A.
 CORPORATE SOURCE: Departamento de Química Organica, Facultad de Ciencias
 SOURCE: Exactas y Naturales, PROFLAME-CONICET, Universidad de Buenos Aires, Buenos Aires, 1428, Argent.
 PUBLISHER: Wiley
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The synthesis and spectral properties of new radioiodinated indolealkylamines like 2-[131I]-iodo-N,N-dimethyltryptamine, 2-[131I]-iodo-N-methyltryptamine, 2-[131I]-iodo-5-methoxy-N,N-dimethyltryptamine, 2-[131I]-iodo-5-hydroxy-N,N-dimethyltryptamine (2-[131I]-iodobufotenine), and 2-[131I]-iodotryptamine and the known 2-[131I]-iodo-N-acetyl-5-methoxytryptamine (2-[131I]-iodomelatonin) are described. The radioiodinated compds. were synthesized via a high-yield novel method, and their spectral properties are fully described. These compds. are of biol. importance and can be used for brain mapping with SPECT technol.
 IT 151290-19-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 RN 151290-19-6 CAPLUS
 CN 1H-Indole-3-acetamide, 5-methoxy-N,N-dimethyl- (CA INDEX NAME)



L4 ANSWER 43 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:456960 CAPLUS
 DOCUMENT NUMBER: 127:95194
 TITLE: New benzisoindole derivatives as inhibitors of farnesyl transferase, their preparation, and pharmaceutical compositions containing them.
 INVENTOR(S): Commercon, Alain; Lebrun, Alain; Mailliet, Patrick; Peyronel, Jean Francois; Sounigo, Fabienne; Truchon, Alain; Zucco, Martine; Cheve, Michel
 PATENT ASSIGNEE(S): Rhone-Poulenc Rorer SA, Fr.
 SOURCE: Fr. Demande 96 pp.
 CODEN: FRXXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2736641	A1	19970117	FR 1995-8296	19950710
FR 2736641	B1	19970822		
TW 438792	B	20010607	TW 1996-85108158	19960705
IN 1996DE01492	A	20050311	IN 1996-DE1492	19960705
CA 2224414	A1	19970130	CA 1996-2224414	19960708
WO 9703050	A1	19970130	WO 1996-FR1062	19960708
W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9665224	A	19970210	AU 1996-65224	19960708
AU 712194	B2	19991028		
EP 839133	A1	19980506	EP 1996-924952	19960708
EP 839133	B1	19991006		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				
FI CN 1190389	A	19980812	CN 1996-195415	19960708
CN 1096448	B	20021218		
JP 11511123	T	19990928	JP 1996-505557	19960708
AT 185341	T	19991015	AT 1996-924952	19960708
ES 2139373	T3	20000201	ES 1996-924952	19960708
IL 122812	A	20010430	IL 1996-122812	19960708
SK 282250	B6	20011203	SK 1998-26	19960708
CZ 291620	B6	20030416	CZ 1998-54	19960708
ZA 9605868	A	19970129	ZA 1996-5868	19960710
BR 9609440	A	19990629	BR 1996-9440	19960710
NO 9800094	A	19980217	NO 1998-94	19980109
NO 309565	B1	20010219		
US 5936097	A	19990810	US 1998-981840	19980723
GR 3031409	T3	20000131	GR 1999-402001	19991007
PRIORITY APPLN. INFO.:				FR 1995-8296 A 19950710
				WO 1996-FR1062 W 19960708

L4 ANSWER 43 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 OTHER SOURCE(S): MARPAT 127:95194
 GI



AB Title compds. I [R = (un)substituted (CH2)mX1(CH2)nZ; X1 = bond, O, S; m = 0-1; n = 0-2; Z = CO2H, alkoxycarbonyl, (un)substituted carbamoyl, etc.; R1, R2 = H, halo, alkyl, (un)substituted alkoxy; or R1R2 form (un)saturated heterocycle; or R2 forms dimer via disulfide bridge; R3 = H, halo, alkyl, alkenyl, alkoxy, alkylthio; X = O, S, NH, CO, CH2, CH2CH2, alkylene, 1,1-cycloalkanedyl; Y = O, S], in racemic form or as optical isomers, are claimed. The compds. are inhibitors of farnesyl transferase, and show marked antitumor and antileukemic properties. For example, cis-3,6-diphenyl-1,4-cyclohexadienecarboxylic acid Me ester (preparation given) reacted with PhCH2N(CH2OBU)(CH2SiMe3) in refluxing CF3CO2H to give the intermediate hexahydroisoindole derivative II.HCl, which was further cyclized by CF3SO3H at 5-20° to give the benz[*f*]isoindole intermediate III. This was then converted in 3 steps to title compound IV. In an assay for inhibition of farnesyl transferase, IV had an IC50 of 0.31 μM.
 IT 191989-96-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of new benzisoindole derivs. farnesyl transferase inhibitors)
 RN 191989-96-5 CAPLUS
 CN 4,9-Ethano-3aH-benz[*f*]isoindole-3a-carboxylic acid, 2-[(5-bromo-1H-indol-3-yl)acetyl]-1,2,3,4,9a-hexahydro-9-phenyl-, (3aα,4β,9aα,9aa)- (9CI) (CA INDEX NAME)
 Relative stereochemistry.


L4 ANSWER 43 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 191989-23-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of new benzisoindole derivs. farnesyl transferase inhibitors)

RN 191989-23-8 CAPLUS
 CN 4,9-Ethano-3aH-benz[*f*]isoindole-3a-carboxylic acid, 2-[(5-bromo-1H-indol-3-yl)acetyl]-1,2,3,4,9a-hexahydro-9-phenyl-, (3aα,4β,9aα,9aa)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L4 ANSWER 44 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:1006753 CAPLUS
 DOCUMENT NUMBER: 124:175829
 TITLE: Substituted naphthalene and indole compounds exhibiting selective leukotriene B4 antagonist activity
 INVENTOR(S): Huang, Fu Chih; Chan, Wan K.; Sutherland, Charles A.; Galenno, Jr Robert A.
 PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
 SOURCE: U.S., 26 pp. Cont.-in-part of U.S. Ser. No. 580,243, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5468898	A	19951121	US 1993-777246	19930423
WO 9204321	A1	19920319	WO 1991-US6447	19910906
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
PRIORITY APPLN. INFO.: US 1990-580243 B2 19900910				
WO 1991-US6447 W 19910906				

OTHER SOURCE(S): MARPAT 124:175829
 GI




AB This invention relates to naphthalene and indole derivs. I and II, resp., containing an amido substituent, a substituent group having a terminal carboxylic acid or derivative thereof and a lipophilic substituent [i.e., at least one of R4, R5, R6, R7, R8, R9 and R10 and R11, R12, R13, R14, R15, R16, R17, R18 are A(CR2)aCONR'(CR2)bB; at least one of R4, R5, R6, R7, R8, R9 and R10 and R11, R12, R13, R14, R15, R16, R17, R18 are (CR2)dD(CR2)eE; and at least one of R4, R5, R6, R7, R8, R9 and R10 and R11, R12, R13, R14, R15, R16, R17, R18 are (CR2)fF(CR2)gG and the remaining R4, R5, R6, R7, R8, R9 and R10 and R11, R12, R13, R14, R15, R16, R17, R18 are H; where A is CRR or O; B and G are (un)substituted Ph; D = e.g., bond, O, CRR; E =

L4 ANSWER 44 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 e.g., CO2R', CONR'R'; F = e.g., bond, O, CRR; R = e.g., H; R' = e.g., H, alkyl; a, b, d, e, f, and g are independently 0-4] having selective LTB4 antagonist properties (no data) and to methods for the treatment of disorders which result from LTB4 activity and pharmaceutical compns. including such compds. Thus, e.g., amidation of bromoacetyl chloride

with N-methyl-N-phenethylamine afforded N-methyl-N-phenethyl-2-bromoacetamide which was used to alkylate 5-hydroxyindole, thus affording 5-[2-(N-methyl-N-phenethyl)amino-2-oxoethoxy]indole; formylation of the latter afforded 5-[2-(N-methyl-N-phenethyl)amino-2-oxoethoxy]indole-3-carboxaldehyde; N-alkylation of the latter with N-methyl-N-phenethyl-2-bromoacetamide afforded N-methyl-N-phenethyl-2-[(5-(2-methylphenethylamino-2-oxoethoxy)-3-formyl)indol-1-yl]acetamide; condensation of the latter with tri-Et phosphonoacetate afforded N-methyl-N-phenethyl-2-[3-(2-carboxyethoxyvinyl)-5-(2-(N-methyl-N-phenethyl)amino-2-oxoethoxy)indol-1-yl]acetamide.

IT 141835-69-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (substituted naphthalene and indole compds. exhibiting selective leukotriene B4 antagonist activity)


RN 141835-69-0 CAPLUS
 CN 2-Propenoic acid, 3-[3-[2-[methyl(2-phenylethyl)amino]-2-oxoethyl]-5-(phenylmethoxy)-1H-indol-1-yl]-, ethyl ester (CA INDEX NAME)



IT 141835-21-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (substituted naphthalene and indole compds. exhibiting selective leukotriene B4 antagonist activity)


RN 141835-21-4 CAPLUS
 CN 2-Propenoic acid, 3-[3-[2-[methyl(2-phenylethyl)amino]-2-oxoethyl]-5-(phenylmethoxy)-1H-indol-1-yl]- (CA INDEX NAME)

L4 ANSWER 44 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 141835-68-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (substituted naphthalene and indole compds. exhibiting selective leukotriene B4 antagonist activity)

RN 141835-68-9 CAPLUS
 CN 1H-Indole-3-acetamide, N-methyl-N-(2-phenylethyl)-5-(phenylmethoxy)- (CA INDEX NAME)




L4 ANSWER 45 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:995279 CAPLUS
 DOCUMENT NUMBER: 124:145907
 TITLE: Preparation of 1-(3-indolylalkyl)-4-(3-indolyl)piperidines as dopamine agonists or antagonists.
 INVENTOR(S): Boettcher, Henning; Maerz, Joachim; Seyfried, Christoph; Greiner, Hartmut; Bartoszyk, Gerd
 PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
 SOURCE: Ger. Offen., 14 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4414113	A1	19951026	DE 1994-4414113	19940422
EP 683166	A1	19951122	EP 1995-105227	19950407
EP 683166	B1	19981028		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 172730	T	19981115	AT 1995-105227	19950407
ES 2125508	T3	19990301	ES 1995-105227	19950407
AU 9516488	A	19951102	AU 1995-16488	19950413
AU 697749	B2	19981015		
JP 07291969	A	19951107	JP 1995-91077	19950417
SK 280881	B6	20000814	SK 1995-508	19950419
CA 2147451	A1	19951023	CA 1995-2147451	19950420
CA 2147451	C	20060328		
CN 1114651	A	19960110	CN 1995-104705	19950420
CN 1047385	B	19991215		
TW 401416	B	20000811	TW 1995-84103916	19950420
NO 9501529	A	19951023	NO 1995-1529	19950421
NO 307831	B1	20000605		
ZA 9503260	A	19960109	ZA 1995-3260	19950421
HU 74096	A2	19961128	HU 1995-1139	19950421
US 5693655	A	19971202	US 1995-426405	19950421
CZ 285369	B6	19990714	CZ 1995-1035	19950421
RU 2151148	C1	20000620	RU 1995-106675	19950421
PL 180781	B1	20010430	PL 1995-308287	19950421
PRIORITY APPLN. INFO.: DE 1994-4414113 A 19940422				

OTHER SOURCE(S): CASREACT 124:145907; MARPAT 124:145907
 GI




L4 ANSWER 45 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


AB Title compds. [I; R1-R4 = H, alkyl, OH, alkoxy, F, Cl, Br, iodo, cyano, CF₃, CO₂H, CONH₂, alkoxycarbonyl, etc.; R1R2, R3R4 = OCH₂O; R5 = H, OH; R6 = H; R5R6 = bond; n = 2-6], were prepared as drugs (no data). Thus, 3-(4-chlorobutyl)-5-methoxyindole and 4-(3-indolyl)piperidine were refluxed 8 h in MeCN to give 3-[1-[4-(5-methoxyindol-3-yl)butyl]-4-piperidinyl]indole hydrochloride.

IT 173150-68-0 173150-69-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 1-(3-indolylalkyl)-4-(3-indolyl)piperidines as dopamine agonists or antagonists)

RN 173150-68-0 CAPLUS
 CN Piperidine,
 4-(5-fluoro-1H-indol-3-yl)-1-[(5-fluoro-1H-indol-3-yl)acetyl]-
 (9CI) (CA INDEX NAME)




RN 173150-69-1 CAPLUS
 CN Piperidine,
 4-(4-fluoro-1H-indol-3-yl)-1-[(5-fluoro-1H-indol-3-yl)acetyl]-
 (9CI) (CA INDEX NAME)



L4 ANSWER 46 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


RN 153438-63-2 CAPLUS
 CN 1H-Indol-4-ol, 2-[(5-fluoro-1H-indol-3-yl)acetyl]octahydro-4-(2-methoxyphenyl)-7,7-diphenyl-, [3aS-(3α,4β,7α)]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 153438-64-3 CAPLUS
 CN 1H-Indol-4-ol, octahydro-2-[(5-methoxy-1H-indol-3-yl)acetyl]-4-(2-methoxyphenyl)-7,7-diphenyl-, [3aS-(3α,4β,7α)]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 46 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:851691 CAPLUS
 DOCUMENT NUMBER: 123:285765
 TITLE: Preparation of perhydroisindole antiemetics
 INVENTOR(S): Garret, Claude; Louvel, Erik
 PATENT ASSIGNEE(S): Rhone-Poulenc Rorer S.A., Fr.
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9509628	A1	19950413	WO 1994-FR1160	19941005
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SE, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2710842	A1	19950414	FR 1993-11945	19931007
FR 2710842	B1	19951124		
AU 9478581	A	19950501	AU 1994-78581	19941005
PRIORITY APPLN. INFO.:			FR 1993-11945	A 19931007
			WO 1994-FR1160	W 19941005

OTHER SOURCE(S): CASREACT 123:285765; MARPAT 123:285765
 GI




AB The title compds. [I; R = (un)substituted Ph; R1 = (un)substituted Ph, cyclohexadienyl, naphthyl, indenyl, (un)substituted heterocyclyl; R2 = H, halogen, OH, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkyloxy, alkylthio, acyloxy, CO₂H, (un)substituted alkyloxy, carbonyl, benzyloxy, carbonyl, NH₂, acylamino; R3 = (un)substituted Ph; R4 = OH or F if R5 = H; etc.] [e.g., (3aS,4S,7aS)-7,7-diphenyl-4-(2-methoxyphenyl)-2-tert-butoxycarbonyl-4-perhydroisindolol], useful as antiemetics, are prepared and I-containing formulations presented.

IT 153438-63-2P 153438-64-3P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of perhydroisindole antiemetics)

L4 ANSWER 47 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:781772 CAPLUS
 DOCUMENT NUMBER: 123:169671
 TITLE: Preparation of spirocyclic compounds as neurokinin antagonists
 INVENTOR(S): MacCoss, Malcolm; Mills, Sander G.; Shah, Shrenik K.; Chiang, Yuan-Ching P.; Dunn, Patrick T.; Koyama, Hiroo; Finkle, Paul E.; Qi, Hongbo; Robichaud, Albert J.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: PCT Int. Appl., 226 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9429309	A1	19941222	WO 1994-US5545	19940517
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, UA, US, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2163995	A1	19941222	CA 1994-2163995	19940517
AU 9472011	A	19950103	AU 1994-72011	19940517
AU 680020	B2	19970717		
EP 702681	A1	19960327	EP 1995-901979	19940517
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08511522	T	19961203	JP 1994-501802	19940517
ZA 9403946	A	19950120	ZA 1994-3946	19940606
PRIORITY APPLN. INFO.:			US 1993-72904	A 19930607
			WO 1994-US5545	W 19940517

OTHER SOURCE(S): MARPAT 123:169671
 GI




I

L4 ANSWER 47 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB Spirocyclic nitrogen-heterocyclic compds. were disclosed as tachykinin receptor antagonists useful for the treatment of inflammatory diseases, pain or migraine, and asthma. In particular, said compds. were shown to be neurokinin antagonists. Many example compds. are claimed. One such specific compound is N-[3-(3,4-dichlorophenyl)-4-[1,2-dihydro-1-(sulfonylmethyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]butyl]-2,2-dimethylpropanamide (I).

IT 167485-09-8P
 RI: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of spirocyclic compds. as kinin receptor antagonists)

RN 167485-09-8 CAPLUS
 CN Spiro[3H-indole-3,4'-piperidine],
 1'-[(5-fluoro-1H-indol-3-yl)acetyl]-1,2-dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)





L4 ANSWER 48 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:772570 CAPLUS
 DOCUMENT NUMBER: 123:169499
 TITLE: Indole derivatives as 5-HT₁-like agonists for use in migraine
 INVENTOR(S): Wythes, Martin James
 PATENT ASSIGNEE(S): Pfizer Ltd., UK; Pfizer Inc.; Pfizer Research and Development Company, N.V./S.A.
 SOURCE: PCT Int. Appl., 124 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9424127	A1	19941027	WO 1994-EP1121	19940411
W: AU, BR, CA, CN, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, US				
WM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2157397	A1	19941027	CA 1994-2157397	19940411
CA 2157397	C	19990706		
AU 9465670	A	19941108	AU 1994-65670	19940411
BR 9406481	A	19960109	BR 1994-6481	19940411
EP 695301	A1	19960207	EP 1994-913573	19940411
EP 695301	B1	19961030		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1121348	A	19960424	CN 1994-191850	19940411
JP 08507083	T	19960730	JP 1994-522726	19940411
HU 73807	A2	19960930	HU 1995-1920	19940411
AT 144773	T	19961115	AT 1994-913573	19940411
ES 2094653	T3	19970116	ES 1994-913573	19940411
ZA 9402722	A	19951020	ZA 1994-2722	19940420
FI 9504944	A	19951017	FI 1995-4944	19951017
NO 9504168	A	19951019	NO 1995-4168	19951019
US 5607960	A	19970304	US 1995-532573	19951020
PRIORITY APPLN. INFO.:			GB 1993-8360	A 19930422
			GB 1993-24433	A 19931127
			WO 1994-EP1121	W 19940411

OTHER SOURCE(S): MARPAT 123:169499
 GI




L4 ANSWER 48 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The title compds., 3-(pyrrolidinylmethyl)indoles and 3-(piperidinylmethyl)indoles I [R1 = (2-pyrrolidinyl)methyl, 3-pyrrolidinyl, 4-piperidinyl, (3-piperidinyl)methyl; R2 = alkyl, oxoalkyl, etc.] were disclosed as selective 5-HT₁-like agonists useful in the treatment of migraine, cluster headache, chronic paroxysmal hemicrania and headache associated with vascular disorders. A specifically claimed example compound is 5-(3-hydroxybutyl)-3-[(R)-(1-methyl-2-pyrrolidinyl)methyl]-1-H-indole (II).

IT 167303-72-2P
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of (aminoalkyl)indoles 5-HT₁-like agonists)

RN 167303-72-2 CAPLUS
 CN 1H-Indole-3-acetamide, 5-bromo-N-methyl-N-(phenylmethyl)- (CA INDEX NAME)




L4 ANSWER 49 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:615038 CAPLUS
 DOCUMENT NUMBER: 123:32956
 TITLE: Preparation of pharmaceutical perhydroisoindole derivatives as neurokinin A antagonists
 INVENTOR(S): Crespo, Andre; Fardin, Veronique; Guillaume, Jean-Marc; Malleron, Jean -Luc; Peyronel, Jean-Francois
 PATENT ASSIGNEE(S): Rhone-Poulenc Rorer S.A., Fr.
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9422822	A1	19941013	WO 1994-FR371	19940401
W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK, UA, US				
WM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2703679	A1	19941014	FR 1993-3965	19930405
FR 2703679	B1	19950623		
CA 2158663	A1	19941013	CA 1994-2158663	19940401
AU 9465068	A	19941024	AU 1994-65068	19940401
EP 693059	A1	19960124	EP 1994-912582	19940401
EP 693059	B1	19970312		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 08508283	T	19960903	JP 1994-521762	19940401
HU 74089	A2	19961128	HU 1995-2902	19940401
AT 150014	T	19970315	AT 1994-912582	19940401
ES 2099601	T3	19970516	ES 1994-912582	19940401
US 5631279	A	19970520	US 1995-448402	19950607
NO 9503913	A	19951002	NO 1995-3913	19951002
FI 9504730	A	19951117	FI 1995-4730	19951004
PRIORITY APPLN. INFO.:			FR 1993-3965	A 19930405
			WO 1994-FR371	W 19940401


OTHER SOURCE(S): MARPAT 123:32956
 GI



AB Title compds. I (R = (substituted)Ph; R1 = (substituted)Ph, PhCh2O, (substituted)-C1-4 alkyl, (substituted)amino, (substituted)heterocyclyl, cyclohexadienyl, naphthyl, indenyl; R2 = H, halo, HO, alkyl, aminoalkyl, allylaminoalkyl, dialkylaminoalkyl, etc.; R3 = (substituted)Ph), are prepared (3AR, 4R, 5R, 7aR)-7,7-diphenyl-4-(2-methoxyphenyl)perhydro-4,5-

L4 ANSWER 49 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 isoindolediol (prepn. given) and 3-indolylacetic acid in CH₂Cl₂ were added to 1-benzotriazolylol hydrate, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and diisopropylethylamine to give (3aR,4R,5R,7aR)-I (R₁ = 3-indolyl, R₂ = H, R₃ = 2-(MeO)C₆H₄) which at 10-1000 nM on human receptor NK₂ showed IC₅₀ of 215 nM. A formulation tablet comprising I is given.
 IT 163838-54-8P 163838-57-1P 163838-58-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of pharmaceutical perhydroisoindole derivs. as neurokinin A antagonists)
 RN 163838-54-8 CAPLUS
 CN 1H-Isoindole-4,5-diol, octahydro-2-[(5-hydroxy-1H-indol-3-yl)acetyl]-4-(2-methoxyphenyl)-7,7-diphenyl-, [3aR-(3aα,4β,5β,7aα)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163838-57-1 CAPLUS
 CN 1H-Isoindole-4,5-diol, 2-[(5-fluoro-1H-indol-3-yl)acetyl]octahydro-4-(2-methoxyphenyl)-7,7-diphenyl-, (3aα,4β,5β,7aα)- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 49 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 163838-58-2 CAPLUS
 CN 1H-Isoindole-4,5-diol, octahydro-2-[(5-methoxy-1H-indol-3-yl)acetyl]-4-(2-methoxyphenyl)-7,7-diphenyl-, (3aα,4β,5β,7aα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 50 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:270102 CAPLUS
 DOCUMENT NUMBER: 120:270102
 TITLE: Perhydroisoindole derivatives as substance P antagonists and their preparation
 INVENTOR(S): Achard, Daniel; Grisoni, Serge; Malleron, Jean Luc; Peyronel, Jean-francois; Tabart, Michel
 PATENT ASSIGNEE(S): Rhone-Poulenc Rorer S.A., Fr.
 SOURCE: PCT Int. Appl., 67 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9321155	A1	19931028	WO 1993-FR352	19930408
W: AU, CA, CZ, FI, HU, JP, KR, KZ, NO, NZ, PL, RU, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2689888	A1	19931015	FR 1992-4390	19920410
FR 2689888	B1	19940610		
IL 105255	A	19970218	IL 1993-105255	19930401
ZA 9302527	A	19931108	ZA 1993-2527	19930408
AU 9339565	A	19931118	AU 1993-39565	19930408
AU 667214	B2	19960314		
EP 635003	A1	19950125	EP 1993-909005	19930408
EP 635003	B1	19980617		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 07505410	T	19950615	JP 1993-518041	19930408
JP 3205557	B2	20010904		
HU 71354	A2	19951128	HU 1994-2911	19930408
PL 172754	B1	19971128	PL 1993-305360	19930408
SK 279032	B6	19980506	SK 1994-1220	19930408
AT 167472	T	19980715	AT 1993-909005	19930408
CZ 284213	B6	19980916	CZ 1994-2482	19930408
ES 2118232	T3	19980916	ES 1993-909005	19930408
RU 2127260	C1	19990310	RU 1994-45855	19930408
NO 9403692	A	19941003	NO 1994-3692	19941003
FI 9404729	A	19941007	FI 1994-4729	19941007
FI 105023	B1	20000531		
US 5484804	A	19960116	US 1994-313121	19941011
PRIORITY APPLN. INFO.:			FR 1992-4390	A 19920410
			WO 1993-FR352	A 19930408


OTHER SOURCE(S): MARPAT 120:270102
 GI

L4 ANSWER 50 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




AB Title compds. I [R = Ph optionally substituted with halogen or Me in position 2 or 3; R₁ = (un)substituted Ph, cyclohexadienyl, naphthyl, indenyl, heterocyclyl; R₂ = H, halo, OH, alkyl, aminoalkyl, CO₂H, amino, etc.; R₃ = Ph optionally substituted in position 2 by Cl-2 alkyl or alkoxy; R₄ = F, OH; R₅ = H; or R₄ = R₅ = OH; or R₄R₅ = bond] and their stereoisomers, isomer mixts., and salts, are claimed (40 synthetic examples). For example, N-acylation of [3a(S),4(S),7a(S)]-7,7-diphenyl-4-[(2-methoxyphenyl)perhydroisoindol-4-yl] (prepared in 4 steps) with (S)-2-(MeO)C₆H₄CHMeCO₂H (prepared in 3 steps) using EDCI in CH₂Cl₂ gave title compound II. The ED₅₀ of II for inhibition of increased capillary permeability induced by peptide (a substance P agonist) in guinea pigs was 0.04 mg/kg i.v. or 3.5 mg/kg p.o. II also countered hypotension and bronchoconstriction induced by substance P in guinea pigs.
 IT 153438-63-2P 153438-64-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as substance P antagonist)
 RN 153438-63-2 CAPLUS
 CN 1H-Isoindol-4-ol, 2-[(5-fluoro-1H-indol-3-yl)acetyl]octahydro-4-(2-methoxyphenyl)-7,7-diphenyl-, [3aS-(3aα,4β,7aα)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 50 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RN 153438-64-3 CAPLUS
 CN 1H-Indolol-4-ol, octahydro-2-[(5-methoxy-1H-indol-3-yl)acetyl]-4-(2-methoxyphenyl)-7,7-diphenyl-, [3aS-(3 α ,4 β ,7 α)]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 51 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:244664 CAPLUS
 DOCUMENT NUMBER: 120:244664
 TITLE: Preparation of perhydroisoindoles as substance P antagonists
 INVENTOR(S): Achard, Daniel; Grisoni, Serge; Malleron, Jean Luc; Peyronel, Jean Francois; Tabart, Michel
 PATENT ASSIGNEE(S): Rhone-Poulenc Rorer S.A., Fr.
 SOURCE: PCT Int. Appl., 57 pp.
 CODEN: FIKXK2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9321154	A1	19931028	WO 1993-FR351	19930408
W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK, US				
FR: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2689889	A1	19931015	FR 1992-4391	19920410
FR 2689889	B1	19940610		
IL 105256	A	19970814	IL 1997-105256	19930401
ZA 9302528	A	19931028	ZA 1993-2528	19930408
AU 9339564	A	19931118	AU 1993-39564	19930408
AU 667365	B2	19960321		
EP 635002	A1	19950125	EP 1993-909004	19930408
EP 635002	B1	19980722		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 07505409	T	19950615	JP 1993-518040	19930408
HU 71330	A2	19951128	HU 1994-2912	19930408
PL 172753	B1	19971128	PL 1993-305359	19930408
AT 168674	T	19980815	AT 1993-909004	19930408
ES 2118954	T3	19981001	ES 1993-909004	19930408
RU 2120438	C1	19981020	RU 1994-45867	19930408
CZ 284596	B6	19990113	CZ 1994-2463	19930408
NO 9403738	A	19941005	NO 1994-3738	19941005
FI 9404728	A	19941007	FI 1994-4728	19941007
FI 105022	B1	20000531		
US 5463077	A	19951031	US 1994-313120	19941011
PRIORITY APPLN. INFO.:			FR 1992-4391	A 19920410
			WO 1993-FR351	A 19930408


OTHER SOURCE(S): MARPAT 120:244664
 GI

L4 ANSWER 51 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB Title compds. (I; R = Ph, 2- or 3-halophenyl, -methylphenyl; R1 = Ph, 2-methyl- or -ethylphenyl, -methoxy- or -ethoxyphenyl; R2 = F, OH; R3 = H, OH; R2R3 = bond; R4 = H, protective group) were prepared. Thus, (3aRS,7aRS)-7,7-diphenylperhydroisoindol-4-one was converted in 3 steps to (S,S)-I (R = Ph, R1R2 = O, R3 = H, R4 = CO2CMe3) which was condensed with the Grignard reagent from 2-(MeO)C6H4Br to give, after deprotection, isoindolol II (R4 = H). The latter was condensed with (S)-2-(MeO)C6H4CHMeCO2H (preparation given) to give II [R4 = (S)-2-(MeO)C6H4CHMeCO] which had ED50 of 0.7mg/kg i.v. against [pro9] substance P-induced bronchospasm in monkeys.
 IT 153438-63-2P 153438-64-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as substance P antagonist)
 RN 153438-63-2 CAPLUS
 CN 1H-Indolol-4-ol, 2-[(5-fluoro-1H-indol-3-yl)acetyl]octahydro-4-(2-methoxyphenyl)-7,7-diphenyl-, [3aS-(3 α ,4 β ,7 α)]- (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 153438-64-3 CAPLUS
 CN 1H-Indolol-4-ol, octahydro-2-[(5-methoxy-1H-indol-3-yl)acetyl]-4-(2-methoxyphenyl)-7,7-diphenyl-, [3aS-(3 α ,4 β ,7 α)]- (9CI)
 (CA INDEX NAME)

L4 ANSWER 51 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)


Absolute stereochemistry.



L4 ANSWER 52 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:671015 CAPLUS
 DOCUMENT NUMBER: 119:271015
 TITLE: (Indolyethyl)piperidine NK2 receptor antagonists
 INVENTOR(S): Cooper, Anthony William James; Hagan, Russell Michael
 PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9314084	A2	19930722	WO 1993-EP101	19930115
WO 9314084	A3	19931014		
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9333513	A	19930803	AU 1993-33513	19930115
PRIORITY APPLN. INFO.:				
			GB 1992-1179	A 19920121
			WO 1993-EP101	A 19930115

OTHER SOURCE(S): MARPAT 119:271015
 GI




AB The title compds. I [R1 = (un)substituted Ph; R2 = H, HO, Cl-4 alkoxy; R3 = H, Cl-4 alkyl; R4 = H, Cl-4 alkoxy; R5 = H, Cl-4 alkyl, CF3, CN, halogen; n = 0-2], useful in the treatment of conditions mediated by tachykinins, including NKA, NKB, and substance P, acting at the NK2 receptor, are prepared Thus, (R)-methylphenyl sulfoxide was reacted with Li bis(trimethylsilyl)amide, and the intermediate reacted with 1-[5-fluoro-1H-indol-3-yl]ethyl]-4-piperidone, followed by methanesulfonic acid, producing (R)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]-4-[(phenylsulfinyl)methyl]-4-piperidinol methanesulfonic acid salt (II).


II demonstrated anxiolytic activity in the mouse light-dark box and the rat elevated plus-maze.

IT 151191-69-4P 151191-70-7P 151191-71-8P
 151191-75-2P 151191-78-5P


L4 ANSWER 52 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN 4-Piperidinol, 1-[(5-fluoro-1H-indol-3-yl)acetyl]-4-[(2-methylphenylthio)methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 52 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and reaction of, in prepn. of NK2 receptor antagonists)
 RN 151191-69-4 CAPLUS
 CN 4-Piperidinone, 1-[(5-fluoro-1H-indol-3-yl)acetyl]- (9CI) (CA INDEX NAME)




RN 151191-70-7 CAPLUS
 CN 4-Piperidinol, 1-[(5-fluoro-1H-indol-3-yl)acetyl]-4-[(phenylsulfinyl)methyl]- (9CI) (CA INDEX NAME)



RN 151191-71-8 CAPLUS
 CN 4-Piperidinol, 1-[(5-fluoro-1H-indol-3-yl)acetyl]-4-[(2-methylphenyl)sulfonylmethyl]- (9CI) (CA INDEX NAME)




RN 151191-75-2 CAPLUS
 CN 4-Piperidinol, 1-[(5-fluoro-1H-indol-3-yl)acetyl]-4-[(2-methylphenyl)sulfonylmethyl]- (9CI) (CA INDEX NAME)



RN 151191-78-5 CAPLUS


L4 ANSWER 53 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:670946 CAPLUS
 DOCUMENT NUMBER: 119:270946
 TITLE: Indolealkylamine metabolism: synthesis of deuterated indolealkylamines as metabolic probes
 AUTHOR(S): Morris, Philip E., Jr.; Chiao, Cheng
 CORPORATE SOURCE: Dep. Chem., Univ. Alabama, Birmingham, AL, 35294, USA
 SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals
 (1993), 33(6), 455-65
 CODEN: JLCRD4; ISSN: 0362-4803
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 119:270946
 GI



AB The synthesis of the deuterium labeled, endogenously occurring, indolealkylamine hallucinogens N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine via reduction of amide intermediates


with lithium aluminum deuteride (LAD) is described. Thus, 2-(3-indolyl)glyoxal chloride was treated with Me2NH to give 2-(3-indolyl)-N,N-dimethylglyoxalamide which was reduced with LAD to give $\alpha,\alpha,\beta,\beta$ -[2H]4-N,N-dimethyltryptamine (I). The compds. were characterized with 1H, 2H and 13C NMR. These compds. were synthesized for use as probes for investigating the metabolism of these compds. by MAO via the in vivo kinetic isotope effect.

IT RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of)
 RN 151290-19-6 CAPLUS
 CN 1H-Indole-3-acetamide, 5-methoxy-N,N-dimethyl- (CA INDEX NAME)




L4 ANSWER 54 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:440466 CAPLUS
 DOCUMENT NUMBER: 119:40466
 TITLE: Inactivation of prostaglandin endoperoxide synthase by
 acylating derivatives of indomethacin
 AUTHOR(S): Wells, Isabelle; Marnett, Lawrence J.
 CORPORATE SOURCE: Sch. Med., Vanderbilt Univ., Nashville, TN, 37232-0146, USA
 SOURCE: Biochemistry (1993), 32(10), 2710-16
 CODEN: BICHAU; ISSN: 0006-2960
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Derivs. of the potent antiinflammatory agent and cyclooxygenase inhibitor indomethacin were synthesized in which the carboxylic acid moiety was converted into reactive acylating agents. Indomethacin imidazole (indomethacin-IM) and indomethacin N-hydroxysuccinimide (indomethacin-NHS) inactivated both the cyclooxygenase and peroxidase activities when incubated with the apo form of purified prostaglandin endoperoxide synthase (PGH synthase) at a stoichiometry of 1:1. Treatment of the inactivated enzyme with hydroxylamine at neutral pH led to recovery of all peroxidase and about 50% of the cyclooxygenase activity. Hydroxylamine did not regenerate the cyclooxygenase activity of the indomethacin-inactivated protein. Reconstitution of the apoprotein with heme protected against inactivation by indomethacin-NHS. Visible spectroscopy established that indomethacin-NHS-inactivated apoenzyme had a reduced capacity to bind heme. Indomethacin-NHS also substantially protected the apoenzyme from cleavage at the trypsin-sensitive Arg277 site. Incubation of [2-14C]indomethacin-NHS with PGH synthase led to incorporation of radioactivity into the protein, but no adduct was detected by reversed-phase HPLC, suggesting it was unstable to the chromatog. conditions. Incubation of indomethacin-NHS with apoprotein followed by HPLC anal. led to the formation of greater amts. of the hydrolysis product indomethacin than did similar treatment of holoprotein. The results suggest that indomethacin-IM and indomethacin-NHS covalently and selectively label PGH synthase near the heme binding site, leading to loss of both catalytic activities of the enzyme.
 IT 148560-94-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and prostaglandin endoperoxide synthase cyclooxygenase and peroxidase activity inactivation by)
 RN 148560-94-5 CAPLUS
 CN 1H-Indole, 1-(4-chlorobenzoyl)-3-[2-(1H-imidazol-1-yl)-2-oxoethyl]-5-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 54 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




L4 ANSWER 55 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:168924 CAPLUS
 DOCUMENT NUMBER: 118:168924
 TITLE: Search for β -adrenoblockers among aminoalkoxypropyl derivatives of 4-hydroxyindolylacetic acid and 4-hydroxyskatoles
 AUTHOR(S): Glushkov, R. G.; Mashkovskii, M. D.; Skryabin, G. K.; Suvorov, N. N.; Kozlovskii, A. G.; Vinograd, L. Kh.; Yuzhakov, S. D.; Arinbasarov, M. U.; Tribunskaya, Yu. I.; et al.
 CORPORATE SOURCE: TSKhLS, VNIKhFI im. S. Ordzhonikidze, Moscow, Russia
 SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1992), 26(6), 18-21
 CODEN: KHFZAN; ISSN: 0023-1134
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 118:168924
 GI


L4 ANSWER 55 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and condensation with acetone)
 RN 145101-61-7 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-N,N-dimethyl- (CA INDEX NAME)




IT 145101-60-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and β -adrenergic antagonist activity of)
 RN 145101-60-6 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-N,N-dimethyl- (CA INDEX NAME)



AB Treating indoles I (R = CH₂CO₂Me, Me, CH₂CONH₂, CH₂CONMe₂) with 2-(chloromethyl)oxirane gave 74-82.5% glycidylalkoxy derivs. which were substituted by Me₂CHNH₂ and Me₃CNH₂ to give 60.5-94.5% aminoalkoxypropoxy derivs. II (R₁ = Me₂CH, CMe₃). The highest blocking activity was displayed by II (R = Me, R₁ = CMe₃) and by II (R = CH₂CO₂Me, R₁ = CMe₃).
 IT 145101-56-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and amination by isopropyl- and tert-butylamines)
 RN 145101-56-0 CAPLUS
 CN 1H-Indole-3-acetamide, N,N-dimethyl-4-(oxiranylmethoxy)- (9CI) (CA INDEX NAME)




IT 145101-61-7P



IT 145296-55-5P 145296-56-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 145296-55-5 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-N,N-dimethyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)


CM 1
 CRN 145101-60-6
 CMF C18 H27 N3 O3




CM 2

L4 ANSWER 55 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.




RN 145296-56-6 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-N,N-dimethyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


IT 145101-52-6
 RL: PROC (Process)
 (substitution of, by epichlorohydrin)
 RN 145101-52-6 CAPLUS
 CN 1H-Indole-3-acetamide, 4-hydroxy-N,N-dimethyl- (CA INDEX NAME)



L4 ANSWER 56 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1992:448333 CAPLUS
 DOCUMENT NUMBER: 117:48333
 TITLE: Preparation of substituted bicyclic arylindole compounds exhibiting selective leukotriene B4 antagonist activity
 INVENTOR(S): Huang, Fu Chih; Chan, Wan K.; Sutherland, Charles A.; Galemno, Robert A., Jr.
 PATENT ASSIGNEE(S): Rhone-Poulenc Rorer International (Holdings), Inc., USA
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9204321	A1	19920319	WO 1991-US6447	19910906
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2091257	A1	19920311	CA 1991-2091257	19910906
AU 9186419	A	19920330	AU 1991-86419	19910906
EP 548250	A1	19930630	EP 1991-917468	19910906
EP 548250	B1	19960327		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06504520	T	19940526	JP 1991-516161	19910906
JP 3334087	B2	20021015		
AT 136026	T	19960415	AT 1991-917468	19910906
US 5468898	A	19951121	US 1993-777246	19930423
PRIORITY APPLN. INFO.:			US 1990-580243	A2 19900910
			WO 1991-US6447	A 19910906

OTHER SOURCE(S): MARPAT 117:48333
 GI




I

AB The title compds., useful as leukotriene B4 antagonists for treatment of disorders which result from LTB4 activity (no data), are prepared To NaH in THF, 5-(benzyloxy)indole-3-carboxaldehyde (preparation given) was added, followed by BrCH2CON(CH2CH2Ph)Me, to give the title indole I. Adnln. title compds. were prepared
 IT 141835-21-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)


L4 ANSWER 56 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (prepn. of, as LTB4 antagonist)

RN 141835-21-4 CAPLUS
 CN 2-Propenoic acid, 3-[3-[2-[methyl(2-phenylethyl)amino]-2-oxoethyl]-5-(phenylmethoxy)-1H-indol-1-yl]- (CA INDEX NAME)




IT 141835-68-9P 141835-69-OP
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as intermediate in preparation of LTB4 antagonist)

RN 141835-68-9 CAPLUS
 CN 1H-Indole-3-acetamide, N-methyl-N-(2-phenylethyl)-5-(phenylmethoxy)- (CA INDEX NAME)




RN 141835-69-0 CAPLUS
 CN 2-Propenoic acid, 3-[3-[2-[methyl(2-phenylethyl)amino]-2-oxoethyl]-5-(phenylmethoxy)-1H-indol-1-yl]-, ethyl ester (CA INDEX NAME)



L4 ANSWER 57 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1991:82562 CAPLUS
 DOCUMENT NUMBER: 114:82562
 TITLE: Preparation of acyl dipeptide amides as tachykinin antagonists
 INVENTOR(S): Matsuo, Masaaki; Hagiwara, Daijiro; Miyake, Hiroshi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: Eur. Pat. Appl., 13 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 394989	A2	19901031	EP 1990-107822	19900425
EP 394989	A3	19910424		
EP 394989	B1	19941221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5164372	A	19921117	US 1990-505457	19900406
CA 2015359	A1	19901028	CA 1990-2015359	19900425
JP 03027399	A	19910205	JP 1990-114129	19900427
PRIORITY APPLN. INFO.:			GB 1989-9795	A 19890428
			GB 1989-17542	A 19890801

OTHER SOURCE(S): MARPAT 114:82562
 GI




AB R1YCOANR2CH(CH2C6H4R3-p)CONR4R5 [R1 = (substituted) alkyl, aryl, arylamino, pyridyl, pyrrolyl, pyrazolopyridyl, quinolyl, Q1; X = CH, N; Z = O, S, NH; R2 = H, alkyl; R3 = H, OH; R4 = (substituted) alkyl; R5 = pyridylalkyl, (substituted) aralkyl; or R4R5 = benzene-condensed alkylene; A = amino acid residue except D-Trp; Y = bond, alkylene, alkenylene], were

prepared Thus, BOC-Q2-Phe-N(Me)CH2Ph [BOC = Me3CO2C, Q2 = (2S,4R)-4-hydroxypropyl residue] (preparation from BOC-Phe-OH given) was deprotected with trifluoroacetic acid and the product was coupled with indole-3-carbonyl chloride (Q3Cl) in CH2Cl2 in the presence of bistrimethylsilylacetic acid to give Q3-Q2-Phe-N(Me)CH2Ph. The latter inhibited substance P-induced bronchoconstriction in guinea pigs with an ED50 of 0.072 mg/kg intratracheally.


IT 131948-37-3P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of, as tachykinin antagonist)
 RN 131948-37-3 CAPLUS

L4 ANSWER 57 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN L-Phenylalaninamide,
 trans-4-hydroxy-1-[(5-hydroxy-1H-indol-3-yl)acetyl]-1-
 prolyl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 58 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1986:552787 CAPLUS
 DOCUMENT NUMBER: 105:152787
 ORIGINAL REFERENCE NO.: 105:24613a,24616a
 TITLE: Synthesis of psilocin labeled with carbon-14 and tritium
 AUTHOR(S): Poon, Grace; Chui, Yun Cheung; Law, Francis C. P.
 CORPORATE SOURCE: Dep. Biol. Sci., Simon Fraser Univ., Burnaby, BC, V5A 1S6, Can.
 SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals
 (1986), 23(2), 167-74
 CODEN: JLCRD4; ISSN: 0362-4803
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 105:152787
 GI




AB 14C- and 3H-labeled psilocin (I, X = CH214CH2; C3H2C3H2) tryptamine), the principal active agent of hallucinogenic mushrooms, was synthesized from 2-methyl-3-nitrophenol via 4-benzyloxyindole. 4-Benzyloxytryptamine was treated with K14CN to give 14C-4-benzyloxy-3-indoleacetic acid, an intermediate for I (X = CH214CH2). LiAlH4 was used to reduce 4-benzyloxy-3-indole-N,N-dimethylglyoxylamide to give I (X = C3H2C3H2).
 IT 104556-01-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of)
 RN 104556-01-6 CAPLUS
 CN 1H-Indole-3-acetamide-carbonyl-14C, N,N-dimethyl-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)




L4 ANSWER 59 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1986:478831 CAPLUS
 DOCUMENT NUMBER: 105:78831
 ORIGINAL REFERENCE NO.: 105:12789a,12792a
 TITLE: 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide
 INVENTOR(S): Oxford, Alexander William
 PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
 SOURCE: Ger. Offen., 57 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3527648	A1	19860213	DE 1985-3527648	19850801
DE 3527648	C2	19930826		
CH 666026	A5	19880630	CH 1985-3296	19850730
HU 40077	A2	19861128	HU 1985-2945	19850731
HU 201738	B	19901228		
DK 8503511	A	19860202	DK 1985-3511	19850801
DK 158942	B	19900806		
DK 158942	C	19910121		
FI 8502969	A	19860202	FI 1985-2969	19850801
FI 78466	B	19890428		
FI 78466	C	19890810		
SE 8503680	A	19860202	SE 1985-3680	19850801
SE 452460	B	19871130		
SE 452460	C	19880310		
BE 903006	A1	19860203	BE 1985-215426	19850801
NO 8503046	A	19860203	NO 1985-3046	19850801
NO 164653	B	19900723		
NO 164653	C	19901107		
GB 2162522	A	19860205	GB 1985-19418	19850801
GB 2162522	B	19880224		
AU 8545689	A	19860206	AU 1985-45689	19850801
AU 573878	B2	19880623		
FR 2568571	A1	19860207	FR 1985-11790	19850801
FR 2568571	B1	19880923		
NL 8502171	A	19860303	NL 1985-2171	19850801
NL 188642	B	19920316		
NL 188642	C	19920817		
JP 61047464	A	19860307	JP 1985-168664	19850801
JP 06023197	B	19940330		
ZA 8505818	A	19860430	ZA 1985-5818	19850801
AT 8502266	A	19871215	AT 1985-2266	19850801
AT 386196	B	19880711		
CA 1241004	A1	19880823	CA 1985-487992	19850801
PL 146005	B1	19881231	PL 1985-254800	19850801
IL 75986	A	19890228	IL 1985-75986	19850801
SU 1498386	A3	19890730	SU 1985-3935745	19850801
ES 2068181	T3	19950416	ES 1987-303761	19870428
US 5037845	A	19910806	US 1989-317682	19890301
SK 277952	B6	19950913	SK 1991-4041	19911223
CZ 280530	B6	19960214	CZ 1991-4041	19911223
PRIORITY APPLN. INFO.:			GB 1984-19575	A 19840801

L4 ANSWER 59 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 US 1985-761392 B1 19850801
 US 1986-858594 A 19860430
 US 1987-35652 A 19870406
 US 1987-82666 B1 19870807
 OTHER SOURCE(S): CASREACT 105:78831
 GI




AB The title compound (I), prepared by 8 methods, is useful in treating migraine headaches at 0.1-100 mg per dose, up to 8 times daily. Hydrogenation of 3-(cyanomethyl)-N-methyl-1H-indole-5-methanesulfonamide over prerduced 10% Pd oxide on active C in methanolic and ethanolic Me2NH for 24 h at room temperature gave I (isolated as the succinate). Several formulations were given.
 IT 103628-52-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of)
 RN 103628-52-0 CAPLUS
 CN 1H-Indole-3-acetamide, N,N-dimethyl-5-[(methylamino)sulfonylmethyl]- (CA INDEX NAME)



L4 ANSWER 60 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1985:560388 CAPLUS
 DOCUMENT NUMBER: 103:160388
 ORIGINAL REFERENCE NO.: 103:25745a,25748a
 TITLE: Indole derivatives and their use
 INVENTOR(S): Oxford, Alexander William; Evans, Brian; Dowle, Michael Dennis; Coates, Ian Harold
 PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
 SOURCE: Ger. Offen., 72 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3444572	A1	19850620	DE 1984-3444572	19841206
DE 3444572	C2	19931014		
FI 8404789	A	19850607	FI 1984-4789	19841205
FI 80260	B	19900131		
FI 80260	C	19900510		
BE 901224	A1	19850606	BE 1984-214125	19841206
DK 8405836	A	19850607	DK 1984-5836	19841206
FR 2555987	A1	19850607	FR 1984-18618	19841206
FR 2555987	B1	19870717		
NO 8404879	A	19850607	NO 1984-4879	19841206
NO 162764	B	19891106		
NO 162764	C	19900214		
SE 8406200	A	19850607	SE 1984-6200	19841206
SE 458446	B	19890403		
SE 458446	C	19890727		
AU 8436367	A	19850613	AU 1984-36367	19841206
AU 575365	B2	19880728		
NL 8403719	A	19850701	NL 1984-3719	19841206
GB 2150932	A	19850710	GB 1984-30810	19841206
GB 2150932	B	19871028		
JP 60155156	A	19850815	JP 1984-258409	19841206
JP 06002733	B	19940112		
AT 8403873	A	19860515	AT 1984-3873	19841206
AT 381934	B	19861210		
ZA 8409498	A	19860924	ZA 1984-9498	19841206
CH 663411	A5	19871215	CH 1984-5810	19841206
CA 1233183	A1	19880223	CA 1984-469528	19841206
IL 73756	A	19880229	IL 1984-73756	19841206
ES 541098	A5	19881216	ES 1985-541098	19850308
HU 40624	A2	19870128	HU 1985-2083	19850530
CN 85104233	A	19870107	CN 1985-104233	19850603
CN 85106225	A	19870218	CN 1985-106225	19850819
CN 1015055	B	19911211		
US 4994483	A	19910219	US 1989-443874	19891130
DK 9002140	A	19900906	DK 1990-2140	19900906
JP 03184958	A	19910812	JP 1990-326200	19901129
PRIORITY APPLN. INFO.:			GB 1983-32435	A 19831206


L4 ANSWER 60 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 GB 1984-6208 A 19840309
 US 1984-678995 B1 19841206
 US 1987-72786 B1 19870713
 OTHER SOURCE(S): CASREACT 103:160388; MARPAT 103:160388
 GI



AB Antimigraine (no data) indolealkanesulfonamides I [R = H, alkyl, alkenyl; R1 = cycloalkyl, Ph, phenylalkyl, R; R2, R3 = H, alkyl, CH2:CHCH2; R2R3 = aralkylidene; Z, Z1 = alkyl-(un)substituted alkylene] were prepared
 Thus, 4-O2NC6H4CH2CH2SO2Cl was amidated with MeNH2, hydrogenated over Pd-C to the aniline, diazotized, and treated with ZnCl2 to give 4-H2NNHC6H4CH2CH2SO2NHMe. The latter compound was stirred in aqueous MeOH with (MeO)2CH(CH2)3Cl at 50°, NH4OAc added to pH 4, then refluxed 5 h to give I (R = Me, R1-R3 = H, Z = Z1 = CH2CH2).
 IT 98622-74-3P 98623-48-4P
 R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and lithium aluminum hydride reduction of)

RN 98622-74-3 CAPLUS
 CN 1H-Indole-3-acetamide,
 N-ethyl-N-methyl-5-[2-[(methylamino)sulfonyl]ethyl]-
 (CA INDEX NAME)



RN 98623-48-4 CAPLUS
 CN 1H-Indole-3-acetamide, N,N-dimethyl-5-[2-[(methylamino)sulfonyl]ethyl]-
 (CA INDEX NAME)


L4 ANSWER 60 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 61 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1977:16538 CAPLUS
 DOCUMENT NUMBER: 86:16538
 ORIGINAL REFERENCE NO.: 86:2689a,2692a
 TITLE: Indolylalkylpiperidines
 INVENTOR(S): Huebner, Charles F.
 PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
 SOURCE: Ger. Offen., 72 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2609289	A1	19760930	DE 1976-2609289	19760306
SE 7602729	A	19760913	SE 1976-2729	19760227
NO 7600774	A	19760913	NO 1976-774	19760305
GB 1534351	A	19781206	GB 1976-8902	19760305
FI 7600584	A	19760911	FI 1976-584	19760308
FR 2303541	A1	19761008	FR 1976-6495	19760308
FR 2303541	B1	19791005		
ES 445874	A1	19770601	ES 1976-445874	19760308
AU 7611750	A	19770915	AU 1976-11750	19760308
IL 49171	A	19781217	IL 1976-49171	19760308
BE 839347	A1	19760909	BE 1976-164977	19760309
DK 7601014	A	19760911	DK 1976-1014	19760309
DK 138893	C	19790423		
DK 138893	B	19781113		
DD 124386	A5	19770216	DD 1976-191763	19760309
NL 7602508	A	19760914	NL 1976-2508	19760310
JP 51113878	A	19761007	JP 1976-26622	19760310
US 4147786	A	19790403	US 1977-797151	19770516
US 4242347	A	19801230	US 1979-50003	19790618
PRIORITY APPLN. INFO.:			US 1975-556600	A 19750310
			US 1976-654254	A3 19760202

OTHER SOURCE(S): CASREACT 86:16538; MARPAT 86:16538
 GI




AB Indolylethylpiperidines (I; R = e.g., H, 5-Cl, 5-Br, 5-F, 7-Me, 7-MeO; R1 = e.g., H, Me; R2 = e.g., H, Me; R3, R4 = e.g., H, H; ethylene, o-phenylene; R5 = e.g., H, Ph; n = 2, 3), useful as antihypertensives, are prepared by various known procedures. Thus, reaction of 3-(2-bromoethyl)indole with 4-ureidopiperidine in DMF 2 days at room temperature in presence of Et3N gives I (R = R1 = R2 = R3 = R4 = R5 = H, n = 2).

L4 ANSWER 61 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (continued)
 IT 61220-26-6P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); SPN (Synthetic preparation); BIOL (Biological
 study); PREP (Preparation)
 (preparation and antihypertensive activity of)
 RN 61220-26-6 CAPLUS
 CN Piperidine,
 1-[(6-chloro-1H-indol-3-yl)acetyl]-4-(2-oxo-1-imidazolidinyl)-
 (9CI) (CA INDEX NAME)




L4 ANSWER 62 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:145952 CAPLUS
 DOCUMENT NUMBER: 80:145952
 ORIGINAL REFERENCE NO.: 80:23549a,23552a
 TITLE: New route for synthesizing psilocine derivatives
 AUTHOR(S): Germain, Claude; Bourdais, Jacques
 CORPORATE SOURCE: Lab. Chim. Heterocyclique Organomet., Univ.
 Paris-Sud,
 Orsay, Fr.
 SOURCE: Chimica Therapeutica (1973), 8(6), 647-51
 CODEN: CHTPBA; ISSN: 0009-4374
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 OTHER SOURCE(S): CASREACT 80:145952
 GI For diagram(s), see printed CA Issue.
 AB Indoles I (R = Me, PhCH₂; R₁ = Me, Me₂CH n = 1.2) were prepared from
 2,3-Cl(O₂N)C₆H₃OH (II). Successive methylation, NCCH₂CONMe₂
 condensation,
 hydrogenation and reductive cyclization of II indolecarboxamide III (R =
 H, R₁ = Me, m = 0), which underwent alkylation and LiAlH₄ reduction to
 give
 indolemethylanilines I (R = PhCH₂, 2-ClC₆H₄CH₂). In 6 steps III (R = H, R₁
 = Me, m = 0) was converted to the indoleacetamide III (m = 1), which was
 reduced to the corresponding indoleethylamine I. Alkylation of III (R =
 H, R₁ = Me, m = 1) and then reduction gave indoleethylamine I (R = Me,
 PhCH₂).
 Similarly, I (R₁ = Me₂CH) were prepared
 IT 52335-79-2P 52335-80-5P 52335-81-6P
 52335-82-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 52335-79-2 CAPLUS
 CN 1H-Indole-3-acetamide, 4-methoxy-N,N-dimethyl- (CA INDEX NAME)




RN 52335-80-5 CAPLUS
 CN 1H-Indole-3-acetamide, N,N-dimethyl-4-(1-methylethoxy)- (CA INDEX NAME)


L4 ANSWER 62 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




RN 2335-81-6 CAPLUS
 CN 1H-Indole-3-acetamide, 4-methoxy-N,N,1-trimethyl- (CA INDEX NAME)




RN 2335-82-7 CAPLUS
 CN 1H-Indole-3-acetamide, 4-methoxy-N,N-dimethyl-1-(phenylmethyl)- (CA
 INDEX NAME)



L4 ANSWER 63 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1969:491200 CAPLUS
 DOCUMENT NUMBER: 71:91200
 ORIGINAL REFERENCE NO.: 71:16963a,16966a
 TITLE: Synthesis and reactions of 4,6-dimethoxyindole, and
 unusual indole system
 AUTHOR(S): Brown, Vernon H.; Skinner, W. A.; DeGraw, Joseph I.
 CORPORATE SOURCE: Dep. of Pharm. Chem., Stanford Res. Inst., Menlo
 Park,
 CA, USA
 SOURCE: Journal of Heterocyclic Chemistry (1969), 6(4),
 539-43
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 71:91200
 GI For diagram(s), see printed CA Issue.
 AB A synthesis of 4,6-dimethoxyindole (I) is described. Formylation or
 oxalation reactions with I gave substitution at position 7 rather than
 the usual 3-substitution characteristic of other indoles. A synthesis of
 N,N-dimethyl-4,6-dimethoxytryptamine is presented along with N.M.R. data
 for 3 and 7-substituted compds. in this series.
 IT 23659-37-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 23659-97-4 CAPLUS
 CN Indole-3-acetamide, 4,6-dimethoxy-N,N-dimethyl- (8CI) (CA INDEX NAME)



L4 ANSWER 64 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1965:36828 CAPLUS
 DOCUMENT NUMBER: 62:36828
 ORIGINAL REFERENCE NO.: 62:6485a-c
 TITLE: Synthesis of some N-phenylpiperazine derivatives as potential central nervous system depressants
 AUTHOR(S): Chou, Chi-Ting; Chi, Ju-Yun
 CORPORATE SOURCE: Acad. Sinica, Shanghai, Peop. Rep. China
 SOURCE: Yaokue Xuebao (1964), 11(10), 692-9
 CODEN: YHHPAL; ISSN: 0513-4870
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese
 AB A series of indolylalkylphenylpiperazines was recently reported to be active central nervous system depressants. Variation in the length of the alkyl chains and change of substituents on the indole moiety or on the Ph group influenced only the strength and specificity of the activity. However, removal of the Ph group or replacement of it by an alkyl or arylalkyl group caused the loss of almost all of the central activities. It would seem possible to get even more favorable central nervous system depressants on further modification of the indole moiety, as long as the N-Ph group was retained. A number of N-phenyl- and -chlorophenylpiperazine derivs., the substituents on the other N being either isosteres of indole or pharmacol. interesting groups, were synthesized. These compds. were synthesized either by condensation of appropriate halides with N-phenyl- or -chlorophenylpiperazine, or by reduction of the corresponding amides by means of LiAlH₄. The amides were in turn prepared by the interaction of acyl chlorides or acyl azides and N-phenyl- or -chlorophenylpiperazine, resp. Two of the amides were afforded on application of the Arndt-Eistert reaction. Two of these compds., 1-(3,4,5-trimethoxyphenethyl)-4-phenylpiperazine and 1-(3,4,5-trimethoxyphenethyl)-4-(p-chlorophenyl)piperazine exhibited marked tranquilizing activity in preliminary pharmacol. exams.
 IT 1109-25-7P, Piperazine, 1-[(1-benzyl-5-methoxyindol-3-yl)acetyl]-4-(p-chlorophenyl)- 1258-69-1P, Piperazine, 1-[(1-benzyl-5-methoxyindol-3-yl)acetyl]-4-phenyl-
 RL: PREP (Preparation)
 (preparation of)
 RN 1109-25-7 CAPLUS
 CN Piperazine, 1-[(1-benzyl-5-methoxyindol-3-yl)acetyl]-4-(p-chlorophenyl)- (7CI, 8CI) (CA INDEX NAME)




RN 1258-69-1 CAPLUS

L4 ANSWER 65 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1964:52796 CAPLUS
 DOCUMENT NUMBER: 60:52796
 ORIGINAL REFERENCE NO.: 60:9293g-h, 9294a-h, 9295a-h, 9296a-b
 TITLE: Indolylpiperazines
 PATENT ASSIGNEE(S): Sterling Drug Inc.
 SOURCE: 41 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 944443		19631211	GB	
US 3188313		19650608	US 1959-842203	19590925
PRIORITY APPLN. INFO.:			US	19590925

GI For diagram(s), see printed CA Issue.
 AB Compds. of type I and II, in which R1 is H, halogen, alkyl, alkoxy, or aryl, R2 is H, alkyl, hydroxyalkyl, or aryl, R3 and R4 is H, alkyl, or aryl, n is 1 to 7, and in which the indole group may be joined in the 2-position or (as shown) the 3-position, were made. These are useful as hypotensive agents, as antinauseants, antipyretics, sedatives, tranquilizers and muscle relaxants; they inhibit apomorphine-induced vomiting, and prolong the narcosis of ether and barbiturates. A solution of 177 g. (PhCH₂)₂NCH₂CH₂NHPh, 120 g. ClCH₂COCl and 650 m. CHCl₃ was refluxed for 5.5 hrs. to yield 190 g. (PhCH₂)₂NCH₂CH₂NPhCOCH₂Cl, an oil. This was dissolved in EtOCH₂CH₂OH, the solution refluxed 4 hrs., cooled, diluted with 650 ml. absolute EtOH, 4 g. Pd-C added, and the mixture reduced by H at 50 lb./in.² to give 1-phenyl-2-piperazinone (VI), m. 100-5° (p-toluenesulfonate m. 220.2-4.6°). Similarly made from (PhCH₂)₂NCH₂CH₂N(4-ClC₆H₄)(COCH₂Cl) (HCl salt m. 161.0-3.8°) was 1-(4-chlorophenyl)-2-piperazinone (HCl salt m. 192.8-4.8°); from 4-benzyl-1-(2,6-dimethylphenyl)-2-piperazinone (HCl salt m. 248.8-64.8°), 1-(2,6-dimethylphenyl)-2-piperazinone (HCl salt m. 224.8-6.0°). The I and II were made by various methods. Method A: A mixture of 5.6 g. 2-(3-indolyl)ethyl bromide (VII), 4.1 g. 1-phenylpiperazine, 2.1 g. NaHCO₃, and 30 ml. absolute EtOH was refluxed for 6 hrs. to yield 1.4 g. I (R1 = R3 = R4 = H, R2 = Ph, n = 2), m. 131.6-6.0°. Similarly prepared were these I (R3 = R4 = H, n = 2; R1, R2, and m.p. given): H, 4-ClC₆H₄, 185.2-6.8°; H, p-tolyl, 147.8-54.8°; 5-MeO, p-tolyl, 108.6-11.0°; H, PhCH₂CH₂, 258.2-63.6°. Also made was 1-(2-(3-indolyl)ethyl)-trans-2,5-dimethylpiperazine, m. 189.2-90.4°, and from VI and VII 1-(2-(3-indolyl)ethyl)-4-phenyl-3-piperazinone, m. 163.2-4.4°. Method B: To a cold solution of 79.2 g. 1-(o-tolyl)piperazine in 500 ml. tetrahydrofuran (VIII) was added 31.2 g. (3-indolyl)glyoxalyl chloride (IX), the white precipitate filtered off, the filtrate evaporated, the residual gum taken up in a warm mixture of 700 ml. H₂O, 120 ml. AcOEt and 25 ml. AcOH, and the solid collected, to give 41.5 g.

L4 ANSWER 64 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 CN Piperazine, 1-[(1-benzyl-5-methoxyindol-3-yl)acetyl]-4-phenyl- (7CI, 8CI) (CA INDEX NAME)




L4 ANSWER 65 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 III (R1 = R3 = R4 = H, R2 = o-tolyl) (X). Similarly prepd. were these

(R3 = R4 = H; R1, R2, and m.p. given): H, Me, --; H, HOCH₂CH₂, --; H, m-tolyl, --; H, 2-MeOC₆H₄, --; H, 4-MeOC₆H₄, 243-5°; H, 3,4-Cl₂MeC₆H₃, 211-14°; 6-MeO, Ph, 205-9°; 6-MeO, o-tolyl, 247-50°; 6-MeO, m-tolyl, 206-8°; 6-MeO, p-tolyl, 196-8°; 6-MeO, 2-MeOC₆H₄, 246-8°; 6-MeO, 4-MeOC₆H₄, 205-10°; 5-PhCH₂O, p-tolyl, 148-55°; 5-PhCH₂O, PhCH₂CH₂, 135-40°; 5-MeS, Ph, 188-91°; 5-MeS, p-tolyl, 211-13°; 5,6-(CH₂O)₂, Ph, 267-9°; 5,6-(CH₂O)₂, o-tolyl, 214.6-15.8°; 5,6-(CH₂O)₂, m-tolyl, 212-16°; 5,6-(CH₂O)₂, p-tolyl, 266.4-78.4°; 5,6-(CH₂O)₂, 2-MeOCH₂CH₂, 205-9°; 5,6-(MeO)₂, Ph, 256.8-8.8°; 5,6-(MeO)₂, o-tolyl, 211-16°; 5,6-(MeO)₂, m-tolyl, 231-8°; 5,6-(MeO)₂, p-tolyl, --; 5,6-(MeO)₂, 2-MeOC₆H₄, 218-22°; 5,6-(MeO)₂, 3-MeOC₆H₄, 234.4-6.4°; 5,6-(MeO)₂, 4-MeOC₆H₄, 228-36°; 5,6-(MeO)₂, 4-MeSC₆H₄, 236.4-8.2°; 5,6-(EtO)₂, Ph, 180.0-1.0°; H, 2-pyridyl, 242-3°; 4-MeO, Ph, --; 5-MeO, Ph, 224-7.5°; 7-MeO, Ph, --; 6-Me, Ph, --; 6-EtO, Ph, 165° (decompn.); 6-MeO, 2-ClC₆H₄, 125.2-8.8°; 6-MeO, 3-ClC₆H₄, 214-16°; 6-MeO, 3-MeOC₆H₄, 211-13°; 6-MeO, 2-EtOC₆H₄, 180-4°; 6-MeO, 2,6-Me₂C₆H₃, 215-18°; 6-MeO, 5,2-Cl(MeO)₂C₆H₃, 208-11°; 5,6-(MeO)₂, PhCH₂, 210.2-11.8°; 5,6-EtO(MeO), Ph, 215-22°; 5,6-(MeO)₂, 2-pyridyl, 249.6-51.6°; 5,6-(OCH₂CH₂O), Ph, 172.5-8.5°; 5,6-(MeO)₂, 2-EtOC₆H₄, 135-43°; 5,6-(MeO)₂, 2,6-Me₂C₆H₃, 253.2-6.2°; 5,6-(CH₂O)₂, 4-MeOC₆H₄, 257-8°; 5,6-(CH₂O)₂, 2-BuOC₆H₄, 164-7.5°; 5,6-(EtO)₂, 2-MeOC₆H₄, 185-6.5°; 5,6-(EtO)₂, 3-MeOC₆H₄, 162-5.5°; H, Ph, 224.2-5.6°; H, PhCH₂, 174.4-5.6°; 5,6-(MeO)₂, 2-ClC₆H₄, approx. 214°; 6-Cl, Ph, 270-4°; 6-MeO, 2-pyridyl, 231-3°; 5,6-(MeO)₂, 2-BuOC₆H₄, 171-4°; 5,6-(MeO)₂, 2-EtOC₆H₄, 193-8°; 5,6-(MeO)₂, 2,5-(MeO)₂C₆H₃, 208-10°; 5,6-(CH₂O)₂, 2-pyridyl, 271-3°; 5,6-(MeO)₂, 2-MeSC₆H₄, 219-21°. Also prepd. were these III (R1, R2, R3, R4, and m.p. given): H, Ph, Me, H, --; 5,6-(MeO)₂, Ph, Me, H, 163-74°; 5,6-(CH₂O)₂, 4-MeOC₆H₄, Me, H, 173-266°; 5,6-(CH₂O)₂, Ph, H, Me, 219-19.8°; 5,6-(MeO)₂, Ph, H, Me, 215-22°; H, Ph, Me, Me, --; 6-MeO, Ph, Me, 218-20°; 6-MeO, Ph, Ph, H, 155-60°; 5,6-(MeO)₂, 2-MeOC₆H₄, Me, H, 211.4-12.6°; 5,6-(MeO)₂, o-tolyl, Me, H, 119-22°; 5,6-(MeO)₂, m-tolyl, Me, H, 120-2°; 5,6-(MeO)₂, 3-MeOC₆H₄, Me, H, 159-63.5°; 5,6-(CH₂O)₂, 2-MeOC₆H₄, Me, H, 233-59°; 5,6-(MeO)₂, Ph, Et, H, 177-84°; 5,6-(EtO)₂, Ph, Me, H, 182-7°. A soln. of 41.5 g. X in 250 ml. VIII was added to a suspension of 27 g. LiAlH₄ in 300 ml. VIII, and the mixt. refluxed 61/2 hrs. to give 28.5 g. I (R1, R3, R4 = H, R2 = o-tolyl n = 2), m. 124.2-6.4°. Similarly prepd. were these I (R3 = R4 = H, n = 2; R1, R2, and m.p. given): H, H, 149.8-52.0°; H, Me, -- (di-HCl salt m. 279.0-83.8°); H, HOCH₂CH₂, -- (di-HCl salt m. 279.0-83.8°); H, 2-MeOC₆H₄, 111.4-14.2°; H, 4-MeOC₆H₄, 129.8-31.6°; H, 3,4-Cl₂MeC₆H₃, 159.2-60.6°; 6-MeO, Ph, 137.4-9.6°; 6-MeO, o-tolyl, 139.2-41.4°; 6-MeO, m-tolyl, 119.8-23.4°; 6-MeO, p-tolyl, 172.2-3.4°; 6-MeO, 2-MeOC₆H₄, 98.2-100.2°; 6-MeO, 4-MeOC₆H₄, 185.6-8.6°; 5-PhCH₂O, p-tolyl, 151.4-3.6°; 5-PhCH₂O, PhCH₂CH₂, 121-3°; 5-MeS, Ph, 110.2-11.6°; 5-MeS, p-tolyl, 111-13.6°; 5,6-(CH₂O)₂, Ph, 141.0-3.2°; 5,6-(CH₂O)₂, o-tolyl, 159.2-60.8°; 5,6-(CH₂O)₂, m-tolyl, 130.0-1.4°; 5,6-(CH₂O)₂, p-tolyl, 187.0-8.8°; 5,6-(CH₂O)₂, 2-MeOC₆H₄,

L4 ANSWER 65 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 158.0-9.4°; 5,6-(MeO)2, Ph, 128.4-30.0°; 5,6-(MeO)2, o-tolyl, -- (HCl salt m. 218.4-23.4°); 5,6-(MeO)2, m-tolyl, 118.4-19.6°; 5,6-(MeO)2, p-tolyl, 137.8-9.2°; 5,6-(MeO)2, 2-MeOC6H4, 116.0-16.6°; 5,6-(MeO)2, 3-MeOC6H4, 123.0-4.0°; 5,6-(MeO)2, 4-MeOC6H4, 158.8-64.0°; 5,6-(MeO)2, 4-MeSC6H4, 175.4-7.2°; 5,6-(EtO)2, Ph, 123.0-5.2°; H, 2-pyridyl, -- (HCl salt m. 232.2-4.4°); 4-MeO, Ph, 177.2-82.2°; 5-MeO, Ph, 147.4-50.0°; 7-MeO, Ph, 122.0-5.2°; 6-Me, Ph, 174.2-5.2°; 6-EtO, Ph, 159.6-63.2°; 6-MeO, 2-ClC6H4, 125.2-8.8°; 6-MeO, 3-ClC6H4, 103.6-4.4°; 6-MeO, 3-MeOC6H4, 142.0-4.6°; 6-MeO, 2-EtOC6H4, 159.4-61.4°; 6-MeO, 2,6-Me2C6H3, 135.2-6.8°; 6-MeO, 2,5-MeOC1C6H3, 121.8-8.6°; 5,6-(MeO)2, PhCH2 (XI), 113-14.4°; 5,6-EtO(MeO), Ph, 129.2-30.6°; 5,6-(MeO)2, 2-pyridyl -- (HCl salt m. 210.2-11.8°; 5,6-(OCH2CH2O), Ph, 170.8-6.8°; 5,6-(MeO)2, 2-EtOC6H4, 120.4-2.0°; 5,6-(MeO)2, 2,6-Me2C6H3, 117.8-19.6°; 5,6-(CH2O2), 4-MeOC6H4, 182.4-4.6°; 5,6-(CH2O2), 2-BuOC6H4, 125.0-6.4°; 5,6-(EtO)2, 2-MeOC6H4, 89.4-92.0°; 5,6-(EtO)2, 3-MeOC6H4, 97.6-8.4°; 6-Cl, Ph, 177.2-8.6°; 6-MeO, 2-pyridyl, 107.2-8.2°; 5,6-(MeO)2, 2-BuOC6H4, 93.8-5.8°; 5,6-(MeO)2, 2-EtC6H4, 104.2-7.2°; 5,6-(MeO)2, 2,5-(MeO)2C6H3, 136.8-7.8°; 5,6-(CH2O2), 2-pyridyl, -- (di-HCl salt m. 200-24°); 5,6-(MeO)2, 2-MeSC6H4, 116-17.8°. Also made were these I (n = 2; R1, R2, R3, R4, and m.p. given): H, Ph, Me, H, 154.2-5.6°; 5,6-(MeO)2, Ph, Me, H, -- (HCl salt m. 249.0-55.4°); 5,6-(CH2O2), 4-MeOC6H4, Me, H, 160.8-2.8°; 6-MeO, Ph, Me, H, -- (HCl salt m. 253.2-6.2°); 6-MeO, Ph, Ph, H, 148.2-8.8°; 5,6-(MeO)2, 2-MeOC6H4, Me, H, -- (di-HCl salt m. 217.4-20.8°); 5,6-(MeO)2, o-tolyl, Me, H, 119.8°-21.6°; 5,6-(MeO)2, m-tolyl, Me, H, -- (di-HCl salt m. 210.2-3.8°); 5,6-(MeO)2, 3-MeOC6H4, Me, H, -- (di-HCl salt m. 182.6-4.2°); 5,6-(CH2O2), 2-MeOC6H4, Me, H, 137.0-43.0°; 5,6-(CH2O2), 2-MeOC6H4, H, Me, 155.4-6.4°; 5,6-(MeO)2, Ph, Me, H, 139.6-40.4°; 5,6-(MeO)2, Ph, Et, H, -- (HCl salt m. 237.6-9.0°); 5,6-(EtO)2, Ph, Me, H, 111.6-13.2°; 5,6-(CH2O2), 2-MeOC6H4, Me, Me, 118.2-19.6°; 5,6-(CH2O2), 2-MeOC6H4, Me, PhCH2, 169.2-70.2°; H, 2-MeOC6H4, H, Me, 74.6-6.4°. Catalytic debenzoylation of XI gave I (R1 = 5,6-(MeO)2, R2, R3, R4 = H, n = 2), m. 109.6-11.4°, which reacted with 2-chloropyrimidine to give I (R1 = 5,6-(MeO)2, R2 = 2-pyrimidinyl, R3, R4 = H, n = 2), m. 127.2-8.2°. III (R4 = alkyl was reduced to II; other II were obtained as by-products in the LiAlH4 redn. of III. Thus were made these II (n = 1; R1, R2, R3, R4, and m.p. given): 5,6-(CH2O2), Ph, H, Me, 171-2.5°; 5,6-(MeO)2, Ph, H, Me, 128.4-30.2°; H, Ph, Me, Me, 136.8-9.6°; 5,6-(MeO)2, p-tolyl, H, H, 193.2-8.0°. Method C: On addn. of 3-(4-benzhydryl-1-piperazinyl)propionyl chloride to a soln. of 5-chloroindole and EtMgBr in ether, there was obtained IV (R1 = 5-Cl, R2 = PhCH2, R3, R4 = H, n = 2) (XII), which with MeI and NaNH2 in liquid NH3 gave IV (R1 = 5-Cl, R2 = PhCH2, R3 = H, R4 = Me, n = 2). Similarly made were these IV (R1, R2, R3, R4, and n given): H, Ph, Ph, H, 3; H, Ph, Ph, PhCH2, 3. XII was reduced by LiAlH4 to I (R1 = 5-Cl, R2 = PhCH2, R3, R4 = H, n = 3), but
 XII reduced by NaBH4 yielded II (R1 = 5-Cl, R2= PhCH2, R3 = R4 = H, n = 2).

L4 ANSWER 65 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 157.2-9.0°. Similarly made was 4-[2-(3-indolyl)ethyl]-1-methyl-1-benzyl-3-oxopiperazinium chloride, m. 229.5-32.5°, and 4-[2-(3-indolyl)ethyl]-2-methyl-1-phenyl-3-piperazinone, m. 186.4-91.8°. The latter, reduced by LiAlH4, gave 1-[2-(3-indolyl)ethyl]-3-methyl-4-phenylpiperazine, m. 116.2-17.6°. IT 96266-49-8P, Piperazine, 1-(o-chlorophenyl)-4-[(5,6-dimethoxyindol-3-yl)acetyl]-
 R1: PREP (Preparation)
 (preparation of)
 RN 96266-49-8 CAPLUS
 CN Piperazine, 1-(o-chlorophenyl)-4-[(5,6-dimethoxyindol-3-yl)acetyl]- (7CI)
 (CA INDEX NAME)




L4 ANSWER 65 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 When IV (R4 = alkyl) was reduced by LiAlH4, then II was obtained. Thus were made these II (R1, R2, R3, R4 and n given): 5-Cl, PhCH2, H, Me, 2; H, Ph, Ph, PhCH2, 3; 6-BuO, Me, H, 4-MeSC6H4CH2CH2, 3; 5,6,7-(MeO)3, Me, H, 4-BuOC6H4CH2CH2, 3; H, Me, H, 3-HOC6H4CH2CH2, 3; H, Me, H, PhCH:CHCH2, 3. Method D: To a cold soln. of 22.5 g. 3-indoleacetic acid and 13.3 g. Et3N in 800 ml. Me2CO was added 18.1 g. ClCO2Bu-iso, the mixt. stirred for 10 min. at -10°, a soln. of 1-phenylpiperazine in little Me2CO added, and the mixt. kept 1.7 hrs. at room temp. to yield 5.4 g. V (R1, R2 = H, R3 = Ph, n = 1), m. 179.4-81.6°. Similarly prep'd. were these V (R3 = H; R1, R2, n, and m.p. given): H, Ph, 2, 136.2-7.4°; H, 3-MeOC6H4, 1, --; H, 2-ClC6H4, 2, --; H, o-tolyl, 2, --; H, 2-MeOC6H4, 2, 173.0-6.0°; H, Ph, 3, --; H, 2-MeOC6H4, 3, 129-32°; H, 3-MeOC6H4, 3, --; 6-MeO, Ph, 2, 169-72°; 6-MeO, 2-MeOC6H4, 2, 120.5-2.0°; 5,6-(MeO)2, 3-ClC6H4, 1, --; 5,6-(CH2O2), Ph, 2, 178-80°; 5,6-(MeO)2, 2-ClC6H4, 1, 185-8.5°; 5,6-(MeO)2, 2-MeOC6H4, 2, 124.8-7.4°; 5,6-(MeO)2, Ph, 2, 120.5-2.0°; 5,6-(MeO)2, 3-MeOC6H4, 2, --. Also obtained was V (R1 = 5,6-(MeO)2, R2 = Ph, R3 = Me, n = 2). Also made was 1-[3-(1-indolyl)propionyl]-4-phenylpiperazine, an oil and 1-[3-(2-methyl-5,6-dimethoxy-3-indolyl)propionyl]-4-phenylpiperazine. By redn. of these V by LiAlH4 in VIII were prep'd. these I (R3 = R4 = H; R1, R2, n, and m.p. given): H, Ph, 2, --; H, Ph, 3, 126.6-7.8°; H, 3-MeOC6H4, 2, 146.4-7.6°; H, 2-ClC6H4, 3, 140.3-3.6°; H, o-tolyl, 3, 102.4-4.2°; 2-MeOC6H4, 3, 156.8-9.2°; H, Ph, 4, 96.0-100.8°; H, 2-MeOC6H4, 4, 120.6-3.8°; H, 3-MeOC6H4, 4, -- (HCl salt, m. 234.2-5.8°); 6-MeO, Ph, 3, 196.4-7.6°; 6-MeO, 2-MeOC6H4, 3, 153.2-5.0°; 5,6-di-MeO, 3-ClC6H4, 2, -- (HCl salt m. 236.8-9.2°); 5,6-(CH2O2), Ph, 3, 142.6-4.2°; 5,6-(MeO)2, 2-ClC6H4, 2, 86.8-9.8°; 5,6-(MeO)2, 2-MeOC6H4, 3, 120.4-1.4°; 5,6-(MeO)2, Ph, 3, 157.4-8.2°; 5,6-(MeO)2, 3-MeOC6H4, 3, 159.0-60.2°. Also made was I (R1 = 5,6-(MeO)2, R2= Ph, R3 = Me, R4 = H, n = 3), m. 117.8-18.8°, and 1-[3-(1-indolyl)propyl]-4-phenylpiperazine, m. 96.7-8.4°. Method E: A soln. of 9.0 g. indole in 100 ml. dioxane was added to a cold soln. of 6.25 ml. 40% aq. CH2O and 13.3 g. 1-phenylpiperazine in 1 l. dioxane to give I (R1 = R3 = R4 = H, R2 = Ph, n = 1), m. 184.6-6.8°. Similarly made was I (R1 = 5,6-(MeO)2, R2 = Ph, R3 = R4 = H, n = 1), m. 159.3-60.2°. Method F: The piperazine ring was formed after a substituted ethylenediamine group had been joined to the indole moiety. Thus, 27 g. IX and 58 g. (PhCH2)NPhCH2CH2NH2 in 300 ml. VIII refluxed for 5 hrs. gave 41.9 g. N-benzyl-N-phenyl-N'-[3-(indolyl)glyoxalyl]ethylenediamine, m. 162.2-2.8°, which was reduced by LiAlH4 to N-benzyl-N-phenyl-N'-[2-(3-indolyl)ethyl]ethylenediamine (XIII) (di-HCl salt m. 171.4-5.4°). Also made were N-benzyl-N-methyl-N'-[(3-indolyl)glyoxalyl]ethylenediamine, m. 124.5-7.0°, and N-benzyl-N-methyl-N'-[2-(3-indolyl)ethyl]ethylenediamine, m. 102-5°. A soln. of 11.1 g. XIII and 3.4 g. ClCH2COCl in CH2Cl2 was refluxed to yield 9.4 g. 4-[2-(3-indolyl)ethyl]-1-phenyl-1-benzyl-1m3-oxopiperazinium chloride, m. 157-9.5°, which was catalytically debenzoylated to 1-[2-(3-indolyl)ethyl]-4-phenyl-2-piperazinone, m.

L4 ANSWER 66 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1962:449171 CAPLUS
 DOCUMENT NUMBER: 57:49171
 ORIGINAL REFERENCE NO.: 57:9785b-1,9786a-1,9787a-b
 TITLE: Research in the indole series. VI. Some substituted tryptamines
 AUTHOR(S): Julia, Marc; Igolen, Jean; Igolen, Hanne
 SOURCE: Bulletin de la Societe Chimique de France (1962) 1060-8
 CODEN: BSCFAS; ISSN: 0037-8968
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 GI For diagram(s), see printed CA Issue.
 AB A series of substituted 3-indolylacetic acids was prepared from secondary aromatic amines and 4-bromo-3-oxo esters; the acids were converted via the amides or the alcs. and bromides to the corresponding tryptamines. PhNH2 (279 g.) and 185 g. PhCH2CH2Br (I) in 500 cc. dry xylene refluxed 12 h. gave 151 g. PhNHCH2CH2Ph, b0.4 155-60°. p-MeOC6H4NH2 (295 g.) and 148 g. I in 350 cc. xylene gave similarly 95 g. unreacted p-MeOC6H4NH2 and 135 g. yellow-green oily p-MeOC6H4NHCH2CH2Ph (II), b0.1 170-5°; HCl salt m. 127-8° (EtOH-Et2O). p-MeOC6H4NH2 (3 mol) and Ph(CH2)3Br gave p-MeOC6H4NH(CH2)3Ph, b0.2 180-90°, needles, m. 44° (EtOH); HCl salt, plates, m. 158-9° (H2O); HBr salt, needles, 129° (EtOH). 4-Aminoveratrole gave similarly 89% 3,4-(MeO)2C6H3NHCH2Ph, b0.2 170-2° [HCl salt, plates, m. 142-5° (iso-PrOH)], and 3,4-(MeO)2C6H3NHCH2CH2OMe-p, 72%, needles, 86.5° (EtOH); HCl salt m. 188° (EtOH). By the direct bromination of the corresponding oxoesters were prepared the following compds.: MeCHBrCOCH2CO2Et, 73%, b0.25 82-5°; BrCH2COCHMeCO2Et, 65%, b0.2 80-5°; BrCH2COCHMe2CO2Et, 95%, -(crude); BrCH2COCH(CO2Et)CO2Et, 66, b0.1 69-72°. II (209 g.) and 96.1 g. BrCH2COCH2CO2Et (III) diluted with cooling with 250 cc. dry Et2O, filtered from 138 g. II.HBr, evaporated, the residue refluxed 15 h. with 63 g. ZnCl2 in 250 cc. absolute EtOH, evaporated, treated with H2O and C6H6, and the organic layer worked up gave 113 g. Et ester (IV) of 1-phenethyl-5-methoxy-3-indolylacetic acid (V), b0.1 215-20°, yellow-orange oil, which refluxed 1-2 h. with KOHMeOH yielded 73% V, m. 129-31° (aqueous EtOH); method A. III (50 g.) and 100 g. p-MeOC6H4NHCH2Ph in 300 cc. absolute EtOH refluxed 40 h., evaporated, the residue treated with H2O and Et2O, and the Et2O phase worked up yielded 44.7 g. Et ester (VI) of 1-benzyl-5-methoxy-3-indolylacetic acid (VII), b0.15 180-5°, yellow-orange oil, which saponified in the usual manner yielded 84% VII, m. 128-9°; method B. VI was also obtained in 64% yield by method A. In the same manner were prepared the following VIII (X, R1, R2, R3, R4, method, % yield of Et ester, b.p./mm. or m.p. of Et ester, % yield of free VIII, m.p., and m.p. of corresponding skatole given): H, PhCH2CH2, H, H, A, 68, 204-8°/0.15, 90, 103° (C6H6) (IX), --; 5-MeO, p-MeOC6H4CH2, H, H, A, 55 (47% by method B), 220-8°/0.05 [m. 50-2° (EtOH)], 85, 116-18° (EtOH) (X), --; 5-MeO, Ph(CH2)3, H, H, A, 72, 230-5°/0.4 (XI), 50, 86° (Et2O-petr. ether) (XII), --; 5,6-(MeO)2, PhCH2, H, H, A, 69, 215-25°/0.15 (m. 64-5°), 82, 141° (EtOH) (XIII), 81.5°; 5,6-(MeO)2, p-MeOC6H4CH2, H, H, B, 82, 86-5.8°.

L4 ANSWER 66 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(EtOH), 100, 127° (EtOH) (XIV), 102° (EtOH); 5-MeO, PhCH₂,
Me, H, H, A, 48, 201-5°/0.01 (m. 70.5-1.5°), 82,
173-4° (EtOH) (XV), --; 5-MeO, PhCH₂, H, Me, H, A, 20,
200-10°/0.6, 45, 108° (Et₂O-petr. ether) (XVI), --; 5-MeO,
PhCH₂, H, Me, Me, A, 65, 210-30°/0.25 (m. 80°), 70,
151-2° (EtOH) (XVII), 58° (EtOH); H, PhCH₂, Me, Me, H, A, 26
(43% by method B), 178-81°/0.05, 63, 160-2° (aq. EtOH)
(XVIII), --; 5-MeO, PhCH₂, Me, Me, H, A, 41 (30% by method B),
190-3°/0.1 (m. 80-1° (MeOH)), 89, 148-51° (EtOH), --;
5-MeO, p-MeOC₆H₄CH₂, Me, Me, H, A, 28, 208-12°/0.1, 76,
159-60° (EtOH), --. IV (8 g.) in 80 cc. MeOH (satd. with NH₃)
heated 24 h. in a sealed tube at 105°, filtered, and evapd. gave
5.2 g. 1-phenethyl-5-methoxy-3-indolylacetamide (XIX), needles, m.
147-8° (abs. EtOH); method D. The amides were also prepd. by
heating the acid with urea; method C. XI (13.6 g.) in 200 cc. CHCl₃ and
4.26 g. Et₃N cooled to -5°, treated rapidly with 4.58 g. ClCO₂Et,
stirred 15 min., treated 5 min. with a stream of dry NH₃, kept 1 h. at
room temp., dild. with H₂O, and the CHCl₃ layer worked up gave 7.7 g.
amide of XII, needles, m. 124-5°; method E. Similarly were prepd.
the amides of the following compds. (m.p., % yield, and method given):
IX, 146-7° (C₆H₆), 70, C; VII, 156-7°, 70, C (6% by method E);
X, 138.5-9.5° (EtOH), 81, C (66% by method D); V, 147-8°
(EtOH), 74, D; XII, 1245° (C₆H₆-petr. ether), 57, E; XIII,
167-8° (EtOH), 67, D; XIV, 166° (EtOH), 95, D; XV,
129-30° (EtOAc-petr. ether), 70, C; XVI, 180.5-82° (EtOH),
39, C; XVII, 183° (EtOH), 81, E; XVIII, 163-4° (EtOH), 70,
C. By the same methods were prepd. the dimethylamides of the following
acids (same data given): IX, -- (oil), 80, E [picrate m. 84°
(EtOAc-petr. ether)]; V, --, 94, E; XII, --, 75, E [picrate m. 97°
(EtOAc-petr. ether)]. The diethylamides of the following acids (same
data given): IX, 63-4° (Et₂O), 50, E [picrate m. 104-5°
(EtOH-Et₂O)]; V, --, 85, E [picrate m. 103-4° (EtOH-Et₂O)]; XII, --,
75, E [picrate m. 117° (EtOAc-petr. ether)]. X (0.5 g.) and 0.17
g. PhNH₂ in 5 cc. CH₂Cl₂ treated with 0.33 g. dicyclohexylcarbodiimide,
kept 16 h. at room temp., filtered from 0.26 g. dicyclohexylurea, treated
with AcOH to ppt. an addnl. 0.08 g. urea, and the filtrate worked up gave
0.4 g. anilide of X, m. 133° (aq. EtOH). VI (28 g.) in 100 cc.
Et₂O added gradually at 0° to 4 g. LiAlH₄ in 900 cc. Et₂O, refluxed
3 h., and worked up gave 21 g.
1-benzyl-3-(2-hydroxyethyl)-5-methoxyindole
(XX), b.o. 172-8°, m. 47-8° (Et₂O-petr. ether);
3,5-dinitrobenzoate, red crystals, m. 158-61° (EtOAc). Similarly
were prepd. the 3-(2-HOCH₂CH₂) analogs of the following compds. (b.p./mm.
and % yield given): X, 185-95°/0.05, 79 [3,5-dinitrobenzoate m.
169-71° (EtOH-Et₂O)]; XIII, 95-6° (Et₂O-petr. ether), 91; V,
195°/0.1, 78 [picrate m. 79-81° (C₆H₆-petr. ether)]; XVIII,
89°, 65; XIV, 81-2° (Et₂O), 80. XX (3 g.) in 140 cc. dry
Et₂O treated dropwise at 0° with 1.8 g. PBr₃ in 30 cc. Et₂O, kept
16 h. at room temp., decanted, the residual resin extd. with Et₂O, and
the ext. worked up gave 2.5 g. 1-benzyl-3(2-bromoethyl)-5-methoxyindole,
prisms, m. 94-5° (abs. EtOH). Similarly were prepd. the


L4 ANSWER 66 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
3-(2-BrCH₂CH₂) analogs of the following compds. (m.p. and % yield given):
V, --, 45; XIII, 77-8° (EtOH), 55; XVIII, 89°, 65. XIX (5.5
g.) and 1.4 g. LiAlH₄ in 500 cc. Et₂O refluxed 66 h. and worked up in the
usual manner yielded 1-phenethyl-5-methoxy-3-(2-aminoethyl)indole-HCl, m.
136-8° (abs. EtOH). Similarly were prepd. the 3-(2-H₂NCH₂CH₂)
analog HCl salts of the following compds. (m.p. and % yield given): IX
(XXI), 128-30° (EtOAc), 72; VII, 156-9° (EtOH-Et₂O), 74
[picrate m. 167-8° (EtOH)]; X, 162-4° (EtOH-Et₂O), 71; V,
136-8° (EtOH), 74; XII, 124-6° (EtOH-Et₂O), 70; XIII,
95-6° (Et₂O-petr. ether), 91; XIV, -- (hygroscopic), 42 [picrate m.
190-3° (EtOH)]; XV (XXII), 229-31° (EtOH), 52; XVI,
168-73° (EtOH-Et₂O), 68; XVII, 228-32° (EtOH-Et₂O), 73;
XVIII, 78-80° (iso-PrOH), 50. The 3-(2-Me₂NCH₂CH₂) analog HCl
salts of the following compds. (same data given): IX (XXIII),
199-200° (EtOH), 58; VII, 189-91° (EtOH), 50; X,
174-6° (EtOH), 55; V (XXIIIA), 122-4° (iso-PrOH-Et₂O), 60
(44) [methiodide m. 194-6° (EtOH), 75%]; XII, 143-5°
(EtOH-Et₂O), 66; XIII, -- (hygroscopic), 35 [picrate m. 172-4°
(EtOAc)]; XVIII, 193-4° (EtOH), 86. In the same manner were prepd.
the 3-(Et₂NCH₂CH₂) analog HCl salts of the following compds. (same data
given): IX (XXIV), 104-5° (EtOH-Et₂O), 72; X, --, 65 [picrate m.
88-9° (C₆H₆)]; V (XXV), 99-100° (EtOH-Et₂O), 60; XII, --
(hygroscopic), 45; XVIII, 167-9° (EtOH-iso-PrO), 30.
1-Benzyl-5-methoxy-3-(2-piperidinoethyl)indole-HCl, m. 202-4°
(iso-PrOH), was obtained in 60% yield by heating the corresponding
3-(2-BrCH₂CH₂) analog (2 g.) with 1.5 g. piperidine in 65 cc. MeOH 15 h.
in a sealed tube at 100°. Similarly was prepd. the
3-(2-piperidinoethyl) analog HCl salt of X, m. 180-3° (iso-PrOH),
in 56% yield. VI (1.62 g.) and 0.32 g. N₂H₄.H₂O in 20 cc. abs. EtOH
refluxed 20 h., cooled, and filtered yielded 1.1 g. hydrazide of VII, m.
140° (EtOH). Similarly were prepd. the hydrazides of the following
acids (m.p. and % yield given): IX, 128-30° (EtOH), 50; X,
144-6° (EtOH), 61; V, 117-18° (EtOH), 68; XIII,
173.5° (EtOH), 63; XIV, 179-82° (EtOH), 82. VII (5.1 g.)
and 3.1 g. NaOAc in 10 cc. Ac₂O refluxed 18 h., cooled, worked up, and
the crude product (1.85 g.) chromatographed on Al₂O₃ gave 409 mg.
1-benzyl-5-methoxy-3-acetylindole, m. 62.5-3.5° (Et₂O-petr.
ether); 2,4-dinitrophenylhydrazones, orange prisms, m. 62.5-63°
(EtOAc); oxime (XXVI), prisms, m. 98.5-9.5° (C₆H₆-petr. ether).
Similarly was prepd. the 3-acetyl analog of XIII in 56% yield;
2,4-dinitrophenylhydrazones m. 186° (EtOH). In the same manner as
XXI was prepd. the 3-(2-H₂NCH₂CH₂) analog HCl salt of VII, 71%, m.
190-2° (EtOH-Et₂O), and the 3-(PhCH₂NMeCH₂CH₂) analog HCl salt of
X, 32%, m. 160° (EtOH-Et₂O). The antiserotonin activities of XXI,
XXIII, XXIIIA, XXIV, and XXV were detd. XXII did not show any
tuberculostatic activity in vivo at the max. tolerable dose.
IT 94916-80-OP, Indole-3-acetamide, 5-methoxy-N,N-dimethyl-1-
phenethyl- 96215-65-5P, Indole-3-acetamide, 5-methoxy-N,N-
dimethyl-1-(3-phenylpropyl)-, picrate 96310-29-1P,
Indole-3-acetamide, N,N-diethyl-5-methoxy-1-phenethyl-, picrate
97076-37-4P, Indole-3-acetamide, N,N-diethyl-5-methoxy-1-(3-
phenylpropyl)-, picrate
RU: PREP (Preparation)

L4 ANSWER 66 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(prepn. of)
RN 94916-80-0 CAPLUS
CN Indole-3-acetamide, 5-methoxy-N,N-dimethyl-1-phenethyl- (7CI) (CA INDEX
NAME)




RN 96215-65-5 CAPLUS
CN Indole-3-acetamide, 5-methoxy-N,N-dimethyl-1-(3-phenylpropyl)-, picrate
(7CI) (CA INDEX NAME)

CM 1
CRN 96215-64-4
CMF C22 H26 N2 O2




CM 2
CRN 88-89-1
CMF C6 H3 N3 O7




RN 96310-29-1 CAPLUS
CN Indole-3-acetamide, N,N-diethyl-5-methoxy-1-phenethyl-, picrate (7CI)
(CA INDEX NAME)

CM 1
CRN 96310-28-0
CMF C23 H28 N2 O2

L4 ANSWER 66 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




CM 2
CRN 88-89-1
CMF C6 H3 N3 O7




RN 97076-37-4 CAPLUS
CN Indole-3-acetamide, N,N-diethyl-5-methoxy-1-(3-phenylpropyl)-, picrate
(7CI) (CA INDEX NAME)

CM 1
CRN 97076-36-3
CMF C24 H30 N2 O2



CM 2
CRN 88-89-1
CMF C6 H3 N3 O7

L4 ANSWER 66 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L4 ANSWER 67 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1962:449170 CAPLUS
 DOCUMENT NUMBER: 57:49170
 ORIGINAL REFERENCE NO.: 57:9784b-1,9785a-b
 TITLE: Research in the indole series. V. Preparation of 3-indolylacetamides and tryptamines
 AUTHOR(S): Julia, Marc; Igolen, Jean
 SOURCE: Bulletin de la Societe Chimique de France (1962) 1056-60
 CODEN: BSCFAS; ISSN: 0037-8968
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 57:49170

AB A series of 3-indolylacetamides was prepared from 4-bromoacetoacetamides with secondary aromatic amines and reduced to the corresponding tryptamines, p-MeOC₆H₄CH₂NPh in AcOEt hydrogenated over PtO₂ yielded p-MeOC₆H₄CH₂NHPh (I), b15 206-8°, m. 48-9°. p-MeOC₆H₄CH₂NC₆H₄Me-p, m. 142° (EtOH), in EtOAc hydrogenated over Raney Ni at 75°/150 atmospheric yielded 90% p-MeOC₆H₄CH₂NHC₆H₄Me-p (II), plates, m. 94-5° (EtOH). 3,4-(EtO)2C₆H₃CH₂NC₆H₄Me-p, m. 96-8° (EtOH), in EtOAc hydrogenated under ambient conditions over PtO₂ yielded 80% 3,4-(EtO)2C₆H₃CH₂NHC₆H₄Me-p (III), b0.15 210-12°, m. 54-5° (petr. ether). N-Piperonylidene-p-anisidine (IV), m. 119-20° (EtOH), gave similarly N-piperonyl-p-anisidine (IV), m. 76-8° (EtOH). AcCH₂CONEt₂ (15.7 g.) treated with 16.0 g. Br in 90 cc. CHCl₃ gave 20 g. crude BrCH₂COCH₂CONEt₂ (V), yellow oil, which decomposed rapidly at 100° and was used without purification. BrCH₂COCH₂CONHPh (VI) (5.12 g.) in 12 cc. HCONMe₂ and 4.28 g. MeNHPh in 6 cc. HCONMe₂ kept overnight, diluted with 300 cc. H₂O, extracted with C₆H₆, the aqueous layer basified, and extracted with Et₂O gave 1.42 g. MeNHPh; the C₆H₆ phase worked up yielded 4.15 g. p-MeC₆H₄NHCH₂COCH₂CONHPh (VII), m. 90-1° (80% EtOH). VII (4 g.) and 4 g. ZnCl₂ heated 45 min. at 100-10°, cooled, dissolved with heating in 40 cc. 4N HCl, extracted with C₆H₆, and the extract worked up gave 3.4 g. crystals, m. 92-112°, which chromatographed from C₆H₆ on Al₂O₃ yielded 2.65 g. 1-methyl-3-indolylacetamide (VIII), needles, m. 111-12° (80% EtOH); method A. VI (5.12 g.), 4.28 g. MeNHPh, and 90 cc. absolute EtOH refluxed 18 hrs., concentrated, diluted with 200 cc. H₂O, extracted with C₆H₆, and the aqueous phase worked up yielded 1.75 g. MeNHPh; the C₆H₆ extract yielded 1.8 g. (crude) VIII, m. 111-12°; method B. VIII (200 mg.) and 15 cc. 5N HCl refluxed 1.5 hrs., refrigerated overnight, and filtered gave 1-methyl-3-indolylacetic acid, m. 123-7° (H₂O). Similarly were prepared the following compds. (appearance, m.p., acetacetanilide, secondary amine, and % yields by methods A and B obtained given): 1-ethyl-3-indolylacetanilide (IX), prisms, 104-5° (70% EtOH), VI, EtNHPh, 3.1, 2.1; 1-benzyl-3-indolylacetanilide (X), needles, 127-8° (EtOH), VI, PhNHCH₂Ph, 2.4, 1.5; 5-MeO derivative of X, --, 136-7° (70% EtOH), VI, p-MeOC₆H₄NHCH₂Ph (XI), 1.1, 1.4; 5-PhCH₂O derivative (XII) of VIII, --, 162-4° (C₆H₆), VI, p-PhCH₂O₂C₆H₄NMePh, --, 4.5; 1-anisyl-3-indolylacetanilide (XIII), needles, 130-1° (absolute EtOH), VI, I, --, 2.3; 5-MeO derivative (XIV) of XIII, prisms, 134°



L4 ANSWER 67 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
 (80% EtOH), VI, II, 5.2, 4.8; 1-(3,4-diethoxybenzyl)-5-methoxy-3-indolylacet anilide (XV), needles, 134-6° (MeOH), VI, III, --, 4.1; 1-piperonyl analog (XVI) of XV, needles, 158-9° (C₆H₆), VI, IV, --, 5.5; N,N-di-Et deriv. (XVII) of VIII, --, 80-1° (petr. ether), V, MeNHPh, 0.25, -- [picrate m. 124-6° (C₆H₆-petr. ether)]; N,N-di-Et deriv. (XVIII) of IX, yellow oil, --, V, EtNHPh, 6.7, -- [picrate, yellow-orange needles, m. 109-11° (C₆H₆-petr. ether)]; N,N-di-Et deriv. of X, prisms, 95-6° (60% EtOH), V, PhNHCH₂Ph, 5.3, -- [PhCH₂NPhCH₂COCH₂NEt₂, 7.1 g., needles, m. 103-5° (abs. EtOH), was obtained as the intermediate]; 1-benzyl-5-methoxy-3-indolyl (N,N-diethyl)acetamide (XIX), -- (oil), --, V, XI, 12.1, -- [picrate, yellow needles, m. 133-5° (C₆H₆-petr. ether)]. X (1 g.), 0.25 g. LiAlH₄, and 300 cc. Et₂O refluxed 14 hrs., worked up, and the base isolated as the HCl salt gave 400 mg. 1-benzyl-3-(2-phenylaminoethyl)indole-HCl (XX), m. 136-8° (C₆H₆-petr. ether). XII (2.2 g.), 0.6, LiAlH₄, and 1100 cc. Et₂O refluxed 18 hrs. gave similarly 1.1 g. 5-PhCH₂O deriv. of XX, m. 151-4° (iso-PrOH). Powd. XIV (5 g.), 3 g. LiAlH₄, and 1600 cc. dry Et₂O refluxed 27 hrs., worked up, the yellow oily residue dissolved in Et₂O, and treated with dry HCl gave 3.8 g. 1-anisyl-5-methoxy-3-(2-anilinoethyl)indole-HCl, m. 147-9° (abs. EtOH). Similarly were prepd. the following compds. (m.p. given): 1-anisyl-3-(2-anilinoethyl)indole-HCl, 151-3° (abs. EtOH) (needles); 1-piperonyl-5-methoxy-3-(2-anilinoethyl)indole-HCl (XXI), 172-5° (abs. EtOH) (needles); 1-[3,4-(EtO)2C₆H₃CH₂] analog of XXI, 142-4° (iso-PrOH); 1-methyl-3-(2-diethylaminoethyl)indole-HCl (XXII), 203° (abs. EtOH) (needles); 1-Et homolog of XXII, 115-16° (iso-PrOH); 1-benzyl-5-methoxy-3-(2-diethylaminoethyl)indole-HCl, 135° (iso-PrOH).

IT 96215-63-3P, Indole-3-acetamide, 1-benzyl-N,N-diethyl-5-methoxy-, picrate
 RL: PREP (Preparation)
 (preparation of)
 RN 96215-63-3 CAPLUS
 CN Indole-3-acetamide, 1-benzyl-N,N-diethyl-5-methoxy-, picrate (7CI) (CA INDEX NAME)

CM 1

CRN 96215-62-2
 CMP C22 H26 N2 O2

L4 ANSWER 67 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2


CRN 88-89-1
 CMP C6 H3 N3 O7

L4 ANSWER 68 OF 71 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1956:89506 CAPLUS
 DOCUMENT NUMBER: 50:89506
 ORIGINAL REFERENCE NO.: 50:16869h-1,16870a-f
 TITLE: (5-Benzyl-5-benzyl-3-indole)alkylamines
 PATENT ASSIGNEE(S): Upjohn Co.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 744773		19560215	GB 1953-8777	19530330

AB Comps. possessing vasoconstrictor properties are prepared by coupling a Grignard reagent prepared from Me₂NOO(CH₂)_nCHRX (R = alkyl, X = halogen) with a 2-alkyl-5-benzyl-3-indole giving a 2-alkyl-5-benzyl-3-indolealkylamine which is reduced to a 2-alkyl-5-benzyl-3-indolealkylamine. Thus to 4.25 g. 4.25 g. MeI and 2.4 g. Mg in 200 ml. Et₂O was added 5.5 g. 5-benzyl-3-indole in 200 ml. Et₂O. After refluxing 30 min., cooling in ice and adding 5.9 g. of BzMeNCOCH₂Cl in 500 ml. Et₂O, the Et₂O was distilled off and the residue heated 3 hrs. on the steam bath, taken up in Et₂O, and decomposed with 5% AcOH, giving 7.5 g. N-methyl-N-benzyl-α-(5-benzyl-3-indolyl)acetamide (I), m. 151-2° (from iso-PrOH). I reduced with LiAlH₄ in tetrahydrofuran gave after acidification with HCl, 71% 5-benzyl-3-[2-(N-benzyl-N-methylamino)ethyl]indole hydrochloride, C₂₅H₂₆N₂O₂·HCl, m. 110-12°. Similarly were prepared the following 5-benzyl-3-R-substituted indoles (R, m.p., m.p. of hydrochloride, and % yield given): (PhCH₂)₂NCH₂CH₂, 101-2°, 232-3°, 65; Me₂NCH₂CH₂, -, 154-5°, 29; 2-piperidinoethyl, -, 208-9.5°, 11.5; Bu₂NCH₂CH₂, -, 218-20°, -, PhCH₂(PhCH₂CH₂)NCH₂CH₂, -, 214-15°, -. Also prepared without phys. consts. given were 2-ethyl-5-benzyl-3-(2-piperidinoethyl)indole, 5-benzyl-3-(1-methyl-2-piperidinoethyl)indole, 5-benzyl-3-(2-morpholinoethyl)indole, 5-benzyl-3-[2-(1-pyrrolidinyl)ethyl]indole, 5-benzyl-3-(2-thiamorpholinoethyl)indole, 5-benzyl-3-(3-piperidinopropyl)indole, 5-benzyl-3-(1-ethyl-3-piperidinopropyl)indole, 5-p-methylbenzyl-3-[2-(N-benzylamino)ethyl]indole, 5-(p-propylbenzyl-3-[2-(N-isopropyl-N-benzylamino)ethyl]indole, 2-methyl-5-(p-ethylbenzyl-3-[2-(N-phenylamino)ethyl]indole, 5-(p,p'-dimethylbenzyl-3-[2-(N-isopropylamino)ethyl]indole, 5-(p-ethylbenzyl-3-[3-(N-benzylamino)propyl]indole, 5-(p-iodobenzyl-3-[2-(N,N-dicyclohexylamino)ethyl]indole, 5-(p-ethylbenzyl-3-[1-ethyl-5-(p-ethylbenzyl-3-[2-(N-methyl-N-benzylamino)ethyl]indole, 5-(p,p'-dichlorobenzyl-3-[3-(N-isopropylamino)propyl]indole, 5-(p-bromobenzyl-3-[1-ethyl-3-(N-methylamino)propyl]indole, 5-(p-methoxybenzyl-3-[2-(N,N-dicyclohexylamino)ethyl]indole, 5-(p,p'-dimethoxybenzyl-3-[1-propyl-2-(N-ethyl-N-cyclohexylamino)ethyl]indole, 2-propyl-5-(p-ethoxybenzyl-3-[2-(N-benzylamino)ethyl]indole, 5-(p,p'-dimethoxybenzyl-3-[2-(N,N-dibenzylamino)ethyl]indole, 5-(p-ethoxybenzyl-3-[1-ethyl-3-(N-benzylamino)propyl]indole, 5-(p-ethoxybenzyl-3-[1-ethyl-3-(N-benzylamino)propyl]indole,

L4 ANSWER 68 OF 71 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 5-benzyl-3-[3-(N-isopropylamino)propyl]indole, 5-benzyl-3-[3-(N,N-dimethylamino)propyl]indole, 5-benzyl-3-[3-(N-methyl-N-benzylamino)propyl]indole, 5-benzyl-3-[1-methyl-3-(N-benzylamino)propyl]indole, 2-ethyl-5-benzyl-3-[3-(N-benzylamino)propyl]indole, 5-benzyl-3-[2-(N-cyclopentyl-N-ethylamino)ethyl]indole, 5-benzyl-3-[1-ethyl-2-(N,N-diphenylamino)ethyl]indole, 2-methyl-5-benzyl-3-[2-(N,N-dicyclohexylamino)ethyl]indole, 5-benzyl-3-[2-(N-cyclohexylamino)ethyl]indole, 5-benzyl-3-[2-(N-methylamino)ethyl]indole, 5-benzyl-3-[3-(N-methyl-N-benzylamino)propyl]indole, and 5-benzyl-3-[1-methyl-3-(N-benzylamino)propyl]indole. Cf. Brit. 744,774 (following abstr.) and C.A. 50, 5035h.
 IT 725227-53-2P, 3-Indoleacetamide, N-benzyl-5-(benzyl-3-indolyl)-N-methyl- (preparation of)
 RN 725227-53-2 CAPLUS
 CN 3-Indoleacetamide, N-benzyl-5-(benzyl-3-indolyl)-N-methyl- (5CI) (CA INDEX NAME)




L4 ANSWER 69 OF 71 CAPLUS COPYRIGHT 2008 ACS ON STN
 ACCESSION NUMBER: 1956:27880 CAPLUS
 DOCUMENT NUMBER: 50:27880
 ORIGINAL REFERENCE NO.: 50:5630c-1,5631a-g
 TITLE: Ergot alkaloids. XL. A new synthesis of bufotenine and related hydroxytryptamines
 AUTHOR(S): Stoll, A.; Troxler, F.; Peyer, J.; Hofmann, A.
 CORPORATE SOURCE: Sandoz, Basel, Switz.
 SOURCE: Helvetica Chimica Acta (1955), 38, 1452-72
 CODEN: HCACAV; ISSN: 0018-019X
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 50:27880
 AB cf. preceding abstract Nitrosation of m-MeC₆H₄OH and oxidation of the NO compound give 63% 2,5-(O₂N)(HO)C₆H₃Me, m. 129-30°, which is converted into 87% 2,5-(O₂N)(PhCH₂O)C₆H₃Me (I). Treating I mole I with 2 mol (CO₂Et)₂ and 2 mol EtOK according to Burton and Stoves (C.A. 32, 550.1) at below 8° gives 87% 2-nitro-5-benzyl-3-phenylpyruvic acid, m. 112-13°, which (55 g.), reductively cyclized in 600 cc. H₂O and 80 cc. 2N NaOH with 70 g. Na₂SO₄ added in small portions until the color reaction (deep red) with NaOH is neg. and acidified with dilute HCl, gives 48.5% 5-benzyl-3-indole-2-carboxylic acid (II), m. 194-6°. Heating II in quinaldine with Cu powder at 245-50° gives 80% 5-benzyl-3-indole (III), m. 103-5°, which, shaken in MeOH with Pd-asbestos (IV) and H, gives 5-hydroxyindole, long needles, m. 107-8°. Treating III in 1:1 EtOH-AcOH with Me₂NH and CH₂O according to Ek and Witkop (C.A. 49, 12437i) gives 84% 5-benzyl-3-indole (V), m. 138°. Adding (20 min.) with stirring 420 cc. MeI to 30 g. V, keeping the mixture 15 h. at 5°, heating the methiodide with 60 g. NaCN in 1.1 l. H₂O 2 h. at 80°, extracting the solution with CHCl₃, evaporating the CHCl₃, taking up the residue (29.6 g.) in 250 cc. Et₂O, and diluting the concentrated Et₂O solution with petr. ether give 85% 5-benzyl-3-indoleacetonitrile (VI), prisms, m. 75-8°. Refluxing 20 g. VI in 140 cc. EtOH and 100 cc. H₂O 15 h. with 45 g. KOH, acidifying the mixture with 60 cc. AcOH, and diluting the filtered solution with 500 cc. H₂O give 20.6 g. 5-benzyl-3-indoleacetic acid, m. 145-7°, which is converted with CH₂N₂ into the Me ester and the latter heated with N₂H₄ 1.5 h. at 135°, giving 95% 5-benzyl-3-indoleacetylhydrazide (VII), leaflets, m. 153-4°. Adding dropwise 60 cc. N HCl to a mixture of 14.7 g. VII in 250 cc. dioxane and 50 cc. N NaNO₂ solution, extracting the acetazide with Et₂O, evaporating the Et₂O, and treating the residual azide with 50 g. anhydrous Me₂NH 3 h. at 5° give 60% 5-benzyl-3-indoleacetdimethylamide (VIII), platelets, m. 139-40°. In a similar way the following addnl. amides are prepared: Me, short prisms, m. 141-2°; Et, prisms, m. 126-8°, di-Et, needles, m. 120-1°; H₂NCH₂CH₂, plates, m. 137-9°; and piperidine, leaflets, m. 129-30°. Adding dropwise 1.26 g. LiAlH₄ in 200 cc. Et₂O in a N arm. to 3.65 g. VIII in 80 cc. THF, stirring the mixture 1 h. at 55°, and working it up in the usual way give 80% 5-benzyl-3-(N,N-dimethyltryptamine) (bufotenine benzyl ether) (IX), pointed prisms, m. 87-9° [acid oxalate (X), fine leaflets, m. 177-8°]. Similar reduction of the corresponding

L4 ANSWER 69 OF 71 CAPLUS COPYRIGHT 2008 ACS ON STN (Continued)
 amides gives the following N-substituted tryptamines: Me, plates, m. 84-6° [acid oxalate (XI), needles, m. 201-3°]; Et, crystals, m. 59-61° (acid oxalate, short needles, m. 187-9°) [the ω-N,N-diethyl homolog does not crystallize (acid oxalate, prisms, m. 162°)]; H₂NCH₂CH₂, does not crystallize (bis-acid oxalate, leaflets, m. 221-2°); N-[β-(5-benzyl-3-indolyl)ethyl]piperidine, prisms, m. 136-8°. Shaking 3.45 g. IX in 75 cc. MeOH with 2 g. 5% IV and H 1.5 h. gives 78% bufotenine (XII), stout prisms, m. 138-40°. With FeCl₃ in AcOH and concd. H₂SO₄, XII gives a reddish color, turning to blue after 1-2 s. The UV absorption curves of XII in EtOH, 0.1N HCl, and 0.1N NaOH, and the IR absorption curves of XII and of natural XII are given. Shaking 1.85 g. X in 200 cc. MeOH with IV in H gives 86% XII acid oxalate, needles, m. 89-90°. Treating 1.1 g. XII in 2 cc. MeOH with 2 cc. MeI 3 h. at 20° gives 1.7 g. XII methiodide, stout prisms, m. 214-15°. Dissolving 2.9 g. XII and 2.3 g. creatinine sulfate (XIII) in 14 cc. N H₂SO₄ and 40 cc. boiling H₂O and dilg. the soln. with Me₂CO give a 5.3 g. XII-XIII complex, fine needles, m. 147-9°. Debenzylation of XI gives 5-hydroxy-ω-N-methyltryptamine (ω-N-methylserotonin), short pointed prisms and plates, m. 153-6°; N-Et homolog, short prisms, m. 239-40°; N,N-di-Et homolog, polyhedrons and prisms, m. 147-9° (oxalate, m. 230-2°); N-H₂NCH₂CH₂ analog, bis-acid oxalate, leaflets, m. 208-9°; N-[β-(5-hydroxy-3-indolyl)ethyl]piperidine, stout prisms, m. 201-3° (oxalate, pointed prisms, m. 243-7°). Refluxing 30.6 g. 2,6-O₂N(HO)C₆H₃Me in 150 cc. EtOH contg. 4.6 g. Na 8 h. with 25.4 g. PhCH₂Cl, adding H₂O, distg. off the EtOH in vacuo, and extg. with Et₂O give 63.8% 2,6-O₂N(PhCH₂O)C₆H₃Me (XIV), b₀ 8 170-6°, m. 65-6°. Condensation of XIV with (CO₂Et)₂ in the presence of EtOK gives the 2-nitro-6-benzyl-3-phenylpyruvic acid which is directly converted into 64% (overall) 4-benzyl-2-indolecarboxylic acid (XV) (purified via its Na salt), m. 241-2°. Decarboxylation of XV in quinaldine in the presence of Cu powder gives 62% 4-benzyl-3-indole (XVI), needles, m. 72-4°, which, treated in MeOH with H in the presence of IV, gives 4-hydroxyindole, hexagonal plates, m. 97-9°. Treating XVI with Me₂NH in the same way as in the prepn. of V gives 89% 4-benzyl-3-indole (XVII), hexagonal leaflets, m. 94-8°. Treating the methiodide of XVII with NaCN gives 60% 4-benzyl-3-indoleacetonitrile, m. 97-100°, which, reduced with LiAlH₄, gives 81% 4-benzyl-3-indole (XVIII), plates, m. 117-20° [acid oxalate (XVIII), hexagonal plates, m. 188-9°]. Shaking 3.3 g. XVIII in 270 cc. MeOH with Pd and H gives 4-hydroxytryptamine (XIX) oxalate, clusters of platelets, m. 269-70°; free base does not crystallize. XIX-XIII complex, needles, m. 250-5°. Condensation of 121.5 g. 2,4-O₂N(PhCH₂O)C₆H₃Me with (CO₂Et)₂ gives 91% 2-nitro-4-benzyl-3-phenylpyruvic acid, m. 133-5° (B. and S. (loc. cit.) found 89-90°), which is converted into 51% 6-benzyl-2-indolecarboxylic acid (XX), m. 199-200° (decompn.). Decarboxylation of XX gives 46% 6-benzyl-3-indole (XXI), leaflets, m. 118-20°, which, with Pd and H in MeOH, gives 6-hydroxyindole (XXI), hexagonal leaflets, m. 124-6°. XXI is converted into 80% 6-benzyl-3-indole (XXII), long rods, m. 136-8°. Converting XXII into the methiodide and treating the latter with NaCN give 75% 6-benzyl-3-indoleacetonitrile, leaflets, m. 136-7°, which, reduced with LiAlH₄ in THF, gives 71% 6-benzyl-3-indole (XXIII), fine needles, m. 92-6° (oxalate, shiny leaflets, m. 260-5°). XXIII, debenzylated with Pd and H,


L4 ANSWER 69 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
gives 6-hydroxytryptamine (XXIV) which does not crystallize. XXIII is converted into its sulfate and the latter (1.4 g.) is shaken in 500 cc. H₂O with 500 mg. IV and H, the filtrate cond. to 100 cc., and 0.72 g. XIII added, giving 85% XXIV-XIII complex, fine needles, m. 212-15°. The UV and IR absorption max. of some of the compds. are given.

IT 409111-49-5P, 3-Indoleacetamide, 5-(benzyloxy)-N,N-dimethyl-
857764-35-3P, 3-Indoleacetamide, 5-(benzyloxy)-N,N-diethyl-
872786-56-6P, Piperidine, 1-[[5-(benzyloxy)-3-indolyl]acetyl]-
RL: PREP (Preparation)
(preparation of)


RN 409111-49-5 CAPLUS
CN 1H-Indole-3-acetamide, N,N-dimethyl-5-(phenylmethoxy)- (CA INDEX NAME)



RN 857764-35-3 CAPLUS
CN 3-Indoleacetamide, 5-(benzyloxy)-N,N-diethyl- (5CI) (CA INDEX NAME)




RN 872786-56-6 CAPLUS
CN Piperidine, 1-[[5-(benzyloxy)-3-indolyl]acetyl]- (5CI) (CA INDEX NAME)



L4 ANSWER 70 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
water-acetone yielded 1.3 g. 5-hydroxy-3-(2-methylaminoethyl)indole creatinine sulfate, m. 220-1°. Similarly were synthesized the following 3-substituted-5-hydroxyindole HCl salts (A) and creatinine sulfates (B) (substituent and m.p. given): Me₂NCH₂CH₂ (B), 141-3°; 2-piperidinoethyl (A), 246-8°; Bu₂NCH₂CH₂ (A), 213-14°; also 2-methyl-5-hydroxy-3-(2-aminoethyl)indole-HCl, m. 225.5-7.0°. In similar reactions with ClCH₂CN in place of the haloalkanoyle amides were synthesized 5-benzyloxytryptamine-HCl, m. 248-50° (decompn.), and serotonin creatinine sulfate, m. 215-16°. The compds. have potent vasoconstrictor qualities.

IT 725227-53-2P, 3-Indoleacetamide, N-benzyl-5-(benzyloxy)-N-methyl-
RL: PREP (Preparation)
(preparation of)

RN 725227-53-2 CAPLUS
CN 3-Indoleacetamide, N-benzyl-5-(benzyloxy)-N-methyl- (5CI) (CA INDEX NAME)



L4 ANSWER 70 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1956:24396 CAPLUS
DOCUMENT NUMBER: 50:24396
ORIGINAL REFERENCE NO.: 50:5035h-i, 5036a-d
TITLE: (Hydroxy-3-indolyl)alkylamines
INVENTOR(S): Speeter, Merrill E.
PATENT ASSIGNEE(S): Upjohn Co.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2708197		19550510	US 1952-289872	19520524

AB (Hydroxy-3-indolyl)alkyl amines are synthesized by the debenzoylation of (benzyloxy-3-indolyl)alkylamines (I) prepared by the reduction of (benzyloxy-3-indolyl)alkanoyle amides (II) with Li-AlH₄. II are prepared by the Grignard reaction from benzyloxyindole with a haloalkanoyle amide. Thus, a Grignard reagent made from 4.25 g. MeI and 2.4 g. Mg in 200 mL ether treated with 5.5 g. 5-benzyloxyindole in 200 mL ether, the mixture refluxed 30 min., cooled in an ice bath, 5.9 g. ClCH₂CONMeCH₂Ph in 200 mL ether added, the mixture stirred, the ether distilled off, the residue warmed 3 h. on the steam bath, cooled, 500 mL ether added, then 5 mL AcOH in 95 mL water, and the precipitate allowed to stand overnight and recrystd. from iso-PrOH, yielded 7.5 g. 5-benzyloxy-N-benzyl-N-methyl-3-indoleacetamide (III), m. 151-2°. III (3.84 g.) in 150 mL THF added with stirring to 3.7 g. LiAlH₄ in THF, the mixture refluxed 0.5 h., concentrated to 75 mL, diluted with 500 mL ether, 50 mL 5% NaOH added, the ether layer decanted, the water layer reexd. with ether, dilute HCl added to the combined ether layers, and the white precipitate filtered, washed with ether, and recrystd. from EtOH yielded 2.9 g. 5-benzyloxy-3-[2-(benzyl-methylamino)ethyl]indole-HCl (IV), m. 110-12°. A suspension of 2.64 g. IV in 100 mL H₂O treated with 25 mL 10% NaOH, then 200 mL ether, the mixture stirred until all the solid dissolved, the ether layer decanted, 3 more extns. with 200-mL portions of ether made, the exts. washed with H₂O, dried over K₂CO₃, the ether distilled off, the residue dissolved in 25 mL absolute EtOH, transferred to a microredn. flask, 0.5 g. 10% Pd-C catalyst added, the mixture shaken with H at a little higher than atmospheric pressure at 25° (the H consumption was complete in 0.5 h.), the catalyst filtered off, 13 mL 0.5N H₂SO₄ added, the solution concentrated to 5 mL, 1.13 g. creatinine sulfate in 10 mL H₂O added, the resulting pink solution filtered (the rinsings brought the volume to 30 mL), the solution heated to 60°, 80 mL acetone added, and the precipitate filtered, dried, and recrystd. from

L4 ANSWER 71 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1955:78071 CAPLUS
DOCUMENT NUMBER: 49:78071
ORIGINAL REFERENCE NO.: 49:14810g-i, 14811a
TITLE: (5-Benzyloxy-3-indolyl)alkanamides
INVENTOR(S): Speeter, Merrill E.
PATENT ASSIGNEE(S): Upjohn Co.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2692882		19541026	US 1952-279931	19520401

GI For diagram(s), see printed CA Issue.

AB I (X is Ph, halophenyl, lower alkoxyphenyl, or lower alkylphenyl; Y is H, Ph, halophenyl, lower alkoxyphenyl, or lower alkylphenyl; R' and R'' are or lower alkyl; n is 0 or 1; and Z is a secondary amine radical) are prepared by the following exemplary procedure. A Grignard reagent prepared from 4.25 g. MeI and 2.4 g. Mg in 200 mL Et₂O added to 5.5 g. 5-benzyloxyindole in 200 mL Et₂O, the solution refluxed 30 min., cooled in an ice-bath, 5.9 g. ClCH₂CONMeCH₂Ph in 200 mL Et₂O added, the mixture stirred, the Et₂O distilled off, the residue warmed 3 hrs. on a steam bath, cooled, about 500 mL Et₂O added, then, with vigorous stirring, 5 mL AcOH and 95 mL H₂O, the mixture allowed to stand overnight, and the product filtered and recrystd. gives 7.5 g. 2-(5-benzyloxy-3-indolyl)-N-benzyl-N-methylacetamide, m. 151-2° (from iso-PrOH). Similarly prepared: in 69% yield, the N,N-di-PhCH₂ analog, m. 156-7°; and in 30% yield, 2-(5-benzyloxy-3-indolyl)benzylacetamide, m. 185-6°.


IT 725227-53-2P, 3-Indoleacetamide, N-benzyl-5-(benzyloxy)-N-methyl-
857776-54-6P, 3-Indoleacetamide, N-benzyl-5-(benzyloxy)-N-isopropyl-
857776-60-4P, 3-Indoleacetamide, N,N-dibenzyl-5-(benzyloxy)-
872786-56-6P, Indole, 5-(benzyloxy)-3-(piperidinocarbonylmethyl)-
RL: PREP (Preparation)
(preparation of)

RN 725227-53-2 CAPLUS
CN 3-Indoleacetamide, N-benzyl-5-(benzyloxy)-N-methyl- (5CI) (CA INDEX NAME)




RN 857776-54-6 CAPLUS
CN 3-Indoleacetamide, N-benzyl-5-(benzyloxy)-N-isopropyl- (5CI) (CA INDEX NAME)

L4 ANSWER 71 OF 71 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 857736-60-4 CAPLUS
CN 3-Indoleacetamide, N,N-dibenzyl-5-(benzyloxy)- (5CI) (CA INDEX NAME)



RN 872786-56-6 CAPLUS
CN Piperidine, 1-[[5-(benzyloxy)-3-indolyl]acetyl]- (5CI) (CA INDEX NAME)

